[{"text": "In particular , H1975 cells contain a second mutation ( T790M ) reported to be linked to gefitinib resistance , but we found that these cells also responded poorly to cetuximab .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [89, 98], "tok_span": [22, 26]}, {"name": "T790M", "ent_type": "variant", "char_span": [56, 61], "tok_span": [12, 16]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [56, 61], "obj_char_span": [89, 98], "rel_type": "resistance or non-response", "sbj_tok_span": [12, 16], "obj_tok_span": [22, 26]}], "umls_entity_list": []}, {"text": "Therefore , in this study we explored the retained antitumor activity of gefitinib in resistant HCC827-GR5 and NCI-H1975 NSCLC cells , carrying MET amplification and T790M mutation , respectively .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [73, 82], "tok_span": [12, 16]}, {"name": "T790M", "ent_type": "variant", "char_span": [166, 171], "tok_span": [38, 42]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [166, 171], "obj_char_span": [73, 82], "rel_type": "resistance or non-response", "sbj_tok_span": [38, 42], "obj_tok_span": [12, 16]}], "umls_entity_list": []}, {"text": "Of note , the continuous exposure of H1975 cells , carrying the T790M mutation , to gefitinib did not modify their migratory phenotype , possibly because of the low affinity of the mutated receptor for this drug .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [84, 93], "tok_span": [21, 25]}, {"name": "T790M", "ent_type": "variant", "char_span": [64, 69], "tok_span": [14, 18]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [64, 69], "obj_char_span": [84, 93], "rel_type": "resistance or non-response", "sbj_tok_span": [14, 18], "obj_tok_span": [21, 25]}], "umls_entity_list": []}, {"text": "The most commonly identified mechanism of resistance is an EGFR mutation at position 790 ( T790M ) , resulting in substitution of a threonine residue with methionine , which abrogates the ability of gefitinib or erlotinib to inhibit EGFR .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [199, 208], "tok_span": [40, 44]}, {"name": "T790M", "ent_type": "variant", "char_span": [91, 96], "tok_span": [16, 20]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [91, 96], "obj_char_span": [199, 208], "rel_type": "resistance or non-response", "sbj_tok_span": [16, 20], "obj_tok_span": [40, 44]}], "umls_entity_list": []}, {"text": "The G719S mutation renders the tumor less sensitive to gefitinib , while erlotinib and the second-generation TKI afatinib have proven to be effective in tumors characterized by this substitution . ", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [55, 64], "tok_span": [12, 16]}, {"name": "G719S", "ent_type": "variant", "char_span": [4, 9], "tok_span": [1, 5]}], "relation_list": [{"subject": "G719S", "object": "gefitinib", "sbj_char_span": [4, 9], "obj_char_span": [55, 64], "rel_type": "sensitivity", "sbj_tok_span": [1, 5], "obj_tok_span": [12, 16]}], "umls_entity_list": []}, {"text": "This has been reported by several prospective trials of gefitinib and erlotinib in EGFR mutated NSCLC , which showed RRs exceeding 70 % in tumors with exon 19 deletions or the L858R mutation , with PFS intervals of 6-14 months and OS times beyond 20-24 months- .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [56, 65], "tok_span": [9, 13]}, {"name": "L858R", "ent_type": "variant", "char_span": [176, 181], "tok_span": [38, 42]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [176, 181], "obj_char_span": [56, 65], "rel_type": "sensitivity", "sbj_tok_span": [38, 42], "obj_tok_span": [9, 13]}], "umls_entity_list": []}, {"text": "An experiment using cell lines transfected concurrently with activating mutations and a T790M mutation also proved that resistance to gefitinib and erlotinib is evident when this mutation is present .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [134, 143], "tok_span": [22, 26]}, {"name": "T790M", "ent_type": "variant", "char_span": [88, 93], "tok_span": [12, 16]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [88, 93], "obj_char_span": [134, 143], "rel_type": "resistance or non-response", "sbj_tok_span": [12, 16], "obj_tok_span": [22, 26]}], "umls_entity_list": []}, {"text": "Although rare , T790M mutations exist as major clones irrespective of gefitinib administration in certain patients .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [70, 79], "tok_span": [14, 18]}, {"name": "T790M", "ent_type": "variant", "char_span": [16, 21], "tok_span": [3, 7]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [16, 21], "obj_char_span": [70, 79], "rel_type": "resistance or non-response", "sbj_tok_span": [3, 7], "obj_tok_span": [14, 18]}], "umls_entity_list": []}, {"text": "At present , the Genius study ( NCT01579630 ) is ongoing to compare the efficacy and safety of gefitinib/pemetrexed versus pemetrexed alone as maintenance therapy in patients EGFR mutation negative or T790M single mutation who responded to pemetrexed/platinum as first-line therapy .", "entity_list": [{"name": "gefitinib/pemetrexed", "ent_type": "drug", "char_span": [95, 115], "tok_span": [24, 33]}, {"name": "T790M", "ent_type": "variant", "char_span": [201, 206], "tok_span": [48, 52]}], "relation_list": [{"subject": "T790M", "object": "gefitinib/pemetrexed", "sbj_char_span": [201, 206], "obj_char_span": [95, 115], "rel_type": "resistance or non-response", "sbj_tok_span": [48, 52], "obj_tok_span": [24, 33]}], "umls_entity_list": []}, {"text": "However , the T790M mutation may exist in only a small fraction of tumor cells before drug treatment , and the tumor cells harboring this mutation may be enriched over time during treatment with gefitinib or erlotinib .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [195, 204], "tok_span": [37, 41]}, {"name": "T790M", "ent_type": "variant", "char_span": [14, 19], "tok_span": [3, 7]}, {"name": "erlotinib", "ent_type": "drug", "char_span": [208, 217], "tok_span": [42, 46]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [14, 19], "obj_char_span": [195, 204], "rel_type": "resistance or non-response", "sbj_tok_span": [3, 7], "obj_tok_span": [37, 41]}, {"subject": "T790M", "object": "erlotinib", "sbj_char_span": [14, 19], "obj_char_span": [208, 217], "rel_type": "resistance or non-response", "sbj_tok_span": [3, 7], "obj_tok_span": [42, 46]}], "umls_entity_list": []}, {"text": "MPR expression induced by gefitinib can facilitate NK cell cytotoxicity in human lung cancer cells with EGFR L858R + T790M resistance mutation .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [26, 35], "tok_span": [5, 9]}, {"name": "T790M", "ent_type": "variant", "char_span": [117, 122], "tok_span": [26, 30]}, {"name": "L858R", "ent_type": "variant", "char_span": [109, 114], "tok_span": [21, 25]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [117, 122], "obj_char_span": [26, 35], "rel_type": "resistance or non-response", "sbj_tok_span": [26, 30], "obj_tok_span": [5, 9]}, {"subject": "L858R", "object": "gefitinib", "sbj_char_span": [109, 114], "obj_char_span": [26, 35], "rel_type": "sensitivity", "sbj_tok_span": [21, 25], "obj_tok_span": [5, 9]}], "umls_entity_list": []}, {"text": "Our results suggest that making use of immunoregulatory property of gefitinib may be a potential new therapeutical option for lung cancer with EGFR L858 + T790M resistance mutation .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [68, 77], "tok_span": [13, 17]}, {"name": "T790M", "ent_type": "variant", "char_span": [155, 160], "tok_span": [34, 38]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [155, 160], "obj_char_span": [68, 77], "rel_type": "resistance or non-response", "sbj_tok_span": [34, 38], "obj_tok_span": [13, 17]}], "umls_entity_list": []}, {"text": "Gefitinib enhanced cytotoxicity of NK cells in human lung cancer cells with EGFR L858R + T790M mutation", "entity_list": [{"name": "Gefitinib", "ent_type": "drug", "char_span": [0, 9], "tok_span": [0, 3]}, {"name": "T790M", "ent_type": "variant", "char_span": [89, 94], "tok_span": [20, 24]}, {"name": "L858R", "ent_type": "variant", "char_span": [81, 86], "tok_span": [15, 19]}], "relation_list": [{"subject": "T790M", "object": "Gefitinib", "sbj_char_span": [89, 94], "obj_char_span": [0, 9], "rel_type": "resistance or non-response", "sbj_tok_span": [20, 24], "obj_tok_span": [0, 3]}, {"subject": "L858R", "object": "Gefitinib", "sbj_char_span": [81, 86], "obj_char_span": [0, 9], "rel_type": "sensitivity", "sbj_tok_span": [15, 19], "obj_tok_span": [0, 3]}], "umls_entity_list": []}, {"text": "As to H1975 with L858R + T790M , gefitinib significantly improved NK cells cytotxicity ( Figure", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [33, 42], "tok_span": [16, 20]}, {"name": "T790M", "ent_type": "variant", "char_span": [25, 30], "tok_span": [11, 15]}, {"name": "L858R", "ent_type": "variant", "char_span": [17, 22], "tok_span": [6, 10]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [25, 30], "obj_char_span": [33, 42], "rel_type": "resistance or non-response", "sbj_tok_span": [11, 15], "obj_tok_span": [16, 20]}, {"subject": "L858R", "object": "gefitinib", "sbj_char_span": [17, 22], "obj_char_span": [33, 42], "rel_type": "sensitivity", "sbj_tok_span": [6, 10], "obj_tok_span": [16, 20]}], "umls_entity_list": []}, {"text": "Those results suggested that gefitinib enhanced cytotoxicity of NK cells to human lung cancer with EGFR L858R + T790M .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [29, 38], "tok_span": [4, 8]}, {"name": "T790M", "ent_type": "variant", "char_span": [112, 117], "tok_span": [24, 28]}, {"name": "L858R", "ent_type": "variant", "char_span": [104, 109], "tok_span": [19, 23]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [112, 117], "obj_char_span": [29, 38], "rel_type": "resistance or non-response", "sbj_tok_span": [24, 28], "obj_tok_span": [4, 8]}, {"subject": "L858R", "object": "gefitinib", "sbj_char_span": [104, 109], "obj_char_span": [29, 38], "rel_type": "sensitivity", "sbj_tok_span": [19, 23], "obj_tok_span": [4, 8]}], "umls_entity_list": []}, {"text": "Our results suggested that gefitinib could enhance the ability of NK cell degradulation to lung cancer cells with EGFR L858R + T790M .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [27, 36], "tok_span": [4, 8]}, {"name": "T790M", "ent_type": "variant", "char_span": [127, 132], "tok_span": [28, 32]}, {"name": "L858R", "ent_type": "variant", "char_span": [119, 124], "tok_span": [23, 27]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [127, 132], "obj_char_span": [27, 36], "rel_type": "resistance or non-response", "sbj_tok_span": [28, 32], "obj_tok_span": [4, 8]}, {"subject": "L858R", "object": "gefitinib", "sbj_char_span": [119, 124], "obj_char_span": [27, 36], "rel_type": "sensitivity", "sbj_tok_span": [23, 27], "obj_tok_span": [4, 8]}], "umls_entity_list": []}, {"text": "Collectively , these results suggested that gefitinib and NK cells could up-regulate the MHC-I in human lung cells with wild type EGFR , while not significantly influence the MHC-I expression on human lung cells with wild type EGFR L858R + T790M .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [44, 53], "tok_span": [6, 10]}, {"name": "T790M", "ent_type": "variant", "char_span": [240, 245], "tok_span": [52, 56]}, {"name": "L858R", "ent_type": "variant", "char_span": [232, 237], "tok_span": [47, 51]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [240, 245], "obj_char_span": [44, 53], "rel_type": "resistance or non-response", "sbj_tok_span": [52, 56], "obj_tok_span": [6, 10]}, {"subject": "L858R", "object": "gefitinib", "sbj_char_span": [232, 237], "obj_char_span": [44, 53], "rel_type": "sensitivity", "sbj_tok_span": [47, 51], "obj_tok_span": [6, 10]}], "umls_entity_list": []}, {"text": "Stat3 is a key factor in gefitinib-resistant EGFR T790M cells .", "entity_list": [{"name": "gefitinib-resistant", "ent_type": "drug", "char_span": [25, 44], "tok_span": [7, 13]}, {"name": "T790M", "ent_type": "variant", "char_span": [50, 55], "tok_span": [14, 18]}], "relation_list": [{"subject": "T790M", "object": "gefitinib-resistant", "sbj_char_span": [50, 55], "obj_char_span": [25, 44], "rel_type": "resistance or non-response", "sbj_tok_span": [14, 18], "obj_tok_span": [7, 13]}], "umls_entity_list": []}, {"text": "Though gefitinib can also restore NKG2D ligands and NKG2D interaction , and inhibit stat3 expression , we did not find significant improvement on NK cells cytotoxicity to A549 cells with wild type EGFR , while there was significant enhancement to H1975 cells with EGFR L858R + T790M resistance mutations .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [7, 16], "tok_span": [1, 5]}, {"name": "T790M", "ent_type": "variant", "char_span": [277, 282], "tok_span": [62, 66]}, {"name": "L858R", "ent_type": "variant", "char_span": [269, 274], "tok_span": [57, 61]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [277, 282], "obj_char_span": [7, 16], "rel_type": "resistance or non-response", "sbj_tok_span": [62, 66], "obj_tok_span": [1, 5]}, {"subject": "L858R", "object": "gefitinib", "sbj_char_span": [269, 274], "obj_char_span": [7, 16], "rel_type": "sensitivity", "sbj_tok_span": [57, 61], "obj_tok_span": [1, 5]}], "umls_entity_list": []}, {"text": "Emerging data suggest that patients with NSCLC and EGFR exon 19 deletion have a longer survival following treatment with gefitinib or erlotinib compared with those with the L858R mutation .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [121, 130], "tok_span": [19, 23]}, {"name": "L858R", "ent_type": "variant", "char_span": [173, 178], "tok_span": [33, 37]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [173, 178], "obj_char_span": [121, 130], "rel_type": "sensitivity", "sbj_tok_span": [33, 37], "obj_tok_span": [19, 23]}], "umls_entity_list": []}, {"text": "Although we could not perform an EGFR mutation test at the time of progression after gefitinib retreatment , the patient had another partial response with irreversible EGFR inhibitor , which is believed to overcome secondary resistance to reversible EGFR-TKI related with T790M mutation .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [85, 94], "tok_span": [15, 19]}, {"name": "T790M", "ent_type": "variant", "char_span": [272, 277], "tok_span": [50, 54]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [272, 277], "obj_char_span": [85, 94], "rel_type": "resistance or non-response", "sbj_tok_span": [50, 54], "obj_tok_span": [15, 19]}], "umls_entity_list": []}, {"text": "So , we suggest that the patient had acquired T790M mutation in addition to the original L858R/L861Q after gefitinib retreatment .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [107, 116], "tok_span": [29, 33]}, {"name": "T790M", "ent_type": "variant", "char_span": [46, 51], "tok_span": [9, 13]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [46, 51], "obj_char_span": [107, 116], "rel_type": "resistance or non-response", "sbj_tok_span": [9, 13], "obj_tok_span": [29, 33]}], "umls_entity_list": []}, {"text": "In this study , we show that the combination of a selective MEK inhibitor and a PI3K/mTOR inhibitor is effective against tumor cell lines refractory to gefitinib by three different mechanisms : an EGFR gatekeeper T790M mutation , MET amplification , and KRAS/PIK3CA mutation .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [152, 161], "tok_span": [30, 34]}, {"name": "T790M", "ent_type": "variant", "char_span": [213, 218], "tok_span": [44, 48]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [213, 218], "obj_char_span": [152, 161], "rel_type": "resistance or non-response", "sbj_tok_span": [44, 48], "obj_tok_span": [30, 34]}], "umls_entity_list": []}, {"text": "Gatekeeper mutations , the T790M mutation in EGFR associated with resistance to gefitinib , are common mechanisms by which tumor cells acquire resistance to molecularly targeted drugs .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [80, 89], "tok_span": [17, 21]}, {"name": "T790M", "ent_type": "variant", "char_span": [27, 32], "tok_span": [6, 10]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [27, 32], "obj_char_span": [80, 89], "rel_type": "resistance or non-response", "sbj_tok_span": [6, 10], "obj_tok_span": [17, 21]}], "umls_entity_list": []}, {"text": "This hypothesis may explain the sensitivity to gefitinib of the patients with EGFR L858R mutation .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [47, 56], "tok_span": [7, 11]}, {"name": "L858R", "ent_type": "variant", "char_span": [83, 88], "tok_span": [16, 20]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [83, 88], "obj_char_span": [47, 56], "rel_type": "sensitivity", "sbj_tok_span": [16, 20], "obj_tok_span": [7, 11]}], "umls_entity_list": []}, {"text": "Adenocarcinoma of esophagogastric junction rarely presents EGFR mutation , especially gefitinib associated mutations such as L858R , or delE746-A750 .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [86, 95], "tok_span": [13, 17]}, {"name": "L858R", "ent_type": "variant", "char_span": [125, 130], "tok_span": [21, 25]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [125, 130], "obj_char_span": [86, 95], "rel_type": "sensitivity", "sbj_tok_span": [21, 25], "obj_tok_span": [13, 17]}], "umls_entity_list": []}, {"text": "This change leads to substitution of methionine for threonine at position 790 ( T790M ) and is associated with acquired resistance to gefitinib and erlotinib .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [134, 143], "tok_span": [27, 31]}, {"name": "T790M", "ent_type": "variant", "char_span": [80, 85], "tok_span": [15, 19]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [80, 85], "obj_char_span": [134, 143], "rel_type": "resistance or non-response", "sbj_tok_span": [15, 19], "obj_tok_span": [27, 31]}], "umls_entity_list": []}, {"text": "The first is the appearance of a `` resistance '' point mutation in the kinase domain ( T790M ) , observed in 50 % of the gefitinib-resistant patients .", "entity_list": [{"name": "gefitinib-resistant", "ent_type": "drug", "char_span": [122, 141], "tok_span": [31, 37]}, {"name": "T790M", "ent_type": "variant", "char_span": [88, 93], "tok_span": [19, 23]}], "relation_list": [{"subject": "T790M", "object": "gefitinib-resistant", "sbj_char_span": [88, 93], "obj_char_span": [122, 141], "rel_type": "resistance or non-response", "sbj_tok_span": [19, 23], "obj_tok_span": [31, 37]}], "umls_entity_list": []}, {"text": "The mechanism of H1975 resistance to gefitinib is due to T790M mutation , whereas that of PC9-IR , which was selected from parental PC9 cells that had been continuously exposed to increasing concentrations of gefitinib , could be associated with persistent activation of ERK pathway , .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [37, 46], "tok_span": [8, 12]}, {"name": "T790M", "ent_type": "variant", "char_span": [57, 62], "tok_span": [15, 19]}, {"name": "gefitinib", "ent_type": "drug", "char_span": [209, 218], "tok_span": [46, 50]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [57, 62], "obj_char_span": [37, 46], "rel_type": "resistance or non-response", "sbj_tok_span": [15, 19], "obj_tok_span": [8, 12]}, {"subject": "T790M", "object": "gefitinib", "sbj_char_span": [57, 62], "obj_char_span": [209, 218], "rel_type": "resistance or non-response", "sbj_tok_span": [15, 19], "obj_tok_span": [46, 50]}], "umls_entity_list": []}, {"text": "T790M ● erlotinib MET amplification ● gefitinib", "entity_list": [{"name": "● gefitinib", "ent_type": "drug", "char_span": [36, 47], "tok_span": [11, 16]}, {"name": "T790M", "ent_type": "variant", "char_span": [0, 5], "tok_span": [0, 4]}, {"name": "● erlotinib", "ent_type": "drug", "char_span": [6, 17], "tok_span": [4, 9]}], "relation_list": [{"subject": "T790M", "object": "● gefitinib", "sbj_char_span": [0, 5], "obj_char_span": [36, 47], "rel_type": "resistance or non-response", "sbj_tok_span": [0, 4], "obj_tok_span": [11, 16]}, {"subject": "T790M", "object": "● erlotinib", "sbj_char_span": [0, 5], "obj_char_span": [6, 17], "rel_type": "resistance or non-response", "sbj_tok_span": [0, 4], "obj_tok_span": [4, 9]}], "umls_entity_list": []}, {"text": "What is remarkable is that the H1975 cell line harbors the T790M and L858R mutations in the HER1 gene ( information obtained from the Sanger Institute website ) , which confer resistance to HER1 kinase inhibitors , Gefitinib and Erlotinib , responded to the irreversible HER1 kinase inhibitor BIBW-2992 .", "entity_list": [{"name": "Gefitinib", "ent_type": "drug", "char_span": [215, 224], "tok_span": [49, 52]}, {"name": "T790M", "ent_type": "variant", "char_span": [59, 64], "tok_span": [14, 18]}, {"name": "L858R", "ent_type": "variant", "char_span": [69, 74], "tok_span": [19, 23]}], "relation_list": [{"subject": "T790M", "object": "Gefitinib", "sbj_char_span": [59, 64], "obj_char_span": [215, 224], "rel_type": "resistance or non-response", "sbj_tok_span": [14, 18], "obj_tok_span": [49, 52]}, {"subject": "L858R", "object": "Gefitinib", "sbj_char_span": [69, 74], "obj_char_span": [215, 224], "rel_type": "sensitivity", "sbj_tok_span": [19, 23], "obj_tok_span": [49, 52]}], "umls_entity_list": []}, {"text": "Moreover , the irreversible HER1/2 kinase inhibitor , BIBW-2992 , was also able to potently inhibit the growth of the H1975 cell line , which harbored the T790M and L858R mutations in the HER1 gene and thus rendering the cells resistant to Gefitinib and Lapatinib treatment .", "entity_list": [{"name": "Gefitinib", "ent_type": "drug", "char_span": [240, 249], "tok_span": [60, 63]}, {"name": "T790M", "ent_type": "variant", "char_span": [155, 160], "tok_span": [38, 42]}, {"name": "L858R", "ent_type": "variant", "char_span": [165, 170], "tok_span": [43, 47]}], "relation_list": [{"subject": "T790M", "object": "Gefitinib", "sbj_char_span": [155, 160], "obj_char_span": [240, 249], "rel_type": "resistance or non-response", "sbj_tok_span": [38, 42], "obj_tok_span": [60, 63]}, {"subject": "L858R", "object": "Gefitinib", "sbj_char_span": [165, 170], "obj_char_span": [240, 249], "rel_type": "sensitivity", "sbj_tok_span": [43, 47], "obj_tok_span": [60, 63]}], "umls_entity_list": []}, {"text": "Results of DNA Sanger sequencing of PCR products of exons 18–21 from H2170 and H358 parental and resistant cells showed no secondary erlotinib/gefitinib T790M or D761Y resistance point mutations .", "entity_list": [{"name": "secondary erlotinib/gefitinib", "ent_type": "drug", "char_span": [123, 152], "tok_span": [28, 38]}, {"name": "erlotinib/gefitinib T790M", "ent_type": "variant", "char_span": [133, 158], "tok_span": [29, 42]}], "relation_list": [{"subject": "erlotinib/gefitinib T790M", "object": "secondary erlotinib/gefitinib", "sbj_char_span": [133, 158], "obj_char_span": [123, 152], "rel_type": "resistance or non-response", "sbj_tok_span": [29, 42], "obj_tok_span": [28, 38]}], "umls_entity_list": []}, {"text": "In this present study , erlotinib- and gefitinib-resistant cell lines were established from two human lung cancer cell lines , PC9 cells harboring delE746-A750 mutation and 11–18 cells harboring L858R mutation , respectively .", "entity_list": [{"name": "erlotinib-", "ent_type": "drug", "char_span": [24, 34], "tok_span": [5, 10]}, {"name": "harboring L858R", "ent_type": "variant", "char_span": [185, 200], "tok_span": [47, 52]}], "relation_list": [{"subject": "harboring L858R", "object": "erlotinib-", "sbj_char_span": [185, 200], "obj_char_span": [24, 34], "rel_type": "sensitivity", "sbj_tok_span": [47, 52], "obj_tok_span": [5, 10]}], "umls_entity_list": []}, {"text": "To isolate erlotinib-resistant cell lines from PC9 cells harboring delE746-A750 , and from 11–18 cells harboring L858R , both cell lines were cultured in stepwise increasing doses of erlotinib from 0.05 to 10 µM , for approximately 6 months , as described previously .", "entity_list": [{"name": "erlotinib-resistant", "ent_type": "drug", "char_span": [11, 30], "tok_span": [2, 8]}, {"name": "harboring L858R", "ent_type": "variant", "char_span": [103, 118], "tok_span": [30, 35]}, {"name": "of erlotinib", "ent_type": "drug", "char_span": [180, 192], "tok_span": [45, 50]}], "relation_list": [{"subject": "harboring L858R", "object": "erlotinib-resistant", "sbj_char_span": [103, 118], "obj_char_span": [11, 30], "rel_type": "sensitivity", "sbj_tok_span": [30, 35], "obj_tok_span": [2, 8]}, {"subject": "harboring L858R", "object": "of erlotinib", "sbj_char_span": [103, 118], "obj_char_span": [180, 192], "rel_type": "sensitivity", "sbj_tok_span": [30, 35], "obj_tok_span": [45, 50]}], "umls_entity_list": []}, {"text": "Erlotinib blocked L858R induced pAkt at 10 nM , and caused relocation of the ectopic protein into fibrils at 100 nM . ", "entity_list": [{"name": "Erlotinib", "ent_type": "drug", "char_span": [0, 9], "tok_span": [0, 3]}, {"name": "L858R", "ent_type": "variant", "char_span": [18, 23], "tok_span": [4, 8]}], "relation_list": [{"subject": "L858R", "object": "Erlotinib", "sbj_char_span": [18, 23], "obj_char_span": [0, 9], "rel_type": "sensitivity", "sbj_tok_span": [4, 8], "obj_tok_span": [0, 3]}], "umls_entity_list": []}, {"text": "Images show that YFP-EGFR T790M did not effectively induce phosphorylation of endogenous Akt in MCF-7 cells , and did not relocate into fibrils upon erlotinib treatment .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [149, 158], "tok_span": [34, 38]}, {"name": "T790M", "ent_type": "variant", "char_span": [26, 31], "tok_span": [7, 11]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [26, 31], "obj_char_span": [149, 158], "rel_type": "resistance or non-response", "sbj_tok_span": [7, 11], "obj_tok_span": [34, 38]}], "umls_entity_list": []}, {"text": "Importantly , the wild type protein formed fibrils only at 10 μM erlotinib , whereas the TKI-sensitive mutants relocated to fibrils in the presence of 10–100 nM erlotinib , and this effect was fully abrogated by the erlotinib-resistant T790M mutation .", "entity_list": [{"name": "μM erlotinib", "ent_type": "drug", "char_span": [62, 74], "tok_span": [11, 17]}, {"name": "erlotinib-resistant T790M", "ent_type": "variant", "char_span": [216, 241], "tok_span": [53, 63]}, {"name": "nM erlotinib", "ent_type": "drug", "char_span": [158, 170], "tok_span": [37, 42]}, {"name": "the erlotinib-resistant", "ent_type": "drug", "char_span": [212, 235], "tok_span": [52, 59]}], "relation_list": [{"subject": "erlotinib-resistant T790M", "object": "μM erlotinib", "sbj_char_span": [216, 241], "obj_char_span": [62, 74], "rel_type": "resistance or non-response", "sbj_tok_span": [53, 63], "obj_tok_span": [11, 17]}, {"subject": "erlotinib-resistant T790M", "object": "nM erlotinib", "sbj_char_span": [216, 241], "obj_char_span": [158, 170], "rel_type": "resistance or non-response", "sbj_tok_span": [53, 63], "obj_tok_span": [37, 42]}, {"subject": "erlotinib-resistant T790M", "object": "the erlotinib-resistant", "sbj_char_span": [216, 241], "obj_char_span": [212, 235], "rel_type": "resistance or non-response", "sbj_tok_span": [53, 63], "obj_tok_span": [52, 59]}], "umls_entity_list": []}, {"text": "Consistent with the increased sensitivity to gefitinib and erlotinib of patient tumors harboring the missense mutations or exon 19 deletions , anchorage independent growth of cells expressing L858R , G719S , or L747_E749del A750P was inhibited by 100 nM erlotinib ( A and B ) or gefitinib ( B and unpublished data ) , although the G719S mutant may be somewhat more resistant to gefitinib ( A and unpublished data ) , consistent with other in vitro studies .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [59, 68], "tok_span": [11, 15]}, {"name": "L858R", "ent_type": "variant", "char_span": [192, 197], "tok_span": [35, 39]}, {"name": "erlotinib", "ent_type": "drug", "char_span": [254, 263], "tok_span": [63, 67]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [192, 197], "obj_char_span": [59, 68], "rel_type": "sensitivity", "sbj_tok_span": [35, 39], "obj_tok_span": [11, 15]}, {"subject": "L858R", "object": "erlotinib", "sbj_char_span": [192, 197], "obj_char_span": [254, 263], "rel_type": "sensitivity", "sbj_tok_span": [35, 39], "obj_tok_span": [63, 67]}], "umls_entity_list": []}, {"text": "( B ) Number of colonies formed in soft agar by clonal NIH-3T3 cells expressing L858R EGFR and D770_N771insNPG EGFR treated with the indicated concentrations of gefitinib or erlotinib immediately prior to suspension in soft agar .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [174, 183], "tok_span": [47, 51]}, {"name": "L858R", "ent_type": "variant", "char_span": [80, 85], "tok_span": [19, 23]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [80, 85], "obj_char_span": [174, 183], "rel_type": "sensitivity", "sbj_tok_span": [19, 23], "obj_tok_span": [47, 51]}], "umls_entity_list": []}, {"text": "This compound was previously found to be active against EGFR containing the exon 20 point mutation T790M , associated with resistance to gefitinib and erlotinib .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [151, 160], "tok_span": [30, 34]}, {"name": "T790M", "ent_type": "variant", "char_span": [99, 104], "tok_span": [16, 20]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [99, 104], "obj_char_span": [151, 160], "rel_type": "resistance or non-response", "sbj_tok_span": [16, 20], "obj_tok_span": [30, 34]}], "umls_entity_list": []}, {"text": "The T790M secondary mutation is not necessary for erlotinib resistance", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [50, 59], "tok_span": [11, 15]}, {"name": "T790M", "ent_type": "variant", "char_span": [4, 9], "tok_span": [1, 5]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [4, 9], "obj_char_span": [50, 59], "rel_type": "resistance or non-response", "sbj_tok_span": [1, 5], "obj_tok_span": [11, 15]}], "umls_entity_list": []}, {"text": "Resistant cells did not display either the T790M or D761Y mutations , suggesting the use of an alternative signaling mechanism to overcome erlotinib susceptibility .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [139, 148], "tok_span": [29, 33]}, {"name": "T790M", "ent_type": "variant", "char_span": [43, 48], "tok_span": [8, 12]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [43, 48], "obj_char_span": [139, 148], "rel_type": "resistance or non-response", "sbj_tok_span": [8, 12], "obj_tok_span": [29, 33]}], "umls_entity_list": []}, {"text": "In vitro studies demonstrated that the effective concentration of erlotinib in tumour cells harbouring both the L858R and T790M mutations has to be 300 times higher to induce apoptosis than in cells only with an activating mutation in codon 858 .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [66, 75], "tok_span": [9, 13]}, {"name": "L858R", "ent_type": "variant", "char_span": [112, 117], "tok_span": [21, 25]}, {"name": "T790M", "ent_type": "variant", "char_span": [122, 127], "tok_span": [26, 30]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [112, 117], "obj_char_span": [66, 75], "rel_type": "sensitivity", "sbj_tok_span": [21, 25], "obj_tok_span": [9, 13]}, {"subject": "T790M", "object": "erlotinib", "sbj_char_span": [122, 127], "obj_char_span": [66, 75], "rel_type": "resistance or non-response", "sbj_tok_span": [26, 30], "obj_tok_span": [9, 13]}], "umls_entity_list": []}, {"text": "In case of occurrence of both L858R and T790M mutations , the concentration of erlotinib should be three times higher in order to achieve a therapeutic effect .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [79, 88], "tok_span": [20, 24]}, {"name": "L858R", "ent_type": "variant", "char_span": [30, 35], "tok_span": [6, 10]}, {"name": "T790M", "ent_type": "variant", "char_span": [40, 45], "tok_span": [11, 15]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [30, 35], "obj_char_span": [79, 88], "rel_type": "sensitivity", "sbj_tok_span": [6, 10], "obj_tok_span": [20, 24]}, {"subject": "T790M", "object": "erlotinib", "sbj_char_span": [40, 45], "obj_char_span": [79, 88], "rel_type": "resistance or non-response", "sbj_tok_span": [11, 15], "obj_tok_span": [20, 24]}], "umls_entity_list": []}, {"text": "Presence of T790M substitution may be an indication for treatment with irreversible EGFR TKI , such as neratinib , keratinib and especially afatinib , which is currently in the third phase of clinical trials . ", "entity_list": [{"name": "T790M", "ent_type": "variant", "char_span": [12, 17], "tok_span": [2, 6]}, {"name": "afatinib", "ent_type": "drug", "char_span": [140, 148], "tok_span": [30, 32]}], "relation_list": [{"subject": "T790M", "object": "afatinib", "sbj_char_span": [12, 17], "obj_char_span": [140, 148], "rel_type": "response", "sbj_tok_span": [2, 6], "obj_tok_span": [30, 32]}], "umls_entity_list": []}, {"text": "T790M mutation in EGFR gene seems to be one of the most important genetic abnormalities involving the resistance for reversible epidermal growth factor receptor tyrosine kinases inhibitors ( EGFR-TKI ) —erlotinib and gefitinib in NSCLC patients . ", "entity_list": [{"name": "—erlotinib", "ent_type": "drug", "char_span": [202, 212], "tok_span": [36, 41]}, {"name": "T790M", "ent_type": "variant", "char_span": [0, 5], "tok_span": [0, 4]}], "relation_list": [{"subject": "T790M", "object": "—erlotinib", "sbj_char_span": [0, 5], "obj_char_span": [202, 212], "rel_type": "resistance or non-response", "sbj_tok_span": [0, 4], "obj_tok_span": [36, 41]}], "umls_entity_list": []}, {"text": "Identification of a Novel Secondary Resistant EGFR Mutation , L747S ( A ) Sequencing chromatograms with the EGFR L747S exon 19 and L858R exon 21 by RT-PCR . ( B ) Amino acid alignments of the tyrosine kinase domain in EGFR , ErbB2 , and ABL1 . ( C ) Active conformation crystal structure of the kinase domain of EGFR in complex with erlotinib .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [333, 342], "tok_span": [81, 85]}, {"name": "L858R", "ent_type": "variant", "char_span": [131, 136], "tok_span": [30, 34]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [131, 136], "obj_char_span": [333, 342], "rel_type": "sensitivity", "sbj_tok_span": [30, 34], "obj_tok_span": [81, 85]}], "umls_entity_list": []}, {"text": "Second-generation TKIs that irreversibly inhibit the EGFR TKI domain may offer the potential for overcoming the resistance of T790M mutation to erlotinib and gefitinib .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [144, 153], "tok_span": [30, 34]}, {"name": "T790M", "ent_type": "variant", "char_span": [126, 131], "tok_span": [24, 28]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [126, 131], "obj_char_span": [144, 153], "rel_type": "resistance or non-response", "sbj_tok_span": [24, 28], "obj_tok_span": [30, 34]}], "umls_entity_list": []}, {"text": "The T790M mutation is rarely found in tumors from patients not treated with either gefitinib or erlotinib , and could be discovered only in progressing tumors , in addition to a primary drug-sensitive mutation in EGFR .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [96, 105], "tok_span": [22, 26]}, {"name": "T790M", "ent_type": "variant", "char_span": [4, 9], "tok_span": [1, 5]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [4, 9], "obj_char_span": [96, 105], "rel_type": "resistance or non-response", "sbj_tok_span": [1, 5], "obj_tok_span": [22, 26]}], "umls_entity_list": []}, {"text": "In addition , the presence of common activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) gene ( exon 19 deletion and exon 21 L858R mutation ) confers strong sensitivity to gefitinib and erlotinib , which are selective tyrosine kinase inhibitors of EGFR .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [232, 241], "tok_span": [46, 50]}, {"name": "L858R", "ent_type": "variant", "char_span": [171, 176], "tok_span": [31, 35]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [171, 176], "obj_char_span": [232, 241], "rel_type": "sensitivity", "sbj_tok_span": [31, 35], "obj_tok_span": [46, 50]}], "umls_entity_list": []}, {"text": "This event is analogous to replacement of threonine 790 with methionine ( T790M ) in erlotinib-resistant lung adenocarcinoma .", "entity_list": [{"name": "erlotinib-resistant", "ent_type": "drug", "char_span": [85, 104], "tok_span": [20, 26]}, {"name": "T790M", "ent_type": "variant", "char_span": [74, 79], "tok_span": [14, 18]}], "relation_list": [{"subject": "T790M", "object": "erlotinib-resistant", "sbj_char_span": [74, 79], "obj_char_span": [85, 104], "rel_type": "resistance or non-response", "sbj_tok_span": [14, 18], "obj_tok_span": [20, 26]}], "umls_entity_list": []}, {"text": "This behavior is consistent with clinical observations in which 100 % of patients who initially respond to erlotinib develop acquired resistance , often mediated by a T790M mutation .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [107, 116], "tok_span": [17, 21]}, {"name": "T790M", "ent_type": "variant", "char_span": [167, 172], "tok_span": [29, 33]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [167, 172], "obj_char_span": [107, 116], "rel_type": "resistance or non-response", "sbj_tok_span": [29, 33], "obj_tok_span": [17, 21]}], "umls_entity_list": []}, {"text": "Somatic mutations included two different EGFR mutations : an activating mutation in a dominant tumor clone as well as a second T790M mutation present in an erlotinib-resistant subclone .", "entity_list": [{"name": "erlotinib-resistant", "ent_type": "drug", "char_span": [156, 175], "tok_span": [30, 36]}, {"name": "T790M", "ent_type": "variant", "char_span": [127, 132], "tok_span": [22, 26]}], "relation_list": [{"subject": "T790M", "object": "erlotinib-resistant", "sbj_char_span": [127, 132], "obj_char_span": [156, 175], "rel_type": "resistance or non-response", "sbj_tok_span": [22, 26], "obj_tok_span": [30, 36]}], "umls_entity_list": []}, {"text": "In this study , we report that BMS-690514 has in vivo efficacy on a panel of NSLCC xenografts , including those with T790M mutations , conferring resistance to EGFR therapies such as Erlotinib or Gefitinib .", "entity_list": [{"name": "Erlotinib", "ent_type": "drug", "char_span": [183, 192], "tok_span": [44, 47]}, {"name": "T790M", "ent_type": "variant", "char_span": [117, 122], "tok_span": [30, 34]}], "relation_list": [{"subject": "T790M", "object": "Erlotinib", "sbj_char_span": [117, 122], "obj_char_span": [183, 192], "rel_type": "resistance or non-response", "sbj_tok_span": [30, 34], "obj_tok_span": [44, 47]}], "umls_entity_list": []}, {"text": "Sensitive detection methods have identified a proportion of tyrosin- kinase- naive tumors that carry T790M , a resistant tumor cell clones that may be selected during the exposure to gefitinib or erlotinib .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [196, 205], "tok_span": [42, 46]}, {"name": "T790M", "ent_type": "variant", "char_span": [101, 106], "tok_span": [19, 23]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [101, 106], "obj_char_span": [196, 205], "rel_type": "resistance or non-response", "sbj_tok_span": [19, 23], "obj_tok_span": [42, 46]}], "umls_entity_list": []}, {"text": "Kim and colleagues demonstrated that the combination of lapatinib with cetuximab overcame gefitinib resistance due to the secondary T790M mutation in NSCLC by inducing enhanced cytotoxicity both in vitro and in vivo .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [71, 80], "tok_span": [12, 16]}, {"name": "T790M", "ent_type": "variant", "char_span": [132, 137], "tok_span": [28, 32]}], "relation_list": [{"subject": "T790M", "object": "cetuximab", "sbj_char_span": [132, 137], "obj_char_span": [71, 80], "rel_type": "response", "sbj_tok_span": [28, 32], "obj_tok_span": [12, 16]}], "umls_entity_list": []}, {"text": "To test whether G719S and G724S EGFR mutants are cetuximab-sensitive in vitro , we ectopically expressed these mutants in Ba/F3 cells , rendering these cells IL-3 independent but dependent on exogenous oncogenic EGFR signaling .", "entity_list": [{"name": "cetuximab-sensitive", "ent_type": "drug", "char_span": [49, 68], "tok_span": [15, 21]}, {"name": "G719S", "ent_type": "variant", "char_span": [16, 21], "tok_span": [3, 7]}, {"name": "G724S", "ent_type": "variant", "char_span": [26, 31], "tok_span": [8, 12]}], "relation_list": [{"subject": "G719S", "object": "cetuximab-sensitive", "sbj_char_span": [16, 21], "obj_char_span": [49, 68], "rel_type": "sensitivity", "sbj_tok_span": [3, 7], "obj_tok_span": [15, 21]}, {"subject": "G724S", "object": "cetuximab-sensitive", "sbj_char_span": [26, 31], "obj_char_span": [49, 68], "rel_type": "sensitivity", "sbj_tok_span": [8, 12], "obj_tok_span": [15, 21]}], "umls_entity_list": []}, {"text": "( A ) Cetuximab suppresses the growth of Ba/F3 cells dependent upon the G719S and G724S mutants , but not control cells .", "entity_list": [{"name": "Cetuximab", "ent_type": "drug", "char_span": [6, 15], "tok_span": [3, 6]}, {"name": "G719S", "ent_type": "variant", "char_span": [72, 77], "tok_span": [18, 22]}, {"name": "G724S", "ent_type": "variant", "char_span": [82, 87], "tok_span": [23, 27]}], "relation_list": [{"subject": "G719S", "object": "Cetuximab", "sbj_char_span": [72, 77], "obj_char_span": [6, 15], "rel_type": "sensitivity", "sbj_tok_span": [18, 22], "obj_tok_span": [3, 6]}, {"subject": "G724S", "object": "Cetuximab", "sbj_char_span": [82, 87], "obj_char_span": [6, 15], "rel_type": "sensitivity", "sbj_tok_span": [23, 27], "obj_tok_span": [3, 6]}], "umls_entity_list": []}, {"text": "Taken together , we found that G719S and G724S mutants are oncogenic in the absence of ligand stimulation and effectively respond to cetuximab in vivo and in vitro .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [133, 142], "tok_span": [28, 32]}, {"name": "G719S", "ent_type": "variant", "char_span": [31, 36], "tok_span": [6, 10]}, {"name": "G724S", "ent_type": "variant", "char_span": [41, 46], "tok_span": [11, 15]}], "relation_list": [{"subject": "G719S", "object": "cetuximab", "sbj_char_span": [31, 36], "obj_char_span": [133, 142], "rel_type": "sensitivity", "sbj_tok_span": [6, 10], "obj_tok_span": [28, 32]}, {"subject": "G724S", "object": "cetuximab", "sbj_char_span": [41, 46], "obj_char_span": [133, 142], "rel_type": "sensitivity", "sbj_tok_span": [11, 15], "obj_tok_span": [28, 32]}], "umls_entity_list": []}, {"text": "Dimerization impairing cis mutations in EGFR , L704N and I941R , significantly reduced the ability of the cetuximab-sensitive G719S and G724S mutants to promote colony formation upon retroviral transduction ( Figure", "entity_list": [{"name": "cetuximab-sensitive", "ent_type": "drug", "char_span": [106, 125], "tok_span": [26, 32]}, {"name": "G719S", "ent_type": "variant", "char_span": [126, 131], "tok_span": [32, 36]}, {"name": "G724S", "ent_type": "variant", "char_span": [136, 141], "tok_span": [37, 41]}], "relation_list": [{"subject": "G719S", "object": "cetuximab-sensitive", "sbj_char_span": [126, 131], "obj_char_span": [106, 125], "rel_type": "sensitivity", "sbj_tok_span": [32, 36], "obj_tok_span": [26, 32]}, {"subject": "G724S", "object": "cetuximab-sensitive", "sbj_char_span": [136, 141], "obj_char_span": [106, 125], "rel_type": "sensitivity", "sbj_tok_span": [37, 41], "obj_tok_span": [26, 32]}], "umls_entity_list": []}, {"text": "Recent data have suggested that tumors with specific KRAS mutations , especially the glycine-to-aspartate mutation in codon 13 ( G13D ) mutation , may be sensitive to cetuximab or panitumumab .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [167, 176], "tok_span": [35, 39]}, {"name": "G13D", "ent_type": "variant", "char_span": [129, 133], "tok_span": [25, 28]}], "relation_list": [{"subject": "G13D", "object": "cetuximab", "sbj_char_span": [129, 133], "obj_char_span": [167, 176], "rel_type": "resistance or non-response", "sbj_tok_span": [25, 28], "obj_tok_span": [35, 39]}], "umls_entity_list": []}, {"text": "The combination of afatinib and cetuximab can even overcome resistance due to the T790M mutation both preclinically as well as clinically .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [32, 41], "tok_span": [6, 10]}, {"name": "T790M", "ent_type": "variant", "char_span": [82, 87], "tok_span": [17, 21]}], "relation_list": [{"subject": "T790M", "object": "cetuximab", "sbj_char_span": [82, 87], "obj_char_span": [32, 41], "rel_type": "response", "sbj_tok_span": [17, 21], "obj_tok_span": [6, 10]}], "umls_entity_list": []}, {"text": "Materials and Methods 49 individual specimens of 21 metastatic CRCs and corresponding metastases collected before and after combined therapy with cetuximab were examined using CGH , certified PCR/DNA sequencing protocols ( KRAS exon 2 , Gl12/13 ; BRAF exon 15 , V600E ) as well as allele-specific PCR .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [146, 155], "tok_span": [21, 25]}, {"name": "V600E", "ent_type": "variant", "char_span": [262, 267], "tok_span": [52, 55]}], "relation_list": [{"subject": "V600E", "object": "cetuximab", "sbj_char_span": [262, 267], "obj_char_span": [146, 155], "rel_type": "resistance or non-response", "sbj_tok_span": [52, 55], "obj_tok_span": [21, 25]}], "umls_entity_list": []}, {"text": "20 of 21 patients show concordance of the KRAS ( exon 2 , Gly 12/13 ) and BRAF ( exon 15 , V600E ) mutation status between samples of primary CRCs and/or corresponding metastases before and after combined cetuximab therapy .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [205, 214], "tok_span": [46, 50]}, {"name": "V600E", "ent_type": "variant", "char_span": [91, 96], "tok_span": [25, 28]}], "relation_list": [{"subject": "V600E", "object": "cetuximab", "sbj_char_span": [91, 96], "obj_char_span": [205, 214], "rel_type": "resistance or non-response", "sbj_tok_span": [25, 28], "obj_tok_span": [46, 50]}], "umls_entity_list": []}, {"text": "The patient was offered off-label sorafenib ( to inhibit B-RAF V600E ) and cetuximab ( to inhibit ERBB1 signaling ) .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [75, 84], "tok_span": [21, 25]}, {"name": "V600E", "ent_type": "variant", "char_span": [63, 68], "tok_span": [16, 19]}], "relation_list": [{"subject": "V600E", "object": "cetuximab", "sbj_char_span": [63, 68], "obj_char_span": [75, 84], "rel_type": "resistance or non-response", "sbj_tok_span": [16, 19], "obj_tok_span": [21, 25]}], "umls_entity_list": []}, {"text": "Cells of the colorectal cancer line HT-29 have a mutated BRAF gene ( V600E ) and are relatively resistant to cytotoxicity by anti-EGFR antibody cetuximab . ", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [144, 153], "tok_span": [30, 34]}, {"name": "V600E", "ent_type": "variant", "char_span": [69, 74], "tok_span": [15, 18]}], "relation_list": [{"subject": "V600E", "object": "cetuximab", "sbj_char_span": [69, 74], "obj_char_span": [144, 153], "rel_type": "resistance or non-response", "sbj_tok_span": [15, 18], "obj_tok_span": [30, 34]}], "umls_entity_list": []}, {"text": "Others stabilise the active conformation of the receptor , which also prevents imatinib binding ( D820Y and N822K ) .", "entity_list": [{"name": "imatinib", "ent_type": "drug", "char_span": [79, 87], "tok_span": [13, 15]}, {"name": "D820Y", "ent_type": "variant", "char_span": [98, 103], "tok_span": [17, 21]}], "relation_list": [{"subject": "D820Y", "object": "imatinib", "sbj_char_span": [98, 103], "obj_char_span": [79, 87], "rel_type": "response", "sbj_tok_span": [17, 21], "obj_tok_span": [13, 15]}], "umls_entity_list": []}, {"text": "GIST-T1R cells were generated by chronic , intermittent culture with imatinib , which resulted in the acquisition of an exon 13 mutation at KIT V654A .", "entity_list": [{"name": "imatinib", "ent_type": "drug", "char_span": [69, 77], "tok_span": [15, 17]}, {"name": "V654A", "ent_type": "variant", "char_span": [144, 149], "tok_span": [31, 35]}], "relation_list": [{"subject": "V654A", "object": "imatinib", "sbj_char_span": [144, 149], "obj_char_span": [69, 77], "rel_type": "resistance", "sbj_tok_span": [31, 35], "obj_tok_span": [15, 17]}], "umls_entity_list": []}, {"text": "Some mutations ( L755S ) resulted in lapatinib resistance ; however this was not an activating mutation .", "entity_list": [{"name": "lapatinib", "ent_type": "drug", "char_span": [37, 46], "tok_span": [10, 13]}, {"name": "L755S", "ent_type": "variant", "char_span": [17, 22], "tok_span": [3, 7]}], "relation_list": [{"subject": "L755S", "object": "lapatinib", "sbj_char_span": [17, 22], "obj_char_span": [37, 46], "rel_type": "resistance or non-response", "sbj_tok_span": [3, 7], "obj_tok_span": [10, 13]}], "umls_entity_list": []}, {"text": "The PDGFRA exon 18 D842V point mutant activates PDGFRA both in vitro and in vivo and is also imatinib resistant in vivo and in vitro , whereas other mutations affecting exon 18 ( D846Y , N848K , Y849K and HDSN845-848P ) are imatinib sensitive .", "entity_list": [{"name": "imatinib", "ent_type": "drug", "char_span": [93, 101], "tok_span": [23, 25]}, {"name": "D842V", "ent_type": "variant", "char_span": [19, 24], "tok_span": [5, 9]}, {"name": "imatinib", "ent_type": "drug", "char_span": [224, 232], "tok_span": [64, 66]}], "relation_list": [{"subject": "D842V", "object": "imatinib", "sbj_char_span": [19, 24], "obj_char_span": [93, 101], "rel_type": "resistance or non-response", "sbj_tok_span": [5, 9], "obj_tok_span": [23, 25]}, {"subject": "D842V", "object": "imatinib", "sbj_char_span": [19, 24], "obj_char_span": [224, 232], "rel_type": "resistance or non-response", "sbj_tok_span": [5, 9], "obj_tok_span": [64, 66]}], "umls_entity_list": []}, {"text": "These data emphasize that mutational status must play a predominant role in the clinical management of patients and that new findings are necessary to establish the mechanisms responsible for imatinib resistance in specific subsets of tumors like PDGFRA D842V mutant and WT GIST .", "entity_list": [{"name": "imatinib", "ent_type": "drug", "char_span": [192, 200], "tok_span": [30, 32]}, {"name": "D842V", "ent_type": "variant", "char_span": [254, 259], "tok_span": [41, 45]}], "relation_list": [{"subject": "D842V", "object": "imatinib", "sbj_char_span": [254, 259], "obj_char_span": [192, 200], "rel_type": "resistance or non-response", "sbj_tok_span": [41, 45], "obj_tok_span": [30, 32]}], "umls_entity_list": []}, {"text": "Imatinib has been found to be effective not only for GIST with C-KIT mutations but also for GIST with PDGFRA mutations and for wild-type GISTs. , However , no adjuvant treatment is recommended in GISTs with the D842V missense mutation in the PDGFRA exon 18 , which are known to be unresponsive to imatinib and showed very favorable outcome after surgery .", "entity_list": [{"name": "Imatinib", "ent_type": "drug", "char_span": [0, 8], "tok_span": [0, 2]}, {"name": "D842V", "ent_type": "variant", "char_span": [211, 216], "tok_span": [49, 53]}, {"name": "imatinib", "ent_type": "drug", "char_span": [297, 305], "tok_span": [72, 74]}], "relation_list": [{"subject": "D842V", "object": "Imatinib", "sbj_char_span": [211, 216], "obj_char_span": [0, 8], "rel_type": "resistance or non-response", "sbj_tok_span": [49, 53], "obj_tok_span": [0, 2]}, {"subject": "D842V", "object": "imatinib", "sbj_char_span": [211, 216], "obj_char_span": [297, 305], "rel_type": "resistance or non-response", "sbj_tok_span": [49, 53], "obj_tok_span": [72, 74]}], "umls_entity_list": []}, {"text": "As for PDGFRA mutated GIST , PDGFRA exon 18 generally benefits from adjuvant imatinib therapy , with the exception of PDGFRA exon 18 D842V mutated GIST .", "entity_list": [{"name": "imatinib", "ent_type": "drug", "char_span": [77, 85], "tok_span": [16, 18]}, {"name": "D842V", "ent_type": "variant", "char_span": [133, 138], "tok_span": [28, 32]}], "relation_list": [{"subject": "D842V", "object": "imatinib", "sbj_char_span": [133, 138], "obj_char_span": [77, 85], "rel_type": "resistance or non-response", "sbj_tok_span": [28, 32], "obj_tok_span": [16, 18]}], "umls_entity_list": []}, {"text": "The PDGFR-α D842V mutant conferred resistance to imatinib as well as to sunitinib in in vitro experiments .", "entity_list": [{"name": "to imatinib", "ent_type": "drug", "char_span": [46, 57], "tok_span": [13, 16]}, {"name": "PDGFR-α D842V", "ent_type": "variant", "char_span": [4, 17], "tok_span": [1, 9]}], "relation_list": [{"subject": "PDGFR-α D842V", "object": "to imatinib", "sbj_char_span": [4, 17], "obj_char_span": [46, 57], "rel_type": "resistance or non-response", "sbj_tok_span": [1, 9], "obj_tok_span": [13, 16]}], "umls_entity_list": []}, {"text": "When tested in Ba/F3 cells driven by ALK mutants identified in crizotinib relapsed patients , NMS-E628 is circa fivefold more potent than crizotinib in inhibiting the proliferation of L1196M ALK and C1156Y ALK-driven-cells in vitro and in vivo ( Ardini et al. , ) .", "entity_list": [{"name": "crizotinib", "ent_type": "drug", "char_span": [63, 73], "tok_span": [15, 19]}, {"name": "L1196M", "ent_type": "variant", "char_span": [184, 190], "tok_span": [46, 50]}, {"name": "crizotinib", "ent_type": "drug", "char_span": [138, 148], "tok_span": [37, 41]}, {"name": "C1156Y", "ent_type": "variant", "char_span": [199, 205], "tok_span": [53, 57]}], "relation_list": [{"subject": "L1196M", "object": "crizotinib", "sbj_char_span": [184, 190], "obj_char_span": [63, 73], "rel_type": "resistance", "sbj_tok_span": [46, 50], "obj_tok_span": [15, 19]}, {"subject": "L1196M", "object": "crizotinib", "sbj_char_span": [184, 190], "obj_char_span": [138, 148], "rel_type": "resistance", "sbj_tok_span": [46, 50], "obj_tok_span": [37, 41]}, {"subject": "C1156Y", "object": "crizotinib", "sbj_char_span": [199, 205], "obj_char_span": [63, 73], "rel_type": "resistance", "sbj_tok_span": [53, 57], "obj_tok_span": [15, 19]}, {"subject": "C1156Y", "object": "crizotinib", "sbj_char_span": [199, 205], "obj_char_span": [138, 148], "rel_type": "resistance", "sbj_tok_span": [53, 57], "obj_tok_span": [37, 41]}], "umls_entity_list": []}, {"text": "LDK378 appears very efficacious in vivo , inducing complete and durable tumor regression in an ALK positive NSCLC dependent model and was also described to be active in tumors bearing the C1156Y mutation that confers crizotinib resistance ( Li et al. , ) .", "entity_list": [{"name": "crizotinib", "ent_type": "drug", "char_span": [217, 227], "tok_span": [43, 47]}, {"name": "C1156Y", "ent_type": "variant", "char_span": [188, 194], "tok_span": [36, 40]}], "relation_list": [{"subject": "C1156Y", "object": "crizotinib", "sbj_char_span": [188, 194], "obj_char_span": [217, 227], "rel_type": "resistance", "sbj_tok_span": [36, 40], "obj_tok_span": [43, 47]}], "umls_entity_list": []}, {"text": "In contrast to crizotinib , alectinib also shows substantial inhibitory activity against the L1196M mutant of ALK , apparently because it is able to maintain an efficient ( CH/π ) interaction with position 1196 even after the substitution of methionine for leucine .", "entity_list": [{"name": "crizotinib", "ent_type": "drug", "char_span": [15, 25], "tok_span": [3, 7]}, {"name": "L1196M", "ent_type": "variant", "char_span": [93, 99], "tok_span": [18, 22]}], "relation_list": [{"subject": "L1196M", "object": "crizotinib", "sbj_char_span": [93, 99], "obj_char_span": [15, 25], "rel_type": "resistance", "sbj_tok_span": [18, 22], "obj_tok_span": [3, 7]}], "umls_entity_list": []}, {"text": "However , while ceritinib is able to effectively suppress many crizotinib-resistant mutations , the G1202R and F1174V/C mutants are resistant to ceritinib .", "entity_list": [{"name": "crizotinib-resistant", "ent_type": "drug", "char_span": [63, 83], "tok_span": [12, 18]}, {"name": "G1202R", "ent_type": "variant", "char_span": [100, 106], "tok_span": [21, 25]}], "relation_list": [{"subject": "G1202R", "object": "crizotinib-resistant", "sbj_char_span": [100, 106], "obj_char_span": [63, 83], "rel_type": "resistance", "sbj_tok_span": [21, 25], "obj_tok_span": [12, 18]}], "umls_entity_list": []}, {"text": "Compared to erlotinib and gefitinib , afatinib shows lower EC50 values and greater potency against wild type ( afatinib vs erlotinib vs gefitinib : 60 nM vs 110 nM vs 157 nM ) and L858R mutated EGFR ( afatinib vs erlotinib vs gefitinib : 0.7 nM vs 40 nM vs 5 nM ) .", "entity_list": [{"name": "afatinib", "ent_type": "drug", "char_span": [38, 46], "tok_span": [12, 14]}, {"name": "L858R", "ent_type": "variant", "char_span": [180, 185], "tok_span": [49, 53]}, {"name": "afatinib", "ent_type": "drug", "char_span": [111, 119], "tok_span": [26, 28]}, {"name": "afatinib", "ent_type": "drug", "char_span": [201, 209], "tok_span": [56, 58]}], "relation_list": [{"subject": "L858R", "object": "afatinib", "sbj_char_span": [180, 185], "obj_char_span": [38, 46], "rel_type": "sensitivity", "sbj_tok_span": [49, 53], "obj_tok_span": [12, 14]}, {"subject": "L858R", "object": "afatinib", "sbj_char_span": [180, 185], "obj_char_span": [111, 119], "rel_type": "sensitivity", "sbj_tok_span": [49, 53], "obj_tok_span": [26, 28]}, {"subject": "L858R", "object": "afatinib", "sbj_char_span": [180, 185], "obj_char_span": [201, 209], "rel_type": "sensitivity", "sbj_tok_span": [49, 53], "obj_tok_span": [56, 58]}], "umls_entity_list": []}, {"text": "Moreover , afatinib is able to inhibit the kinase activity in vitro and in animal models when a resistant T790M mutation is concomitant to a sensitivity mutation .", "entity_list": [{"name": "afatinib", "ent_type": "drug", "char_span": [11, 19], "tok_span": [2, 4]}, {"name": "T790M", "ent_type": "variant", "char_span": [106, 111], "tok_span": [20, 24]}], "relation_list": [{"subject": "T790M", "object": "afatinib", "sbj_char_span": [106, 111], "obj_char_span": [11, 19], "rel_type": "response", "sbj_tok_span": [20, 24], "obj_tok_span": [2, 4]}], "umls_entity_list": []}, {"text": "In addition , afatinib should be active in patients with the T790M mutation and in those with HER2 amplification , representing 60 % –70 % of the resistant population .", "entity_list": [{"name": "afatinib", "ent_type": "drug", "char_span": [14, 22], "tok_span": [3, 5]}, {"name": "T790M", "ent_type": "variant", "char_span": [61, 66], "tok_span": [12, 16]}], "relation_list": [{"subject": "T790M", "object": "afatinib", "sbj_char_span": [61, 66], "obj_char_span": [14, 22], "rel_type": "response", "sbj_tok_span": [12, 16], "obj_tok_span": [3, 5]}], "umls_entity_list": []}, {"text": "Both cDzT and BIBW-2992 alone inhibited growth and signaling in EGFR T790M mutant cells ( H1975TM/LR and CL97TM/GA ) , albeit through different mechanisms .", "entity_list": [{"name": "BIBW-2992", "ent_type": "drug", "char_span": [14, 23], "tok_span": [6, 11]}, {"name": "T790M", "ent_type": "variant", "char_span": [69, 74], "tok_span": [18, 22]}], "relation_list": [{"subject": "T790M", "object": "BIBW-2992", "sbj_char_span": [69, 74], "obj_char_span": [14, 23], "rel_type": "response", "sbj_tok_span": [18, 22], "obj_tok_span": [6, 11]}], "umls_entity_list": []}, {"text": "cDzT cleaves EGFR T790M mRNA , which leads to a decrease in EGFR protein levels , whereas BIBW-2992 is a second-line TKI that irreversibly binds to the intracellular kinase domain of EGFR and suppresses its downstream signaling .", "entity_list": [{"name": "BIBW-2992", "ent_type": "drug", "char_span": [90, 99], "tok_span": [24, 29]}, {"name": "T790M", "ent_type": "variant", "char_span": [18, 23], "tok_span": [7, 11]}], "relation_list": [{"subject": "T790M", "object": "BIBW-2992", "sbj_char_span": [18, 23], "obj_char_span": [90, 99], "rel_type": "response", "sbj_tok_span": [7, 11], "obj_tok_span": [24, 29]}], "umls_entity_list": []}, {"text": "H1975 cancer cell line with mutations in EGFR exons 21 ( L858R ) and 20 ( T790M ) was refractory to reversible EGFR-TKIs , gefitinib , and erlotinib , but was sensitive to irreversible EGFR-TKIs , such as BIBW2992 ( afatinib ) .", "entity_list": [{"name": "afatinib", "ent_type": "drug", "char_span": [216, 224], "tok_span": [63, 65]}, {"name": "L858R", "ent_type": "variant", "char_span": [57, 62], "tok_span": [13, 17]}, {"name": "T790M", "ent_type": "variant", "char_span": [74, 79], "tok_span": [21, 25]}], "relation_list": [{"subject": "L858R", "object": "afatinib", "sbj_char_span": [57, 62], "obj_char_span": [216, 224], "rel_type": "sensitivity", "sbj_tok_span": [13, 17], "obj_tok_span": [63, 65]}, {"subject": "T790M", "object": "afatinib", "sbj_char_span": [74, 79], "obj_char_span": [216, 224], "rel_type": "response", "sbj_tok_span": [21, 25], "obj_tok_span": [63, 65]}], "umls_entity_list": []}, {"text": "The ability of irreversible pan-HER inhibitors such as afatinib and dacomitinib to overcome T790M mediated resistance to gefitinib has been demonstrated in some preclinical studies ; therefore , they are being actively investigated .", "entity_list": [{"name": "afatinib", "ent_type": "drug", "char_span": [55, 63], "tok_span": [10, 12]}, {"name": "T790M", "ent_type": "variant", "char_span": [92, 97], "tok_span": [19, 23]}], "relation_list": [{"subject": "T790M", "object": "afatinib", "sbj_char_span": [92, 97], "obj_char_span": [55, 63], "rel_type": "response", "sbj_tok_span": [19, 23], "obj_tok_span": [10, 12]}], "umls_entity_list": []}, {"text": "Kim et al. demonstrated a role for the IL-6R/JAK1/STAT3 signaling pathway , leading to STAT3 activation , in de novo resistance to irreversible EGFR-TKIs , such as afatinib , in NSCLC cells with EGFR T790M .", "entity_list": [{"name": "afatinib", "ent_type": "drug", "char_span": [164, 172], "tok_span": [41, 43]}, {"name": "T790M", "ent_type": "variant", "char_span": [200, 205], "tok_span": [49, 53]}], "relation_list": [{"subject": "T790M", "object": "afatinib", "sbj_char_span": [200, 205], "obj_char_span": [164, 172], "rel_type": "response", "sbj_tok_span": [49, 53], "obj_tok_span": [41, 43]}], "umls_entity_list": []}, {"text": "Second-generation EGFR TKIs – such as neratinib , afatinib and dacomitinib – are effective in preclinical gefitinib- and erlotinib-resistant EGFR T790M models , but to date their delivery in EGFR TKI-resistant patients have shown disappointing results in the clinic .", "entity_list": [{"name": ", afatinib", "ent_type": "drug", "char_span": [48, 58], "tok_span": [13, 16]}, {"name": "EGFR T790M", "ent_type": "variant", "char_span": [141, 151], "tok_span": [38, 43]}], "relation_list": [{"subject": "EGFR T790M", "object": ", afatinib", "sbj_char_span": [141, 151], "obj_char_span": [48, 58], "rel_type": "response", "sbj_tok_span": [38, 43], "obj_tok_span": [13, 16]}], "umls_entity_list": []}, {"text": "A subgroup analysis of progression-free survival in sporadic MTC patients suggested that RET M918T mutation positive patients had a higher response rate to vandetanib compared with RET M918T mutation negative patients. ,", "entity_list": [{"name": "vandetanib", "ent_type": "drug", "char_span": [156, 166], "tok_span": [29, 33]}, {"name": "M918T", "ent_type": "variant", "char_span": [93, 98], "tok_span": [16, 20]}], "relation_list": [{"subject": "M918T", "object": "vandetanib", "sbj_char_span": [93, 98], "obj_char_span": [156, 166], "rel_type": "response", "sbj_tok_span": [16, 20], "obj_tok_span": [29, 33]}], "umls_entity_list": []}, {"text": "KIT W557R V559A/D L576P K642E D816H 23 % Acral 16 % Mucosal 28 % CSD , , Sensitive to : Imatinib Nilotinib Sunitinib Dasatinib Decreased sensitivity to : Imatinib ( D816H only ) , , , ,", "entity_list": [{"name": "Nilotinib", "ent_type": "drug", "char_span": [97, 106], "tok_span": [44, 48]}, {"name": "L576P", "ent_type": "variant", "char_span": [18, 23], "tok_span": [12, 16]}], "relation_list": [{"subject": "L576P", "object": "Nilotinib", "sbj_char_span": [18, 23], "obj_char_span": [97, 106], "rel_type": "resistance or non-response", "sbj_tok_span": [12, 16], "obj_tok_span": [44, 48]}], "umls_entity_list": []}, {"text": "Ponatinib inhibits growth and induces apoptosis in K562 and T315I mutant cells", "entity_list": [{"name": "Ponatinib", "ent_type": "drug", "char_span": [0, 9], "tok_span": [0, 2]}, {"name": "T315I", "ent_type": "variant", "char_span": [60, 65], "tok_span": [12, 16]}], "relation_list": [{"subject": "T315I", "object": "Ponatinib", "sbj_char_span": [60, 65], "obj_char_span": [0, 9], "rel_type": "response", "sbj_tok_span": [12, 16], "obj_tok_span": [0, 2]}], "umls_entity_list": []}, {"text": "It has been reported that ponatinib has potent activity against T315I mutant cells .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [26, 35], "tok_span": [5, 9]}, {"name": "T315I", "ent_type": "variant", "char_span": [64, 69], "tok_span": [13, 17]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [64, 69], "obj_char_span": [26, 35], "rel_type": "response", "sbj_tok_span": [13, 17], "obj_tok_span": [5, 9]}], "umls_entity_list": []}, {"text": "In concordance with previously reported results , ponatinib inhibited growth in Ba/F3 T315I cells at low concentrations ( ) .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [50, 59], "tok_span": [7, 11]}, {"name": "T315I", "ent_type": "variant", "char_span": [86, 91], "tok_span": [18, 22]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [86, 91], "obj_char_span": [50, 59], "rel_type": "response", "sbj_tok_span": [18, 22], "obj_tok_span": [7, 11]}], "umls_entity_list": []}, {"text": "( D ) Ba/F3 T315I cells were treated with ponatinib for 24 h , and total extracts were examined by immunoblot analysis with anti-phospho ABL , anti-Crk-L , anti cleaved caspase 3 , anti-PARP , and anti-tubulin antibodies .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [42, 51], "tok_span": [15, 19]}, {"name": "T315I", "ent_type": "variant", "char_span": [12, 17], "tok_span": [7, 11]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [12, 17], "obj_char_span": [42, 51], "rel_type": "response", "sbj_tok_span": [7, 11], "obj_tok_span": [15, 19]}], "umls_entity_list": []}, {"text": "( B ) K562 or Ba/F3 T315I cells were treated with ponatinib and/or vorinostat for 24 h , and total extracts were examined by immunoblot analysis with anti-phospho ABL , Crk-L , γH2A.X , cleaved caspase 3 , PARP , acetyl histone H4 , and tubulin antibodies .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [50, 59], "tok_span": [19, 23]}, {"name": "T315I", "ent_type": "variant", "char_span": [20, 25], "tok_span": [11, 15]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [20, 25], "obj_char_span": [50, 59], "rel_type": "response", "sbj_tok_span": [11, 15], "obj_tok_span": [19, 23]}], "umls_entity_list": []}, {"text": "Thus , co-treatment with ponatinib and vorinostat inhibited tumor growth and induced apoptosis in T315I positive Ba/F3 cells in the xenograft .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [25, 34], "tok_span": [6, 10]}, {"name": "T315I", "ent_type": "variant", "char_span": [98, 103], "tok_span": [22, 26]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [98, 103], "obj_char_span": [25, 34], "rel_type": "response", "sbj_tok_span": [22, 26], "obj_tok_span": [6, 10]}], "umls_entity_list": []}, {"text": "Since vorinostat was effective against T315I mutant cells , we investigated whether ponatinib-resistant cells were inhibited by this HDACi .", "entity_list": [{"name": "ponatinib-resistant", "ent_type": "drug", "char_span": [84, 103], "tok_span": [18, 24]}, {"name": "T315I", "ent_type": "variant", "char_span": [39, 44], "tok_span": [8, 12]}], "relation_list": [{"subject": "T315I", "object": "ponatinib-resistant", "sbj_char_span": [39, 44], "obj_char_span": [84, 103], "rel_type": "response", "sbj_tok_span": [8, 12], "obj_tok_span": [18, 24]}], "umls_entity_list": []}, {"text": "Vorinostat induced growth arrest and apoptosis , thus aggravating the apoptotic and cytotoxic effects of ponatinib on Ba/F3 T315I mutant cells .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [105, 114], "tok_span": [19, 23]}, {"name": "T315I", "ent_type": "variant", "char_span": [124, 129], "tok_span": [28, 32]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [124, 129], "obj_char_span": [105, 114], "rel_type": "response", "sbj_tok_span": [28, 32], "obj_tok_span": [19, 23]}], "umls_entity_list": []}, {"text": "However , no mechanistic explanation has been found for the contributions of these molecules to the gefitinib sensitivity of the L858R mutation .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [100, 109], "tok_span": [16, 20]}, {"name": "L858R", "ent_type": "variant", "char_span": [129, 134], "tok_span": [23, 27]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [129, 134], "obj_char_span": [100, 109], "rel_type": "sensitivity", "sbj_tok_span": [23, 27], "obj_tok_span": [16, 20]}], "umls_entity_list": []}, {"text": "We confirmed that L858R model A with other parameter sets that have similar cost function values yields the same trends with regard to the role of Mig6 in gefitinib sensitivity ( data not shown ) .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [155, 164], "tok_span": [33, 37]}, {"name": "L858R", "ent_type": "variant", "char_span": [18, 23], "tok_span": [3, 7]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [18, 23], "obj_char_span": [155, 164], "rel_type": "sensitivity", "sbj_tok_span": [3, 7], "obj_tok_span": [33, 37]}], "umls_entity_list": []}, {"text": "after 1st PS Response PFS to 2nd TKI OS from 2nd TKI 1 50 F Current Ad NA 9.8 G→E 7.9 CBDCA+GEM 1 PD 0.9 13.1 2 46 F Never Ad NA 11.8 G→G 4.5 DOC1 PR 6.4 24.6 3 58 F Ex Ad 19 deletion 38.4 G→G 2.8 DOC1 SD 7.3 24.1 4 70 F Never Sq NA 10.2 G→E12.8 GEM 1 SD 1.7 4.3 5 60 F Never Ad NA 13 G→G 5.4 GEM 1 PD1.6 2.1 6 63 F Never Ad NA 7.4 G→E 2.6 - 3 SD 3.6 7.8 7 52 M Never Ad L858R 5.8 G→E1 - 4 SD 6.4 6.4 8 51 M Current Ad NA 4.3 G→E1.6 AMR 3 PD 0.6 0.9 9 61 F Never Ad NA 8.5 G→E 2.3 VNR 3 SD 2.9 4 10 53 F Never Ad NA 12.9 G→E 0 - 4 SD 6.2 7.3 11 54 M Current Ad 19 deletion 3.8 G→E 7.3 VNR 1 SD 3.2 5 Response to the initial gefitinib treatment During the 1st EGFR-TKI treatment with gefitinib , 8 patients achieved PR as the best response ( 73 % , Table ) , and 3 patients ( 27 % ) were SD .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [683, 692], "tok_span": [306, 310]}, {"name": "Never Ad", "ent_type": "variant", "char_span": [362, 370], "tok_span": [171, 173]}], "relation_list": [{"subject": "Never Ad", "object": "gefitinib", "sbj_char_span": [362, 370], "obj_char_span": [683, 692], "rel_type": "sensitivity", "sbj_tok_span": [171, 173], "obj_tok_span": [306, 310]}], "umls_entity_list": []}, {"text": "These T790M mutation seemed to be the cause of gefitinib resistance .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [47, 56], "tok_span": [12, 16]}, {"name": "T790M", "ent_type": "variant", "char_span": [6, 11], "tok_span": [1, 5]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [6, 11], "obj_char_span": [47, 56], "rel_type": "resistance or non-response", "sbj_tok_span": [1, 5], "obj_tok_span": [12, 16]}], "umls_entity_list": []}, {"text": "These missense ( G719S/C and L858R ) and deletion mutations ( in the region spanning codons 746-759 ) are located in exons 18 through 21 of EGFR and appear to confer tumor susceptibility to gefitinib .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [190, 199], "tok_span": [47, 51]}, {"name": "L858R", "ent_type": "variant", "char_span": [29, 34], "tok_span": [11, 15]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [29, 34], "obj_char_span": [190, 199], "rel_type": "sensitivity", "sbj_tok_span": [11, 15], "obj_tok_span": [47, 51]}], "umls_entity_list": []}, {"text": "Further , patients with nonsmall cell lung cancer who initially responded to erlotinib or gefitinib therapy showed progression after a median of 12–13 months. , After patients developed acquired resistance confirmed on medical imaging , continuing use of erlotinib or gefitinib would lead to a surge in the rate of EGFR T790M mutation which , in vitro , conferred resistance to treatment with erlotinib and gefitinib .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [90, 99], "tok_span": [19, 23]}, {"name": "EGFR T790M", "ent_type": "variant", "char_span": [315, 325], "tok_span": [67, 72]}, {"name": "or gefitinib", "ent_type": "drug", "char_span": [265, 277], "tok_span": [53, 58]}, {"name": "and gefitinib", "ent_type": "drug", "char_span": [403, 416], "tok_span": [88, 93]}], "relation_list": [{"subject": "EGFR T790M", "object": "gefitinib", "sbj_char_span": [315, 325], "obj_char_span": [90, 99], "rel_type": "resistance or non-response", "sbj_tok_span": [67, 72], "obj_tok_span": [19, 23]}, {"subject": "EGFR T790M", "object": "or gefitinib", "sbj_char_span": [315, 325], "obj_char_span": [265, 277], "rel_type": "resistance or non-response", "sbj_tok_span": [67, 72], "obj_tok_span": [53, 58]}, {"subject": "EGFR T790M", "object": "and gefitinib", "sbj_char_span": [315, 325], "obj_char_span": [403, 416], "rel_type": "resistance or non-response", "sbj_tok_span": [67, 72], "obj_tok_span": [88, 93]}], "umls_entity_list": []}, {"text": "Contrarily , a point mutation in the EGFR gene , which results in the substitution of methionine for threonine at position 790 ( T790M ) , decreases the ability of erlotinib or gefitinib to inhibit EGFR .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [177, 186], "tok_span": [41, 45]}, {"name": "T790M", "ent_type": "variant", "char_span": [129, 134], "tok_span": [26, 30]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [129, 134], "obj_char_span": [177, 186], "rel_type": "resistance or non-response", "sbj_tok_span": [26, 30], "obj_tok_span": [41, 45]}], "umls_entity_list": []}, {"text": "In vitro studies showed that exon 19 deleted mutants and L858R mutant receptors appear to be more sensitive to gefitinib inhibition as compared to wild type receptors .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [111, 120], "tok_span": [22, 26]}, {"name": "L858R", "ent_type": "variant", "char_span": [57, 62], "tok_span": [10, 14]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [57, 62], "obj_char_span": [111, 120], "rel_type": "sensitivity", "sbj_tok_span": [10, 14], "obj_tok_span": [22, 26]}], "umls_entity_list": []}, {"text": "Several studies have reported that advanced NSCLC patients with EGFR exon 19 deletion had a longer overall survival ( OS ) and/or progression-free survival ( PFS ) following treatment with gefitinib or erlotinib compared with those with the L858R mutation , , , but this result has not been shown in all reports , , , , .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [189, 198], "tok_span": [34, 38]}, {"name": "L858R", "ent_type": "variant", "char_span": [241, 246], "tok_span": [48, 52]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [241, 246], "obj_char_span": [189, 198], "rel_type": "sensitivity", "sbj_tok_span": [48, 52], "obj_tok_span": [34, 38]}], "umls_entity_list": []}, {"text": "The possibility of detection of T790M mutation in EGFR-TKIs naive patients forces to expand the diagnostics of EGFR gene status during qualification for erlotinib or gefitinib treatment and to consider the new therapy modalities in carriers of this mutation .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [166, 175], "tok_span": [35, 39]}, {"name": "T790M", "ent_type": "variant", "char_span": [32, 37], "tok_span": [5, 9]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [32, 37], "obj_char_span": [166, 175], "rel_type": "resistance or non-response", "sbj_tok_span": [5, 9], "obj_tok_span": [35, 39]}], "umls_entity_list": []}, {"text": "Direct measurement of the binding affinity of gefitinib to the wild type and mutant kinases revealed that gefitinib binds the L858R mutant 20-fold more tightly than the wild-type kinase .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [46, 55], "tok_span": [7, 11]}, {"name": "L858R", "ent_type": "variant", "char_span": [126, 131], "tok_span": [26, 30]}, {"name": "gefitinib", "ent_type": "drug", "char_span": [106, 115], "tok_span": [20, 24]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [126, 131], "obj_char_span": [46, 55], "rel_type": "sensitivity", "sbj_tok_span": [26, 30], "obj_tok_span": [7, 11]}, {"subject": "L858R", "object": "gefitinib", "sbj_char_span": [126, 131], "obj_char_span": [106, 115], "rel_type": "sensitivity", "sbj_tok_span": [26, 30], "obj_tok_span": [20, 24]}], "umls_entity_list": []}, {"text": "In this study , we examined whether the selective KOR agonist U50 ,488H could inhibit the growth of gefitinib-sensitive and EGFR mutant ( delE746-A750 , L858R ) NSCLC cells ( HCC827 ) and gefitinib-resistant and EGFR mutant ( T790M ) NSCLC cells ( H1975 ) , and investigated the signalling mechanism of the KOR mediated inhibitory effect on tumour cell growth .", "entity_list": [{"name": "gefitinib-sensitive", "ent_type": "drug", "char_span": [100, 119], "tok_span": [22, 28]}, {"name": "T790M", "ent_type": "variant", "char_span": [226, 231], "tok_span": [64, 68]}, {"name": "gefitinib-resistant", "ent_type": "drug", "char_span": [188, 207], "tok_span": [54, 60]}, {"name": "L858R", "ent_type": "variant", "char_span": [153, 158], "tok_span": [41, 45]}], "relation_list": [{"subject": "T790M", "object": "gefitinib-sensitive", "sbj_char_span": [226, 231], "obj_char_span": [100, 119], "rel_type": "resistance or non-response", "sbj_tok_span": [64, 68], "obj_tok_span": [22, 28]}, {"subject": "T790M", "object": "gefitinib-resistant", "sbj_char_span": [226, 231], "obj_char_span": [188, 207], "rel_type": "resistance or non-response", "sbj_tok_span": [64, 68], "obj_tok_span": [54, 60]}, {"subject": "L858R", "object": "gefitinib-sensitive", "sbj_char_span": [153, 158], "obj_char_span": [100, 119], "rel_type": "sensitivity", "sbj_tok_span": [41, 45], "obj_tok_span": [22, 28]}, {"subject": "L858R", "object": "gefitinib-resistant", "sbj_char_span": [153, 158], "obj_char_span": [188, 207], "rel_type": "sensitivity", "sbj_tok_span": [41, 45], "obj_tok_span": [54, 60]}], "umls_entity_list": []}, {"text": "Many of the patients that do relapse often harbor pre existing T790M EGFR mutation at very low levels within the original tumor population , leading to resistance after gefitinib treatment .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [169, 178], "tok_span": [31, 35]}, {"name": "T790M", "ent_type": "variant", "char_span": [63, 68], "tok_span": [11, 15]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [63, 68], "obj_char_span": [169, 178], "rel_type": "resistance or non-response", "sbj_tok_span": [11, 15], "obj_tok_span": [31, 35]}], "umls_entity_list": []}, {"text": "This method has recently been adapted for the detection of T790M EGFR mutation in gefitinib-refractory disease by the use of the PNA “clamp” to inhibit the amplification of wild type DNA , .", "entity_list": [{"name": "gefitinib-refractory", "ent_type": "drug", "char_span": [82, 102], "tok_span": [17, 23]}, {"name": "T790M", "ent_type": "variant", "char_span": [59, 64], "tok_span": [10, 14]}], "relation_list": [{"subject": "T790M", "object": "gefitinib-refractory", "sbj_char_span": [59, 64], "obj_char_span": [82, 102], "rel_type": "resistance or non-response", "sbj_tok_span": [10, 14], "obj_tok_span": [17, 23]}], "umls_entity_list": []}, {"text": "In addition , previous reports showed the presence of signaling cross-activation between MET and EGFR in both A549 and H1975 cells , and both the T790M mutation of EGFR and c-Met amplification are known mechanisms of acquired gefitinib ( TKI ) resistance in lung cancer .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [226, 235], "tok_span": [47, 51]}, {"name": "T790M", "ent_type": "variant", "char_span": [146, 151], "tok_span": [30, 34]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [146, 151], "obj_char_span": [226, 235], "rel_type": "resistance or non-response", "sbj_tok_span": [30, 34], "obj_tok_span": [47, 51]}], "umls_entity_list": []}, {"text": "All of the patients had the EGFR gene mutations in exon 19 ( delE746-A750 ) or exon 21 ( L858R ) , and had received or were receiving gefitinib or erlotinib for treatment against advanced diseases at the blood sampling . ", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [134, 143], "tok_span": [38, 42]}, {"name": "L858R", "ent_type": "variant", "char_span": [89, 94], "tok_span": [26, 30]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [89, 94], "obj_char_span": [134, 143], "rel_type": "sensitivity", "sbj_tok_span": [26, 30], "obj_tok_span": [38, 42]}], "umls_entity_list": []}, {"text": "Second-generation EGFR TKIs – such as neratinib , afatinib and dacomitinib – are effective in preclinical gefitinib- and erlotinib-resistant EGFR T790M models , but to date their delivery in EGFR TKI-resistant patients have shown disappointing results in the clinic . ", "entity_list": [{"name": "preclinical gefitinib-", "ent_type": "drug", "char_span": [94, 116], "tok_span": [25, 31]}, {"name": "EGFR T790M", "ent_type": "variant", "char_span": [141, 151], "tok_span": [38, 43]}], "relation_list": [{"subject": "EGFR T790M", "object": "preclinical gefitinib-", "sbj_char_span": [141, 151], "obj_char_span": [94, 116], "rel_type": "resistance or non-response", "sbj_tok_span": [38, 43], "obj_tok_span": [25, 31]}], "umls_entity_list": []}, {"text": "Erlotinib is an orally bioavailable EGFR inhibitor , which is indicated for first-line treatment of patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 ( L858R ) substitution mutations . ", "entity_list": [{"name": "L858R", "ent_type": "variant", "char_span": [185, 190], "tok_span": [35, 39]}, {"name": "Erlotinib", "ent_type": "drug", "char_span": [0, 9], "tok_span": [0, 3]}], "relation_list": [{"subject": "L858R", "object": "Erlotinib", "sbj_char_span": [185, 190], "obj_char_span": [0, 9], "rel_type": "sensitivity", "sbj_tok_span": [35, 39], "obj_tok_span": [0, 3]}], "umls_entity_list": []}, {"text": "In our case , a biopsy ( ‘re-biopsy’ ) revealed the T790M mutation in the EGFR gene , which was widely known as a second mutation resistant to EGFR TKIs , such as gefitinib and erlotinib .", "entity_list": [{"name": "as gefitinib", "ent_type": "drug", "char_span": [160, 172], "tok_span": [40, 45]}, {"name": "the T790M", "ent_type": "variant", "char_span": [48, 57], "tok_span": [14, 19]}], "relation_list": [{"subject": "the T790M", "object": "as gefitinib", "sbj_char_span": [48, 57], "obj_char_span": [160, 172], "rel_type": "resistance or non-response", "sbj_tok_span": [14, 19], "obj_tok_span": [40, 45]}], "umls_entity_list": []}, {"text": "Introduction : Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors ( TKIs ) such as gefitinib are one of gold standard treatment options for non-small-cell lung cancer ( NSCLC ) patients , which eventually fail due to the acquired resistance and relapse because of the development of secondary activating mutations such as T790M in EGFR .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [99, 108], "tok_span": [19, 23]}, {"name": "T790M", "ent_type": "variant", "char_span": [338, 343], "tok_span": [63, 67]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [338, 343], "obj_char_span": [99, 108], "rel_type": "resistance or non-response", "sbj_tok_span": [63, 67], "obj_tok_span": [19, 23]}], "umls_entity_list": []}, {"text": "In this study , we report that BMS-690514 has in vivo efficacy on a panel of NSLCC xenografts , including those with T790M mutations , conferring resistance to EGFR therapies such as Erlotinib or Gefitinib .", "entity_list": [{"name": "Gefitinib", "ent_type": "drug", "char_span": [196, 205], "tok_span": [48, 51]}, {"name": "T790M", "ent_type": "variant", "char_span": [117, 122], "tok_span": [30, 34]}], "relation_list": [{"subject": "T790M", "object": "Gefitinib", "sbj_char_span": [117, 122], "obj_char_span": [196, 205], "rel_type": "resistance or non-response", "sbj_tok_span": [30, 34], "obj_tok_span": [48, 51]}], "umls_entity_list": []}, {"text": "This change leads to substitution of methionine for threonine at position 790 ( T790M ) and is associated with acquired resistance to gefitinib and erlotinib .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [148, 157], "tok_span": [32, 36]}, {"name": "T790M", "ent_type": "variant", "char_span": [80, 85], "tok_span": [15, 19]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [80, 85], "obj_char_span": [148, 157], "rel_type": "resistance or non-response", "sbj_tok_span": [15, 19], "obj_tok_span": [32, 36]}], "umls_entity_list": []}, {"text": "H1975 cells were insensitive to erlotinib due to the drug-resistant T790M mutation .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [32, 41], "tok_span": [7, 11]}, {"name": "T790M", "ent_type": "variant", "char_span": [68, 73], "tok_span": [17, 21]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [68, 73], "obj_char_span": [32, 41], "rel_type": "resistance or non-response", "sbj_tok_span": [17, 21], "obj_tok_span": [7, 11]}], "umls_entity_list": []}, {"text": "Consistent with this , the H1975 NSCLC cell line reported here to contain both T790M and L858R did not to our knowledge undergo any prior treatment with gefitinib or erlotinib ; the doubly mutated cells must have become dominant over time through multiple passages in vitro .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [166, 175], "tok_span": [40, 44]}, {"name": "L858R", "ent_type": "variant", "char_span": [89, 94], "tok_span": [21, 25]}, {"name": "T790M", "ent_type": "variant", "char_span": [79, 84], "tok_span": [16, 20]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [89, 94], "obj_char_span": [166, 175], "rel_type": "sensitivity", "sbj_tok_span": [21, 25], "obj_tok_span": [40, 44]}, {"subject": "T790M", "object": "erlotinib", "sbj_char_span": [79, 84], "obj_char_span": [166, 175], "rel_type": "resistance or non-response", "sbj_tok_span": [16, 20], "obj_tok_span": [40, 44]}], "umls_entity_list": []}, {"text": "Sequencing Chromatograms with the T790M EGFR Exon 20 Mutation in Various Clinical Specimens and the NSCLC Cell Line H1975 ( A–C ) In all three patients—patient 1 ( A ) , patient 2 ( B ) , and patient 3 ( C ) —the secondary T790M mutation was observed only in lesions obtained after progression on either gefitinib or erlotinib . ( D ) Cell line H1975 contains both an exon 21 L858R mutation ( upper panel ) and the exon 20 T790M mutation ( lower panel ) .", "entity_list": [{"name": "or erlotinib", "ent_type": "drug", "char_span": [314, 326], "tok_span": [78, 83]}, {"name": "L858R", "ent_type": "variant", "char_span": [376, 381], "tok_span": [97, 101]}, {"name": "T790M", "ent_type": "variant", "char_span": [34, 39], "tok_span": [5, 9]}], "relation_list": [{"subject": "L858R", "object": "or erlotinib", "sbj_char_span": [376, 381], "obj_char_span": [314, 326], "rel_type": "sensitivity", "sbj_tok_span": [97, 101], "obj_tok_span": [78, 83]}, {"subject": "T790M", "object": "or erlotinib", "sbj_char_span": [34, 39], "obj_char_span": [314, 326], "rel_type": "resistance or non-response", "sbj_tok_span": [5, 9], "obj_tok_span": [78, 83]}], "umls_entity_list": []}, {"text": "EGFR Mutants Containing the T790M Mutation Are Resistant to Inhibition by Gefitinib or Erlotinib 293T cells were transiently transfected with plasmids encoding wild-type ( WT ) EGFR or EGFR mutants with the following changes : T790M , L858R , L858R + T790M , del L747–E749 ; A750P , or del L747–E749 ; A750P + T790M .", "entity_list": [{"name": "Erlotinib", "ent_type": "drug", "char_span": [87, 96], "tok_span": [21, 24]}, {"name": "L858R", "ent_type": "variant", "char_span": [235, 240], "tok_span": [53, 57]}, {"name": "T790M", "ent_type": "variant", "char_span": [28, 33], "tok_span": [6, 10]}], "relation_list": [{"subject": "L858R", "object": "Erlotinib", "sbj_char_span": [235, 240], "obj_char_span": [87, 96], "rel_type": "sensitivity", "sbj_tok_span": [53, 57], "obj_tok_span": [21, 24]}, {"subject": "T790M", "object": "Erlotinib", "sbj_char_span": [28, 33], "obj_char_span": [87, 96], "rel_type": "resistance or non-response", "sbj_tok_span": [6, 10], "obj_tok_span": [21, 24]}], "umls_entity_list": []}, {"text": "Analogously , the T790M mutation , in conjunction with the drug-responsive del L747–E749 ; A750P EGFR mutant , prevents inhibition of p-EGFR by erlotinib ( C ) . ", "entity_list": [{"name": "by erlotinib", "ent_type": "drug", "char_span": [141, 153], "tok_span": [39, 44]}, {"name": "T790M", "ent_type": "variant", "char_span": [18, 23], "tok_span": [4, 8]}], "relation_list": [{"subject": "T790M", "object": "by erlotinib", "sbj_char_span": [18, 23], "obj_char_span": [141, 153], "rel_type": "resistance or non-response", "sbj_tok_span": [4, 8], "obj_tok_span": [39, 44]}], "umls_entity_list": []}, {"text": "On the other hand , erlotinib could not inhibit EGFR phosphorylation in H1975 cells because the T790M mutation in EGFR causes a conformation change at the ATP binding pocket , thus decreasing the affinity between erlotinib and EGFR .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [20, 29], "tok_span": [5, 9]}, {"name": "T790M", "ent_type": "variant", "char_span": [96, 101], "tok_span": [21, 25]}, {"name": "erlotinib", "ent_type": "drug", "char_span": [213, 222], "tok_span": [43, 47]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [96, 101], "obj_char_span": [20, 29], "rel_type": "resistance or non-response", "sbj_tok_span": [21, 25], "obj_tok_span": [5, 9]}, {"subject": "T790M", "object": "erlotinib", "sbj_char_span": [96, 101], "obj_char_span": [213, 222], "rel_type": "resistance or non-response", "sbj_tok_span": [21, 25], "obj_tok_span": [43, 47]}], "umls_entity_list": []}, {"text": "The best therapy for those who have initially responded to erlotinib and have subsequently lost their response either through development of the T790M mutation or another resistance mechanism , remains another area of active research .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [59, 68], "tok_span": [10, 14]}, {"name": "T790M", "ent_type": "variant", "char_span": [145, 150], "tok_span": [25, 29]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [145, 150], "obj_char_span": [59, 68], "rel_type": "resistance or non-response", "sbj_tok_span": [25, 29], "obj_tok_span": [10, 14]}], "umls_entity_list": []}, {"text": "One of the proposed mechanisms of resistance to gefitinib and erlotinib is the T790M mutation on exon 20 .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [62, 71], "tok_span": [13, 17]}, {"name": "T790M", "ent_type": "variant", "char_span": [79, 84], "tok_span": [19, 23]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [79, 84], "obj_char_span": [62, 71], "rel_type": "resistance or non-response", "sbj_tok_span": [19, 23], "obj_tok_span": [13, 17]}], "umls_entity_list": []}, {"text": "A randomized phase II trial compared erlotinib to erlotinib plus bevacizumab in patients with activating EGFR mutations ( defined as exon 19 deletion and exon 21 L858R point mutations ) and advanced stage NSCLC ( n = 152 ) .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [37, 46], "tok_span": [6, 10]}, {"name": "L858R", "ent_type": "variant", "char_span": [162, 167], "tok_span": [33, 37]}, {"name": "erlotinib", "ent_type": "drug", "char_span": [50, 59], "tok_span": [11, 15]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [162, 167], "obj_char_span": [37, 46], "rel_type": "sensitivity", "sbj_tok_span": [33, 37], "obj_tok_span": [6, 10]}, {"subject": "L858R", "object": "erlotinib", "sbj_char_span": [162, 167], "obj_char_span": [50, 59], "rel_type": "sensitivity", "sbj_tok_span": [33, 37], "obj_tok_span": [11, 15]}], "umls_entity_list": []}, {"text": "A ribbon structure of erlotinib bound to the EGFR kinase domain ( ) shows the threonine residue at position 790 in green and the positions of the exon 19 and L858R gain-of-function mutations .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [22, 31], "tok_span": [5, 9]}, {"name": "L858R", "ent_type": "variant", "char_span": [158, 163], "tok_span": [36, 40]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [158, 163], "obj_char_span": [22, 31], "rel_type": "sensitivity", "sbj_tok_span": [36, 40], "obj_tok_span": [5, 9]}], "umls_entity_list": []}, {"text": "The mechanism of resistance in three patients was acquisition of a T790M substitution in EGFR that was not present at time of diagnosis , but was detected with progression of disease after initial response to gefitinib or erlotinib .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [222, 231], "tok_span": [43, 47]}, {"name": "T790M", "ent_type": "variant", "char_span": [67, 72], "tok_span": [11, 15]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [67, 72], "obj_char_span": [222, 231], "rel_type": "resistance or non-response", "sbj_tok_span": [11, 15], "obj_tok_span": [43, 47]}], "umls_entity_list": []}, {"text": "In addition , only half of this small cohort of patients with NSCLC with clinical resistance to gefitinib or erlotinib had the T790M substitution .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [109, 118], "tok_span": [22, 26]}, {"name": "T790M", "ent_type": "variant", "char_span": [127, 132], "tok_span": [28, 32]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [127, 132], "obj_char_span": [109, 118], "rel_type": "resistance or non-response", "sbj_tok_span": [28, 32], "obj_tok_span": [22, 26]}], "umls_entity_list": []}, {"text": "NSCLC patients harboring exon 19 deletion or exon 21 L858R somatic mutations experience significant tumor regression when prescribed the reversible small molecular tyrosine kinase inhibitors ( TKIs ) such as gefitinib and erlotinib .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [222, 231], "tok_span": [39, 43]}, {"name": "L858R", "ent_type": "variant", "char_span": [53, 58], "tok_span": [9, 13]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [53, 58], "obj_char_span": [222, 231], "rel_type": "sensitivity", "sbj_tok_span": [9, 13], "obj_tok_span": [39, 43]}], "umls_entity_list": []}, {"text": "Indeed , in non-small cell lung cancers treated with gefitinib or erlotinib , sensitive patients have the EGFR T790M mutation in only a few cells , whereas resistant patients exhibit EGFR T790M in the majority of the tumour cells ( ; ) . ", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [66, 75], "tok_span": [16, 20]}, {"name": "T790M", "ent_type": "variant", "char_span": [111, 116], "tok_span": [26, 30]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [111, 116], "obj_char_span": [66, 75], "rel_type": "resistance or non-response", "sbj_tok_span": [26, 30], "obj_tok_span": [16, 20]}], "umls_entity_list": []}, {"text": "The H1975 and H820 cell lines had EGFR T790M mutations in exon 20 , associated with gefitinib and erlotinib resistance .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [98, 107], "tok_span": [28, 32]}, {"name": "T790M", "ent_type": "variant", "char_span": [39, 44], "tok_span": [12, 16]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [39, 44], "obj_char_span": [98, 107], "rel_type": "resistance or non-response", "sbj_tok_span": [12, 16], "obj_tok_span": [28, 32]}], "umls_entity_list": []}, {"text": "Similarly , the gatekeeper mutation T790M in EGFR causes resistance to gefitinib and erlotinib , and has been detected in lung cancer patients before drug treatment and in the germ line of a family pedigree with several cases of lung cancer , .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [85, 94], "tok_span": [21, 25]}, {"name": "T790M", "ent_type": "variant", "char_span": [36, 41], "tok_span": [7, 11]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [36, 41], "obj_char_span": [85, 94], "rel_type": "resistance or non-response", "sbj_tok_span": [7, 11], "obj_tok_span": [21, 25]}], "umls_entity_list": []}, {"text": "In particular , H1975 cells contain a second mutation ( T790M ) reported to be linked to gefitinib resistance , but we found that these cells also responded poorly to cetuximab .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [167, 176], "tok_span": [38, 42]}, {"name": "T790M", "ent_type": "variant", "char_span": [56, 61], "tok_span": [12, 16]}], "relation_list": [{"subject": "T790M", "object": "cetuximab", "sbj_char_span": [56, 61], "obj_char_span": [167, 176], "rel_type": "response", "sbj_tok_span": [12, 16], "obj_tok_span": [38, 42]}], "umls_entity_list": []}, {"text": "In a study by De Roock et al. , a pooled data set of 579 mCRC patients across various clinical trials treated with cetuximab plus/minus chemotherapy demonstrated that overall and progression-free survival was significantly longer in patients with G13D KRAS mutant tumors .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [115, 124], "tok_span": [28, 32]}, {"name": "G13D", "ent_type": "variant", "char_span": [247, 251], "tok_span": [50, 53]}], "relation_list": [{"subject": "G13D", "object": "cetuximab", "sbj_char_span": [247, 251], "obj_char_span": [115, 124], "rel_type": "resistance or non-response", "sbj_tok_span": [50, 53], "obj_tok_span": [28, 32]}], "umls_entity_list": []}, {"text": "This year at ASCO , Tejpar et al. further supported this finding by presenting retrospective analyses of two large phase III multicenter trials ( CRYSTAL and OPUS ) representing 83 patients with G13D KRAS mutant mCRC tumors who had longer overall survival and progression free survival on average post cetuximab treatment then other KRAS mutant subtypes .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [302, 311], "tok_span": [62, 66]}, {"name": "G13D", "ent_type": "variant", "char_span": [195, 199], "tok_span": [40, 43]}], "relation_list": [{"subject": "G13D", "object": "cetuximab", "sbj_char_span": [195, 199], "obj_char_span": [302, 311], "rel_type": "resistance or non-response", "sbj_tok_span": [40, 43], "obj_tok_span": [62, 66]}], "umls_entity_list": []}, {"text": "Furthermore , De Roock and colleagues recently reported that chemotherapy-refractory metastatic colorectal cancers harboring a G13D KRAS mutation were more sensitive to treatment with the epidermal growth factor receptor (EGFR) inhibitor cetuximab compared to tumors with other KRAS mutations .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [238, 247], "tok_span": [39, 43]}, {"name": "G13D", "ent_type": "variant", "char_span": [127, 131], "tok_span": [18, 21]}], "relation_list": [{"subject": "G13D", "object": "cetuximab", "sbj_char_span": [127, 131], "obj_char_span": [238, 247], "rel_type": "resistance or non-response", "sbj_tok_span": [18, 21], "obj_tok_span": [39, 43]}], "umls_entity_list": []}, {"text": "Another approach for T790M mediated resistance is the dual inhibition of EGFR with afatinib and cetuximab , an EGFR blocking antibody resembling the synergistic combination of lapatinib and trastuzumab in ErbB2 positive breast cancer .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [96, 105], "tok_span": [19, 23]}, {"name": "T790M", "ent_type": "variant", "char_span": [21, 26], "tok_span": [3, 7]}], "relation_list": [{"subject": "T790M", "object": "cetuximab", "sbj_char_span": [21, 26], "obj_char_span": [96, 105], "rel_type": "response", "sbj_tok_span": [3, 7], "obj_tok_span": [19, 23]}], "umls_entity_list": []}, {"text": "Relapse in one patient was associated with the detection of the T674I mutation in PDGFRA that confers resistance to imatinib .", "entity_list": [{"name": "imatinib", "ent_type": "drug", "char_span": [116, 124], "tok_span": [24, 26]}, {"name": "T674I", "ent_type": "variant", "char_span": [64, 69], "tok_span": [12, 16]}], "relation_list": [{"subject": "T674I", "object": "imatinib", "sbj_char_span": [64, 69], "obj_char_span": [116, 124], "rel_type": "resistance", "sbj_tok_span": [12, 16], "obj_tok_span": [24, 26]}], "umls_entity_list": []}, {"text": "Treatment of two patients resistant to imatinib with nilotinib was successful. , Another patient intolerant to imatinib responded to nilotinib and dasatinib. , The sensitivity of the T674I mutation to second generation TKIs has been a matter of debate .", "entity_list": [{"name": "imatinib", "ent_type": "drug", "char_span": [39, 47], "tok_span": [6, 8]}, {"name": "T674I", "ent_type": "variant", "char_span": [183, 188], "tok_span": [38, 42]}, {"name": "imatinib", "ent_type": "drug", "char_span": [111, 119], "tok_span": [22, 24]}], "relation_list": [{"subject": "T674I", "object": "imatinib", "sbj_char_span": [183, 188], "obj_char_span": [39, 47], "rel_type": "resistance", "sbj_tok_span": [38, 42], "obj_tok_span": [6, 8]}, {"subject": "T674I", "object": "imatinib", "sbj_char_span": [183, 188], "obj_char_span": [111, 119], "rel_type": "resistance", "sbj_tok_span": [38, 42], "obj_tok_span": [22, 24]}], "umls_entity_list": []}, {"text": "Other small molecules have been tested against imatinib-resistant FIP1L1-PDGFRA T674I .", "entity_list": [{"name": "imatinib-resistant", "ent_type": "drug", "char_span": [47, 65], "tok_span": [7, 11]}, {"name": "T674I", "ent_type": "variant", "char_span": [80, 85], "tok_span": [19, 23]}], "relation_list": [{"subject": "T674I", "object": "imatinib-resistant", "sbj_char_span": [80, 85], "obj_char_span": [47, 65], "rel_type": "resistance", "sbj_tok_span": [19, 23], "obj_tok_span": [7, 11]}], "umls_entity_list": []}, {"text": "Mutation T798M at the gatekeeper residue and an ATP binding site mutation ( L755S and L755P ) showed reduced response to lapatinib , with IC50s of up to 50 times higher relative to wild-type HER2 .", "entity_list": [{"name": "lapatinib", "ent_type": "drug", "char_span": [121, 130], "tok_span": [32, 35]}, {"name": "L755S", "ent_type": "variant", "char_span": [76, 81], "tok_span": [18, 22]}], "relation_list": [{"subject": "L755S", "object": "lapatinib", "sbj_char_span": [76, 81], "obj_char_span": [121, 130], "rel_type": "resistance or non-response", "sbj_tok_span": [18, 22], "obj_tok_span": [32, 35]}], "umls_entity_list": []}, {"text": "These results suggest that acquired resistance to adjuvant imatinib was infrequent , especially since both arms included patients with mutations known to be less sensitive or resistant to imatinib ( e.g. , platelet derived growth factor receptor alpha [PDGFRA ] D842V ) .", "entity_list": [{"name": "imatinib", "ent_type": "drug", "char_span": [59, 67], "tok_span": [8, 10]}, {"name": "D842V", "ent_type": "variant", "char_span": [262, 267], "tok_span": [48, 52]}, {"name": "imatinib", "ent_type": "drug", "char_span": [188, 196], "tok_span": [30, 32]}], "relation_list": [{"subject": "D842V", "object": "imatinib", "sbj_char_span": [262, 267], "obj_char_span": [59, 67], "rel_type": "resistance or non-response", "sbj_tok_span": [48, 52], "obj_tok_span": [8, 10]}, {"subject": "D842V", "object": "imatinib", "sbj_char_span": [262, 267], "obj_char_span": [188, 196], "rel_type": "resistance or non-response", "sbj_tok_span": [48, 52], "obj_tok_span": [30, 32]}], "umls_entity_list": []}, {"text": "KIT W557R V559A/D L576P K642E D816H 23 % Acral 16 % Mucosal 28 % CSD , , Sensitive to : Imatinib Nilotinib Sunitinib Dasatinib Decreased sensitivity to : Imatinib ( D816H only ) , , , ,", "entity_list": [{"name": "Imatinib", "ent_type": "drug", "char_span": [88, 96], "tok_span": [42, 44]}, {"name": "L576P", "ent_type": "variant", "char_span": [18, 23], "tok_span": [12, 16]}, {"name": "Imatinib", "ent_type": "drug", "char_span": [154, 162], "tok_span": [58, 60]}], "relation_list": [{"subject": "L576P", "object": "Imatinib", "sbj_char_span": [18, 23], "obj_char_span": [88, 96], "rel_type": "resistance or non-response", "sbj_tok_span": [12, 16], "obj_tok_span": [42, 44]}, {"subject": "L576P", "object": "Imatinib", "sbj_char_span": [18, 23], "obj_char_span": [154, 162], "rel_type": "resistance or non-response", "sbj_tok_span": [12, 16], "obj_tok_span": [58, 60]}], "umls_entity_list": []}, {"text": "Tumors that harbor BRAF V600E mutations display high radiographic response rates to mutant-specific inhibitors such as PLX4032/RG7204/vemurafinib ( Plexxikon/Roche ) , and GSK2118436 ( GlaxoSmithKline ) , while patients whose tumors have certain KIT mutations ( L576P , K642E , V559A ) have disease sensitive to the KIT inhibitor , imatinib ( ) , , , , , , , , .", "entity_list": [{"name": "imatinib", "ent_type": "drug", "char_span": [332, 340], "tok_span": [94, 96]}, {"name": "L576P", "ent_type": "variant", "char_span": [262, 267], "tok_span": [70, 74]}], "relation_list": [{"subject": "L576P", "object": "imatinib", "sbj_char_span": [262, 267], "obj_char_span": [332, 340], "rel_type": "resistance or non-response", "sbj_tok_span": [70, 74], "obj_tok_span": [94, 96]}], "umls_entity_list": []}, {"text": "The PDGFRA mutation D842V , sporadic wild-type GISTs , mutations with succinate dehydrogenase or BRAF mutated GISTs are unlikely to respond to imatinib . ", "entity_list": [{"name": "imatinib", "ent_type": "drug", "char_span": [143, 151], "tok_span": [31, 33]}, {"name": "D842V", "ent_type": "variant", "char_span": [20, 25], "tok_span": [4, 8]}], "relation_list": [{"subject": "D842V", "object": "imatinib", "sbj_char_span": [20, 25], "obj_char_span": [143, 151], "rel_type": "resistance or non-response", "sbj_tok_span": [4, 8], "obj_tok_span": [31, 33]}], "umls_entity_list": []}, {"text": "The V600E B-RAF mutation appears in 4 % –15 % of CRC.– The possible relationship between of B-RAF mutational status and response to treatment with panitumumab in 48 patients with mCRC was investigated by Benvenuti et al . ", "entity_list": [{"name": "panitumumab", "ent_type": "drug", "char_span": [147, 158], "tok_span": [37, 40]}, {"name": "V600E", "ent_type": "variant", "char_span": [4, 9], "tok_span": [1, 4]}], "relation_list": [{"subject": "V600E", "object": "panitumumab", "sbj_char_span": [4, 9], "obj_char_span": [147, 158], "rel_type": "resistance or non-response", "sbj_tok_span": [1, 4], "obj_tok_span": [37, 40]}], "umls_entity_list": []}, {"text": "Preclinical cell studies indicate that dasatinib may inhibit the KIT D816V mutation that is resistant to imatinib .", "entity_list": [{"name": "dasatinib", "ent_type": "drug", "char_span": [39, 48], "tok_span": [7, 9]}, {"name": "D816V", "ent_type": "variant", "char_span": [69, 74], "tok_span": [14, 18]}], "relation_list": [{"subject": "D816V", "object": "dasatinib", "sbj_char_span": [69, 74], "obj_char_span": [39, 48], "rel_type": "response", "sbj_tok_span": [14, 18], "obj_tok_span": [7, 9]}], "umls_entity_list": []}, {"text": "Eight months after starting the treatment , when patients still responded to the dasatinib , authors sequenced kinase domain of DDR2 gene and identified the S768R mutation .", "entity_list": [{"name": "dasatinib", "ent_type": "drug", "char_span": [81, 90], "tok_span": [13, 15]}, {"name": "S768R", "ent_type": "variant", "char_span": [157, 162], "tok_span": [28, 32]}], "relation_list": [{"subject": "S768R", "object": "dasatinib", "sbj_char_span": [157, 162], "obj_char_span": [81, 90], "rel_type": "response", "sbj_tok_span": [28, 32], "obj_tok_span": [13, 15]}], "umls_entity_list": []}, {"text": "They had found a de novo secondary mutation G2032R in CD74-ROS1 , and this mutation conferred serious resistance to crizotinib .", "entity_list": [{"name": "crizotinib", "ent_type": "drug", "char_span": [116, 126], "tok_span": [27, 31]}, {"name": "G2032R", "ent_type": "variant", "char_span": [44, 50], "tok_span": [8, 12]}], "relation_list": [{"subject": "G2032R", "object": "crizotinib", "sbj_char_span": [44, 50], "obj_char_span": [116, 126], "rel_type": "resistance", "sbj_tok_span": [8, 12], "obj_tok_span": [27, 31]}], "umls_entity_list": []}, {"text": "The mutated site G2032R , P-loop region , and crizotinib in WT-ROS1 and G2032R-ROS1 are shown in green surface , orange surface , green stick , and pink stick models , respectively , in panels A and B .", "entity_list": [{"name": "crizotinib", "ent_type": "drug", "char_span": [46, 56], "tok_span": [14, 18]}, {"name": "G2032R", "ent_type": "variant", "char_span": [17, 23], "tok_span": [3, 7]}], "relation_list": [{"subject": "G2032R", "object": "crizotinib", "sbj_char_span": [17, 23], "obj_char_span": [46, 56], "rel_type": "resistance", "sbj_tok_span": [3, 7], "obj_tok_span": [14, 18]}], "umls_entity_list": []}, {"text": "As shown in , the separation PMF in G2032R-ROS1 was much lower than that in WT-ROS1 , suggesting that serious crizotinib resistance could be induced by the mutation G2032R in the ROS1 tyrosine kinase .", "entity_list": [{"name": "crizotinib", "ent_type": "drug", "char_span": [110, 120], "tok_span": [30, 34]}, {"name": "G2032R", "ent_type": "variant", "char_span": [165, 171], "tok_span": [41, 45]}], "relation_list": [{"subject": "G2032R", "object": "crizotinib", "sbj_char_span": [165, 171], "obj_char_span": [110, 120], "rel_type": "resistance", "sbj_tok_span": [41, 45], "obj_tok_span": [30, 34]}], "umls_entity_list": []}, {"text": "By using the combination of US , ABF , and Roux 's absolute binding free energy calculation scheme , we accurately characterized the one-dimensional ( 1D ) free energy profile of crizotinib separated from the binding sites of the WT and G2032R mutated ROS1 to the bulk .", "entity_list": [{"name": "crizotinib", "ent_type": "drug", "char_span": [179, 189], "tok_span": [37, 41]}, {"name": "G2032R", "ent_type": "variant", "char_span": [237, 243], "tok_span": [50, 54]}], "relation_list": [{"subject": "G2032R", "object": "crizotinib", "sbj_char_span": [237, 243], "obj_char_span": [179, 189], "rel_type": "resistance", "sbj_tok_span": [50, 54], "obj_tok_span": [37, 41]}], "umls_entity_list": []}, {"text": "Both in vivo and in vitro models have shown that afatinib has increased affinity for the EGFR L858R mutation compared to the first-generation EGFR-TKIs .", "entity_list": [{"name": "afatinib", "ent_type": "drug", "char_span": [49, 57], "tok_span": [10, 12]}, {"name": "L858R", "ent_type": "variant", "char_span": [94, 99], "tok_span": [18, 22]}], "relation_list": [{"subject": "L858R", "object": "afatinib", "sbj_char_span": [94, 99], "obj_char_span": [49, 57], "rel_type": "sensitivity", "sbj_tok_span": [18, 22], "obj_tok_span": [10, 12]}], "umls_entity_list": []}, {"text": "Among the 308 patients with the common mutations exon 19 deletion or exon 21 L858R mutation , the difference in PFS was even more striking : 13.6 months with afatinib compared to 6.9 months in the chemotherapy group ( HR 0.47 , P & lt ; 0.0001 ) . ", "entity_list": [{"name": "afatinib", "ent_type": "drug", "char_span": [158, 166], "tok_span": [34, 36]}, {"name": "L858R", "ent_type": "variant", "char_span": [77, 82], "tok_span": [14, 18]}], "relation_list": [{"subject": "L858R", "object": "afatinib", "sbj_char_span": [77, 82], "obj_char_span": [158, 166], "rel_type": "sensitivity", "sbj_tok_span": [14, 18], "obj_tok_span": [34, 36]}], "umls_entity_list": []}, {"text": "Additionally , afatinib has higher potency than reversible EGFR-TKIs in reducing survival of NSCLC cell lines with the T790M resistance mutation ( ) and in cell lines with the less common secondary resistance mutation T854A .", "entity_list": [{"name": "afatinib", "ent_type": "drug", "char_span": [15, 23], "tok_span": [2, 4]}, {"name": "T790M", "ent_type": "variant", "char_span": [119, 124], "tok_span": [22, 26]}], "relation_list": [{"subject": "T790M", "object": "afatinib", "sbj_char_span": [119, 124], "obj_char_span": [15, 23], "rel_type": "response", "sbj_tok_span": [22, 26], "obj_tok_span": [2, 4]}], "umls_entity_list": []}, {"text": "Intermittent , high-dose afatinib ( NCT01647711 ) I Must have known T790M mutation 2nd/3rd line after progression on 1st-generation EGFR-TKI Afatinib at pulsatile , high doses MTD None , trial ongoing", "entity_list": [{"name": "afatinib", "ent_type": "drug", "char_span": [25, 33], "tok_span": [7, 9]}, {"name": "T790M", "ent_type": "variant", "char_span": [68, 73], "tok_span": [22, 26]}, {"name": "Afatinib", "ent_type": "drug", "char_span": [141, 149], "tok_span": [44, 46]}], "relation_list": [{"subject": "T790M", "object": "afatinib", "sbj_char_span": [68, 73], "obj_char_span": [25, 33], "rel_type": "response", "sbj_tok_span": [22, 26], "obj_tok_span": [7, 9]}, {"subject": "T790M", "object": "Afatinib", "sbj_char_span": [68, 73], "obj_char_span": [141, 149], "rel_type": "response", "sbj_tok_span": [22, 26], "obj_tok_span": [44, 46]}], "umls_entity_list": []}, {"text": "In addition , ponatinib has proven efficacy in mouse models of CML and was also found to be effective in a small cohort of patients with T315I mutations in two recent clinical trials ( phase 1 : NCT00660920 ; phase 2 : NCT01207440 ; http : //www.clinicaltrials.gov ) .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [14, 23], "tok_span": [3, 7]}, {"name": "T315I", "ent_type": "variant", "char_span": [137, 142], "tok_span": [29, 33]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [137, 142], "obj_char_span": [14, 23], "rel_type": "response", "sbj_tok_span": [29, 33], "obj_tok_span": [3, 7]}], "umls_entity_list": []}, {"text": "As a whole our findings confirmed the efficacy of ponatinib on the T315I mutation , but also highlighted the notion that ponatinib is effective on all types of imatinib-resistant CML cells , whatever their mode of resistance .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [50, 59], "tok_span": [9, 13]}, {"name": "T315I", "ent_type": "variant", "char_span": [67, 72], "tok_span": [15, 19]}, {"name": "ponatinib", "ent_type": "drug", "char_span": [121, 130], "tok_span": [27, 31]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [67, 72], "obj_char_span": [50, 59], "rel_type": "response", "sbj_tok_span": [15, 19], "obj_tok_span": [9, 13]}, {"subject": "T315I", "object": "ponatinib", "sbj_char_span": [67, 72], "obj_char_span": [121, 130], "rel_type": "response", "sbj_tok_span": [15, 19], "obj_tok_span": [27, 31]}], "umls_entity_list": []}, {"text": "In BaF3-WT-BCR-ABL and T315I cells , ponatinib efficiently inhibited BCR-ABL phosphorylation , but dephosphorylation of CRLK necessitated higher doses of ponatinib ( Figure ) .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [37, 46], "tok_span": [18, 22]}, {"name": "T315I", "ent_type": "variant", "char_span": [23, 28], "tok_span": [12, 16]}, {"name": "ponatinib", "ent_type": "drug", "char_span": [154, 163], "tok_span": [45, 49]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [23, 28], "obj_char_span": [37, 46], "rel_type": "response", "sbj_tok_span": [12, 16], "obj_tok_span": [18, 22]}, {"subject": "T315I", "object": "ponatinib", "sbj_char_span": [23, 28], "obj_char_span": [154, 163], "rel_type": "response", "sbj_tok_span": [12, 16], "obj_tok_span": [45, 49]}], "umls_entity_list": []}, {"text": "Interestingly , in our hands the cells carrying the G250E mutation seems less sensitive to the effect of ponatinib that the one carrying the T315I mutation .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [105, 114], "tok_span": [20, 24]}, {"name": "T315I", "ent_type": "variant", "char_span": [141, 146], "tok_span": [29, 33]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [141, 146], "obj_char_span": [105, 114], "rel_type": "response", "sbj_tok_span": [29, 33], "obj_tok_span": [20, 24]}], "umls_entity_list": []}, {"text": "Our results suggest that in addition to T315I patients , ponatinib could be widely used in resistant CML patients , whatever the supposed mode of resistance to first line ITKs .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [57, 66], "tok_span": [13, 17]}, {"name": "T315I", "ent_type": "variant", "char_span": [40, 45], "tok_span": [7, 11]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [40, 45], "obj_char_span": [57, 66], "rel_type": "response", "sbj_tok_span": [7, 11], "obj_tok_span": [13, 17]}], "umls_entity_list": []}, {"text": "The T315I is a unique mutation because of its resistance to all approved Bcr-Abl inhibitors , prior to ponatinib .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [103, 112], "tok_span": [25, 29]}, {"name": "T315I", "ent_type": "variant", "char_span": [4, 9], "tok_span": [1, 5]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [4, 9], "obj_char_span": [103, 112], "rel_type": "response", "sbj_tok_span": [1, 5], "obj_tok_span": [25, 29]}], "umls_entity_list": []}, {"text": "Ponatinib is a potent BCR-ABL inhibitor with activity against the T315I mutation. ", "entity_list": [{"name": "Ponatinib", "ent_type": "drug", "char_span": [0, 9], "tok_span": [0, 2]}, {"name": "T315I", "ent_type": "variant", "char_span": [66, 71], "tok_span": [14, 18]}], "relation_list": [{"subject": "T315I", "object": "Ponatinib", "sbj_char_span": [66, 71], "obj_char_span": [0, 9], "rel_type": "response", "sbj_tok_span": [14, 18], "obj_tok_span": [0, 2]}], "umls_entity_list": []}, {"text": "If the mutation is T315I , the choice will be always ponatinib , even if the first-line was imatinib. , ,,", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [53, 62], "tok_span": [14, 18]}, {"name": "T315I", "ent_type": "variant", "char_span": [19, 24], "tok_span": [4, 8]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [19, 24], "obj_char_span": [53, 62], "rel_type": "response", "sbj_tok_span": [4, 8], "obj_tok_span": [14, 18]}], "umls_entity_list": []}, {"text": "Ponatinib BCR-ABL with mutations , including T315I + + Sen et al", "entity_list": [{"name": "Ponatinib", "ent_type": "drug", "char_span": [0, 9], "tok_span": [0, 2]}, {"name": "T315I", "ent_type": "variant", "char_span": [45, 50], "tok_span": [10, 14]}], "relation_list": [{"subject": "T315I", "object": "Ponatinib", "sbj_char_span": [45, 50], "obj_char_span": [0, 9], "rel_type": "response", "sbj_tok_span": [10, 14], "obj_tok_span": [0, 2]}], "umls_entity_list": []}, {"text": "For example , dasatinib is recommended for patients with F359V or Y253H , nilotinib for patients with F317L , and ponatinib for patients with T315I .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [114, 123], "tok_span": [32, 36]}, {"name": "T315I", "ent_type": "variant", "char_span": [142, 147], "tok_span": [39, 43]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [142, 147], "obj_char_span": [114, 123], "rel_type": "response", "sbj_tok_span": [39, 43], "obj_tok_span": [32, 36]}], "umls_entity_list": []}, {"text": "The second-generation TKIs such as afatinib ( BIBW2992 ) described above irreversibly inhibit RTKs of EGFR family , as well as the T790M variant of EGFR .", "entity_list": [{"name": "afatinib", "ent_type": "drug", "char_span": [35, 43], "tok_span": [8, 10]}, {"name": "T790M", "ent_type": "variant", "char_span": [131, 136], "tok_span": [31, 35]}], "relation_list": [{"subject": "T790M", "object": "afatinib", "sbj_char_span": [131, 136], "obj_char_span": [35, 43], "rel_type": "response", "sbj_tok_span": [31, 35], "obj_tok_span": [8, 10]}], "umls_entity_list": []}, {"text": "We and others have recently demonstrated that the V600E mutation can also preclude responsiveness to panitumumab or cetuximab in mCRC patients and cellular models of CRC . ", "entity_list": [{"name": "panitumumab", "ent_type": "drug", "char_span": [101, 112], "tok_span": [18, 21]}, {"name": "V600E", "ent_type": "variant", "char_span": [50, 55], "tok_span": [8, 11]}], "relation_list": [{"subject": "V600E", "object": "panitumumab", "sbj_char_span": [50, 55], "obj_char_span": [101, 112], "rel_type": "resistance or non-response", "sbj_tok_span": [8, 11], "obj_tok_span": [18, 21]}], "umls_entity_list": []}, {"text": "A recently published experience found a correlation between BRAF V600E activating mutation , mutually exclusive with KRAS ones , and resistance to the treatment with cetuximab and panitumumab administered alone or in combination with chemotherapy ( ) .", "entity_list": [{"name": "panitumumab", "ent_type": "drug", "char_span": [180, 191], "tok_span": [33, 36]}, {"name": "V600E", "ent_type": "variant", "char_span": [65, 70], "tok_span": [9, 12]}], "relation_list": [{"subject": "V600E", "object": "panitumumab", "sbj_char_span": [65, 70], "obj_char_span": [180, 191], "rel_type": "resistance or non-response", "sbj_tok_span": [9, 12], "obj_tok_span": [33, 36]}], "umls_entity_list": []}, {"text": "Thus , we tested the efficacy of these irreversible inhibitors CL-387785 and WZ-4002 ( ) on lapatinib-resistant ERBB2 point mutations ( L755S , L755P and T798M ) .", "entity_list": [{"name": "lapatinib-resistant", "ent_type": "drug", "char_span": [92, 111], "tok_span": [24, 29]}, {"name": "L755S", "ent_type": "variant", "char_span": [136, 141], "tok_span": [35, 39]}], "relation_list": [{"subject": "L755S", "object": "lapatinib-resistant", "sbj_char_span": [136, 141], "obj_char_span": [92, 111], "rel_type": "resistance or non-response", "sbj_tok_span": [35, 39], "obj_tok_span": [24, 29]}], "umls_entity_list": []}, {"text": "The point mutation T790M of the EGFR gene and MET amplification are known to be involved in the majority of cases of acquired resistance to gefitinib .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [140, 149], "tok_span": [28, 32]}, {"name": "T790M", "ent_type": "variant", "char_span": [19, 24], "tok_span": [3, 7]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [19, 24], "obj_char_span": [140, 149], "rel_type": "resistance or non-response", "sbj_tok_span": [3, 7], "obj_tok_span": [28, 32]}], "umls_entity_list": []}, {"text": "First , a secondary mutation in exon 20 , leading to a substitution of methionine for threonine at position 790 ( T790M ) in the kinase domain , is reported in 2 of 5 patients with acquired resistance to gefitinib or erlotinib .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [204, 213], "tok_span": [44, 48]}, {"name": "T790M", "ent_type": "variant", "char_span": [114, 119], "tok_span": [23, 27]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [114, 119], "obj_char_span": [204, 213], "rel_type": "resistance or non-response", "sbj_tok_span": [23, 27], "obj_tok_span": [44, 48]}], "umls_entity_list": []}, {"text": "The appearance of a second mutation represents a mechanism of resistance : in fact the authors demonstrate that the insertion of T790M into test cells renders them resistant to gefitinib in vitro .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [177, 186], "tok_span": [32, 36]}, {"name": "T790M", "ent_type": "variant", "char_span": [129, 134], "tok_span": [21, 25]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [129, 134], "obj_char_span": [177, 186], "rel_type": "resistance or non-response", "sbj_tok_span": [21, 25], "obj_tok_span": [32, 36]}], "umls_entity_list": []}, {"text": "The second-generation TKIs may overcome resistance to the treatment of erlotinib or gefitinib via the T790M gatekeeper mutation . ", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [84, 93], "tok_span": [18, 22]}, {"name": "T790M", "ent_type": "variant", "char_span": [102, 107], "tok_span": [24, 28]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [102, 107], "obj_char_span": [84, 93], "rel_type": "resistance or non-response", "sbj_tok_span": [24, 28], "obj_tok_span": [18, 22]}], "umls_entity_list": []}, {"text": "This type of resistant cell with stem cell features was observed only after exposure to high concentrations of gefitinib , whereas the EGFR T790M mutation or MET amplification were found after the stepwise escalation method .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [111, 120], "tok_span": [18, 22]}, {"name": "T790M", "ent_type": "variant", "char_span": [140, 145], "tok_span": [26, 30]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [140, 145], "obj_char_span": [111, 120], "rel_type": "resistance or non-response", "sbj_tok_span": [26, 30], "obj_tok_span": [18, 22]}], "umls_entity_list": []}, {"text": "These results suggest that the addition of CX-4945 to EGFR-TKI may overcome T790M mediated resistance through the increased activity of EGFR-TKI to suppress EGFR signals by the down-regulation of EGFR . 10.1371/journal.pone.0114000.g004Addition of CX-4945 to EGFR-TKIs substantially suppressed the EGFR signaling pathway in gefitinib/erlotinib-resistant , PC-9 cells .", "entity_list": [{"name": "gefitinib/erlotinib-resistant", "ent_type": "drug", "char_span": [324, 353], "tok_span": [80, 91]}, {"name": "T790M", "ent_type": "variant", "char_span": [76, 81], "tok_span": [18, 22]}], "relation_list": [{"subject": "T790M", "object": "gefitinib/erlotinib-resistant", "sbj_char_span": [76, 81], "obj_char_span": [324, 353], "rel_type": "resistance or non-response", "sbj_tok_span": [18, 22], "obj_tok_span": [80, 91]}], "umls_entity_list": []}, {"text": "Afatinib exhibits superior anticancer activity in lung cancer patients harboring gefitinib/erlotinib-resistant mutant EGFR ( including T790M , exon 20 insertion , and T790M/L858R double mutation ) .", "entity_list": [{"name": "gefitinib/erlotinib-resistant", "ent_type": "drug", "char_span": [81, 110], "tok_span": [11, 22]}, {"name": "T790M", "ent_type": "variant", "char_span": [135, 140], "tok_span": [26, 30]}], "relation_list": [{"subject": "T790M", "object": "gefitinib/erlotinib-resistant", "sbj_char_span": [135, 140], "obj_char_span": [81, 110], "rel_type": "resistance or non-response", "sbj_tok_span": [26, 30], "obj_tok_span": [11, 22]}], "umls_entity_list": []}, {"text": "Furthermore , the only one patient with PSCCE identified for EGFR mutation was L858R missense mutation in exon 21 , termed as gefitinib associated mutations .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [126, 135], "tok_span": [28, 32]}, {"name": "L858R", "ent_type": "variant", "char_span": [79, 84], "tok_span": [15, 19]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [79, 84], "obj_char_span": [126, 135], "rel_type": "sensitivity", "sbj_tok_span": [15, 19], "obj_tok_span": [28, 32]}], "umls_entity_list": []}, {"text": "Furthermore , EGFR mutations in PSCCE are rare but do exist , especially gefitinib associated mutations such as L858R , therefore gefitinib based gene targeted therapy at EGFR but not KRAS and PIK3CA genes , probably should be included in this carcinoma treatment regimens for patients harboring L858R mutation .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [73, 82], "tok_span": [15, 19]}, {"name": "L858R", "ent_type": "variant", "char_span": [112, 117], "tok_span": [23, 27]}, {"name": "gefitinib", "ent_type": "drug", "char_span": [130, 139], "tok_span": [29, 33]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [112, 117], "obj_char_span": [73, 82], "rel_type": "sensitivity", "sbj_tok_span": [23, 27], "obj_tok_span": [15, 19]}, {"subject": "L858R", "object": "gefitinib", "sbj_char_span": [112, 117], "obj_char_span": [130, 139], "rel_type": "sensitivity", "sbj_tok_span": [23, 27], "obj_tok_span": [29, 33]}], "umls_entity_list": []}, {"text": "On the other hand , a missense mutation in exon 20 , especially T790M , showed gefitinib resistance , as previously reported ( ; ) .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [79, 88], "tok_span": [20, 24]}, {"name": "T790M", "ent_type": "variant", "char_span": [64, 69], "tok_span": [14, 18]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [64, 69], "obj_char_span": [79, 88], "rel_type": "resistance or non-response", "sbj_tok_span": [14, 18], "obj_tok_span": [20, 24]}], "umls_entity_list": []}, {"text": "In this regard , certain mutations , such as the T790M amino acid change , have been shown to confer resistance to gefitinib and erlotinib ] .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [115, 124], "tok_span": [25, 29]}, {"name": "T790M", "ent_type": "variant", "char_span": [49, 54], "tok_span": [10, 14]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [49, 54], "obj_char_span": [115, 124], "rel_type": "resistance or non-response", "sbj_tok_span": [10, 14], "obj_tok_span": [25, 29]}], "umls_entity_list": []}, {"text": "One patient with a T790M mutation caused by prior gefitinib treatment achieved SD after exposure to dacomitinib in the NCT00783328 trial .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [50, 59], "tok_span": [12, 16]}, {"name": "T790M", "ent_type": "variant", "char_span": [19, 24], "tok_span": [4, 8]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [19, 24], "obj_char_span": [50, 59], "rel_type": "resistance or non-response", "sbj_tok_span": [4, 8], "obj_tok_span": [12, 16]}], "umls_entity_list": []}, {"text": "A similar theme exists in NSCLCs with a mutation in the EGFR – secondary mutations confer insensitivity to the EGFR tyrosine kinase inhibitor ( EGFR-TKI ) gefitinib , and have been identified in patients with clinical resistance to gefitinib , but also in untreated patients ( ) . analysed NSCLC samples for one such mutation in EGFR , the T790M mutation , from treatment-naïve patients , and from patients before and during treatment with EGFR-TKIs .", "entity_list": [{"name": ") gefitinib", "ent_type": "drug", "char_span": [153, 164], "tok_span": [30, 35]}, {"name": "T790M", "ent_type": "variant", "char_span": [340, 345], "tok_span": [70, 74]}, {"name": "to gefitinib", "ent_type": "drug", "char_span": [229, 241], "tok_span": [45, 50]}], "relation_list": [{"subject": "T790M", "object": ") gefitinib", "sbj_char_span": [340, 345], "obj_char_span": [153, 164], "rel_type": "resistance or non-response", "sbj_tok_span": [70, 74], "obj_tok_span": [30, 35]}, {"subject": "T790M", "object": "to gefitinib", "sbj_char_span": [340, 345], "obj_char_span": [229, 241], "rel_type": "resistance or non-response", "sbj_tok_span": [70, 74], "obj_tok_span": [45, 50]}], "umls_entity_list": []}, {"text": "Inhibition of epidermal growth factor receptor (EGFR) kinase activity by EGFR tyrosine kinase inhibitors ( EGFR-TKIs ) , such as gefitinib and erlotinib , can result in improved response and prolonged progression-free survival ( PFS ) in selected non-small cell lung cancer ( NSCLC ) patients harboring sensitizing EGFR mutations , especially the exon 19del and exon 21 L858R mutations – . ", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [129, 138], "tok_span": [25, 29]}, {"name": "L858R", "ent_type": "variant", "char_span": [370, 375], "tok_span": [75, 79]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [370, 375], "obj_char_span": [129, 138], "rel_type": "sensitivity", "sbj_tok_span": [75, 79], "obj_tok_span": [25, 29]}], "umls_entity_list": []}, {"text": "The drug resistance mutation T790M was detected in CTCs collected from patients with EGFR mutations that had received tyrosine kinase inhibitors Gefitinib ( Iressa ) or Erlotinib ( Tarceva ) .", "entity_list": [{"name": "Gefitinib", "ent_type": "drug", "char_span": [145, 154], "tok_span": [25, 28]}, {"name": "T790M", "ent_type": "variant", "char_span": [29, 34], "tok_span": [4, 8]}, {"name": "Iressa", "ent_type": "drug", "char_span": [157, 163], "tok_span": [29, 32]}], "relation_list": [{"subject": "T790M", "object": "Gefitinib", "sbj_char_span": [29, 34], "obj_char_span": [145, 154], "rel_type": "resistance or non-response", "sbj_tok_span": [4, 8], "obj_tok_span": [25, 28]}, {"subject": "T790M", "object": "Iressa", "sbj_char_span": [29, 34], "obj_char_span": [157, 163], "rel_type": "resistance or non-response", "sbj_tok_span": [4, 8], "obj_tok_span": [29, 32]}], "umls_entity_list": []}, {"text": "Development of EMT was observed in a NSCLC patient who acquired resistance to erlotinib in the absence of known resistance mechanisms , such as the EGFR T790M mutation and MET amplification .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [78, 87], "tok_span": [13, 17]}, {"name": "T790M", "ent_type": "variant", "char_span": [153, 158], "tok_span": [29, 33]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [153, 158], "obj_char_span": [78, 87], "rel_type": "resistance or non-response", "sbj_tok_span": [29, 33], "obj_tok_span": [13, 17]}], "umls_entity_list": []}, {"text": "Some data suggest that patients with EGFR exon 19 deletions are more susceptible to the activity of reversible EGFR-TKIs compared to those with the exon 21 L858R mutation. , Further studies then compared first-generation EGFR-TKIs ( erlotinib and gefitinib ) to chemotherapy in patients with EGFR activating mutations in advanced NSCLC .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [233, 242], "tok_span": [48, 52]}, {"name": "L858R", "ent_type": "variant", "char_span": [156, 161], "tok_span": [29, 33]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [156, 161], "obj_char_span": [233, 242], "rel_type": "sensitivity", "sbj_tok_span": [29, 33], "obj_tok_span": [48, 52]}], "umls_entity_list": []}, {"text": "The T790M mutation accounts for approximately 50 % of cases in which acquired resistance to erlotinib or gefitinib occurs , , .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [92, 101], "tok_span": [18, 22]}, {"name": "T790M", "ent_type": "variant", "char_span": [4, 9], "tok_span": [1, 5]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [4, 9], "obj_char_span": [92, 101], "rel_type": "resistance or non-response", "sbj_tok_span": [1, 5], "obj_tok_span": [18, 22]}], "umls_entity_list": []}, {"text": "The study showed that , among the 5 tumor samples collected at the time of XL647 failure , only one harbored the T790M mutation and that three patients treated with second line erlotinib derived additional long-term benefit from the EGFR TKI .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [177, 186], "tok_span": [38, 42]}, {"name": "T790M", "ent_type": "variant", "char_span": [113, 118], "tok_span": [25, 29]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [113, 118], "obj_char_span": [177, 186], "rel_type": "resistance or non-response", "sbj_tok_span": [25, 29], "obj_tok_span": [38, 42]}], "umls_entity_list": []}, {"text": "BMS-690514 , a reversible oral inhibitor of EGFR , HER-2 and −4 , VEGFRs-1 to −3 , showed antitumour activity in tumour xenograft models and in cell lines containing the EGFR T790M mutation , suggesting a role against erlotinib-resistant tumours .", "entity_list": [{"name": "against erlotinib-resistant", "ent_type": "drug", "char_span": [210, 237], "tok_span": [53, 60]}, {"name": "EGFR T790M", "ent_type": "variant", "char_span": [170, 180], "tok_span": [43, 48]}], "relation_list": [{"subject": "EGFR T790M", "object": "against erlotinib-resistant", "sbj_char_span": [170, 180], "obj_char_span": [210, 237], "rel_type": "resistance or non-response", "sbj_tok_span": [43, 48], "obj_tok_span": [53, 60]}], "umls_entity_list": []}, {"text": "Emerging data suggest that patients with NSCLC and EGFR exon 19 deletion have a longer survival following treatment with gefitinib or erlotinib compared with those with L858R mutation .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [134, 143], "tok_span": [24, 28]}, {"name": "L858R", "ent_type": "variant", "char_span": [169, 174], "tok_span": [32, 36]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [169, 174], "obj_char_span": [134, 143], "rel_type": "sensitivity", "sbj_tok_span": [32, 36], "obj_tok_span": [24, 28]}], "umls_entity_list": []}, {"text": "Interestingly , it was discovered that the T790M mutation does not confer resistance to gefitinib and erlotinib by preventing their binding as originally thought .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [102, 111], "tok_span": [22, 26]}, {"name": "T790M", "ent_type": "variant", "char_span": [43, 48], "tok_span": [7, 11]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [43, 48], "obj_char_span": [102, 111], "rel_type": "resistance or non-response", "sbj_tok_span": [7, 11], "obj_tok_span": [22, 26]}], "umls_entity_list": []}, {"text": "Patients with exon 19 harboring deletions were found to have longer survival following treatment with gefitinib or erlotinib compared with those having L858R mutations in NSCLC ; however , Marks et al. reported no difference in survival between exon 19 deletions and L858R mutations in the absence of EGFR targeted therapy .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [115, 124], "tok_span": [20, 24]}, {"name": "L858R", "ent_type": "variant", "char_span": [152, 157], "tok_span": [28, 32]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [152, 157], "obj_char_span": [115, 124], "rel_type": "sensitivity", "sbj_tok_span": [28, 32], "obj_tok_span": [20, 24]}], "umls_entity_list": []}, {"text": "Since a secondary T790M mutation was found on a liver biopsy , but not in the CSF , the patient received erlotinib , and the brain metastasis responded well to treatment .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [105, 114], "tok_span": [24, 28]}, {"name": "T790M", "ent_type": "variant", "char_span": [18, 23], "tok_span": [3, 7]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [18, 23], "obj_char_span": [105, 114], "rel_type": "resistance or non-response", "sbj_tok_span": [3, 7], "obj_tok_span": [24, 28]}], "umls_entity_list": []}, {"text": "In a retrospective analysis of an erlotinib retrial , Becker et al. reported five cases of the T790M mutation and exon 19 deletions in rebiopsy specimens taken before the retrial of erlotinib .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [34, 43], "tok_span": [6, 10]}, {"name": "T790M", "ent_type": "variant", "char_span": [95, 100], "tok_span": [22, 26]}, {"name": "erlotinib", "ent_type": "drug", "char_span": [182, 191], "tok_span": [43, 47]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [95, 100], "obj_char_span": [34, 43], "rel_type": "resistance or non-response", "sbj_tok_span": [22, 26], "obj_tok_span": [6, 10]}, {"subject": "T790M", "object": "erlotinib", "sbj_char_span": [95, 100], "obj_char_span": [182, 191], "rel_type": "resistance or non-response", "sbj_tok_span": [22, 26], "obj_tok_span": [43, 47]}], "umls_entity_list": []}, {"text": "Two patients harboring EGFR T790M mutation had received EGFR-TKI treatment : one received gefitinib and had an occurrence of brain metastasis in the sixth month ; the other received erlotinib to control the metastasis to the liver .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [182, 191], "tok_span": [38, 42]}, {"name": "T790M", "ent_type": "variant", "char_span": [28, 33], "tok_span": [4, 8]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [28, 33], "obj_char_span": [182, 191], "rel_type": "resistance or non-response", "sbj_tok_span": [4, 8], "obj_tok_span": [38, 42]}], "umls_entity_list": []}, {"text": "( B ) Drugs such as the 4-anilinoquinazolines gefitinib ( Iressa ) and erlotinib ( Tarceva ) can inhibit the activity of EGFR L858R mutant .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [71, 80], "tok_span": [24, 28]}, {"name": "L858R", "ent_type": "variant", "char_span": [126, 131], "tok_span": [39, 43]}, {"name": "Tarceva", "ent_type": "drug", "char_span": [83, 90], "tok_span": [29, 32]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [126, 131], "obj_char_span": [71, 80], "rel_type": "sensitivity", "sbj_tok_span": [39, 43], "obj_tok_span": [24, 28]}, {"subject": "L858R", "object": "Tarceva", "sbj_char_span": [126, 131], "obj_char_span": [83, 90], "rel_type": "sensitivity", "sbj_tok_span": [39, 43], "obj_tok_span": [29, 32]}], "umls_entity_list": []}, {"text": "Panitumumab can still bind to an EGFR mutant S492R to which cetuximab can not bind to .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [60, 69], "tok_span": [16, 20]}, {"name": "S492R", "ent_type": "variant", "char_span": [45, 50], "tok_span": [10, 14]}], "relation_list": [{"subject": "S492R", "object": "cetuximab", "sbj_char_span": [45, 50], "obj_char_span": [60, 69], "rel_type": "resistance", "sbj_tok_span": [10, 14], "obj_tok_span": [16, 20]}], "umls_entity_list": []}, {"text": "Patients with G13D respond better to cetuximab than patients with K-Ras codon 12 mutations .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [37, 46], "tok_span": [8, 12]}, {"name": "G13D", "ent_type": "variant", "char_span": [14, 18], "tok_span": [2, 5]}], "relation_list": [{"subject": "G13D", "object": "cetuximab", "sbj_char_span": [14, 18], "obj_char_span": [37, 46], "rel_type": "resistance or non-response", "sbj_tok_span": [2, 5], "obj_tok_span": [8, 12]}], "umls_entity_list": []}, {"text": "It has even been observed that cells that have been induced to become cetuximab-resistant by continuously exposing them to cetuximab have acquired either K-Ras G12V or K-Ras G13D mutations .", "entity_list": [{"name": "cetuximab-resistant", "ent_type": "drug", "char_span": [70, 89], "tok_span": [13, 19]}, {"name": "G13D", "ent_type": "variant", "char_span": [174, 178], "tok_span": [42, 45]}, {"name": "cetuximab", "ent_type": "drug", "char_span": [123, 132], "tok_span": [25, 29]}], "relation_list": [{"subject": "G13D", "object": "cetuximab-resistant", "sbj_char_span": [174, 178], "obj_char_span": [70, 89], "rel_type": "resistance or non-response", "sbj_tok_span": [42, 45], "obj_tok_span": [13, 19]}, {"subject": "G13D", "object": "cetuximab", "sbj_char_span": [174, 178], "obj_char_span": [123, 132], "rel_type": "resistance or non-response", "sbj_tok_span": [42, 45], "obj_tok_span": [25, 29]}], "umls_entity_list": []}, {"text": "A and D ) Detroit 562 cells ( harboring PIK3CA H1047R mutations ) and UMSCC17B cells ( expressing HRAS Q61L mutant oncogene ) were transplanted into athymic mice , and mice were treated with cetuximab or rapamycin alone , or cetuximab together with rapamycin , as indicated .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [191, 200], "tok_span": [52, 56]}, {"name": "H1047R", "ent_type": "variant", "char_span": [47, 53], "tok_span": [16, 20]}, {"name": "cetuximab", "ent_type": "drug", "char_span": [225, 234], "tok_span": [61, 65]}], "relation_list": [{"subject": "H1047R", "object": "cetuximab", "sbj_char_span": [47, 53], "obj_char_span": [191, 200], "rel_type": "resistance or non-response", "sbj_tok_span": [16, 20], "obj_tok_span": [52, 56]}, {"subject": "H1047R", "object": "cetuximab", "sbj_char_span": [47, 53], "obj_char_span": [225, 234], "rel_type": "resistance or non-response", "sbj_tok_span": [16, 20], "obj_tok_span": [61, 65]}], "umls_entity_list": []}, {"text": "However , they also noted that the addition of cetuximab to first-line chemotherapy may benefit patients with KRAS G13D mutation .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [47, 56], "tok_span": [9, 13]}, {"name": "G13D", "ent_type": "variant", "char_span": [115, 119], "tok_span": [24, 27]}], "relation_list": [{"subject": "G13D", "object": "cetuximab", "sbj_char_span": [115, 119], "obj_char_span": [47, 56], "rel_type": "resistance or non-response", "sbj_tok_span": [24, 27], "obj_tok_span": [9, 13]}], "umls_entity_list": []}, {"text": "This indicates that panitumumab may be effective in patients with the S492R mutation after failure of cetuximab .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [102, 111], "tok_span": [21, 25]}, {"name": "S492R", "ent_type": "variant", "char_span": [70, 75], "tok_span": [13, 17]}, {"name": "panitumumab", "ent_type": "drug", "char_span": [20, 31], "tok_span": [3, 6]}], "relation_list": [{"subject": "S492R", "object": "cetuximab", "sbj_char_span": [70, 75], "obj_char_span": [102, 111], "rel_type": "resistance", "sbj_tok_span": [13, 17], "obj_tok_span": [21, 25]}, {"subject": "S492R", "object": "panitumumab", "sbj_char_span": [70, 75], "obj_char_span": [20, 31], "rel_type": "response", "sbj_tok_span": [13, 17], "obj_tok_span": [3, 6]}], "umls_entity_list": []}, {"text": "We didn’t observe that patients with KRAS G13D mutation had better response rate ( ) . 10.1371/journal.pone.0068022.t002Patients’ characteristics of the 35 patients receiving cetuximab .", "entity_list": [{"name": "receiving cetuximab", "ent_type": "drug", "char_span": [165, 184], "tok_span": [48, 53]}, {"name": "KRAS G13D", "ent_type": "variant", "char_span": [37, 46], "tok_span": [8, 13]}], "relation_list": [{"subject": "KRAS G13D", "object": "receiving cetuximab", "sbj_char_span": [37, 46], "obj_char_span": [165, 184], "rel_type": "resistance or non-response", "sbj_tok_span": [8, 13], "obj_tok_span": [48, 53]}], "umls_entity_list": []}, {"text": "Clinically approved patient selection biomarkers for anti-EGFR treatments cetuximab and panitumumab include assessment of EGFR levels and KRAS G12D mutation status .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [74, 83], "tok_span": [11, 15]}, {"name": "G12D", "ent_type": "variant", "char_span": [143, 147], "tok_span": [27, 30]}], "relation_list": [{"subject": "G12D", "object": "cetuximab", "sbj_char_span": [143, 147], "obj_char_span": [74, 83], "rel_type": "sensitivity", "sbj_tok_span": [27, 30], "obj_tok_span": [11, 15]}], "umls_entity_list": []}, {"text": "Other examples of useful biomarkers are KRAS mutation testing to predict benefit from monoclonal antibodies against EGFR , cetuximab and panitumumab , in metastatic colon cancer and BRAF V600E mutation analysis in metastatic melanoma in order to predict responsiveness to BRAF inhibitors such as vemurafenib .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [123, 132], "tok_span": [19, 23]}, {"name": "V600E", "ent_type": "variant", "char_span": [187, 192], "tok_span": [34, 37]}], "relation_list": [{"subject": "V600E", "object": "cetuximab", "sbj_char_span": [187, 192], "obj_char_span": [123, 132], "rel_type": "resistance or non-response", "sbj_tok_span": [34, 37], "obj_tok_span": [19, 23]}], "umls_entity_list": []}, {"text": "However , acquired resistance to imatinib can occur because of point mutations in the ATP binding site ( e.g. , T674I and D842V ) .", "entity_list": [{"name": "imatinib", "ent_type": "drug", "char_span": [33, 41], "tok_span": [5, 7]}, {"name": "T674I", "ent_type": "variant", "char_span": [112, 117], "tok_span": [24, 28]}, {"name": "D842V", "ent_type": "variant", "char_span": [122, 127], "tok_span": [29, 33]}], "relation_list": [{"subject": "T674I", "object": "imatinib", "sbj_char_span": [112, 117], "obj_char_span": [33, 41], "rel_type": "resistance", "sbj_tok_span": [24, 28], "obj_tok_span": [5, 7]}, {"subject": "D842V", "object": "imatinib", "sbj_char_span": [122, 127], "obj_char_span": [33, 41], "rel_type": "resistance or non-response", "sbj_tok_span": [29, 33], "obj_tok_span": [5, 7]}], "umls_entity_list": []}, {"text": "It showed to be 135-fold more potent than imatinib against primary gastrointestinal stromal tumors cells expressing PDGFRα with D842V deletion and IC50 of approximately 10 nmol/L .", "entity_list": [{"name": "imatinib", "ent_type": "drug", "char_span": [42, 50], "tok_span": [10, 12]}, {"name": "with D842V", "ent_type": "variant", "char_span": [123, 133], "tok_span": [23, 28]}], "relation_list": [{"subject": "with D842V", "object": "imatinib", "sbj_char_span": [123, 133], "obj_char_span": [42, 50], "rel_type": "resistance or non-response", "sbj_tok_span": [23, 28], "obj_tok_span": [10, 12]}], "umls_entity_list": []}, {"text": "The most common PDGFRα mutation ( 62.6 % of PDGFRα mutations ) , the exon 18 D842V mutation , is insensitive to imatinib .", "entity_list": [{"name": "to imatinib", "ent_type": "drug", "char_span": [109, 120], "tok_span": [30, 33]}, {"name": "18 D842V", "ent_type": "variant", "char_span": [74, 82], "tok_span": [21, 26]}], "relation_list": [{"subject": "18 D842V", "object": "to imatinib", "sbj_char_span": [74, 82], "obj_char_span": [109, 120], "rel_type": "resistance or non-response", "sbj_tok_span": [21, 26], "obj_tok_span": [30, 33]}], "umls_entity_list": []}, {"text": "To identify additional drivers or modifiers of GIST biology that can be targeted , we integrated array based analysis of DNA CN and gene expression results from tumors resistant to imatinib , i.e. wild-type and PDGFRA D842V GISTs ( summarized in ) .", "entity_list": [{"name": "imatinib", "ent_type": "drug", "char_span": [181, 189], "tok_span": [33, 35]}, {"name": "D842V", "ent_type": "variant", "char_span": [218, 223], "tok_span": [46, 50]}], "relation_list": [{"subject": "D842V", "object": "imatinib", "sbj_char_span": [218, 223], "obj_char_span": [181, 189], "rel_type": "resistance or non-response", "sbj_tok_span": [46, 50], "obj_tok_span": [33, 35]}], "umls_entity_list": []}, {"text": "These observations were validated in clinical samples by qRT-PCR : CN gain of GSTT1 was detected in 90 % of wild-type and 100 % of PDGFRA D842V GISTs , and all cases with GSTT1 CN gain showed disease progression during imatinib therapy .", "entity_list": [{"name": "imatinib", "ent_type": "drug", "char_span": [219, 227], "tok_span": [53, 55]}, {"name": "D842V", "ent_type": "variant", "char_span": [138, 143], "tok_span": [33, 37]}], "relation_list": [{"subject": "D842V", "object": "imatinib", "sbj_char_span": [138, 143], "obj_char_span": [219, 227], "rel_type": "resistance or non-response", "sbj_tok_span": [33, 37], "obj_tok_span": [53, 55]}], "umls_entity_list": []}, {"text": "Additionally , imatinib-resistant KIT exon 9 or PDGFRα exon 18 D842V mutations – or even no detectable mutation at all – could be the cause of the resistance. , It is also important that secondary mutations located on KIT exon 11 can cause low response to imatinib treatment.– Taking into consideration the fact that in 5 % –15 % of GISTs these mutations are absent , scientists consider it possible that there is an additional pathway that has not yet been discovered .", "entity_list": [{"name": "imatinib-resistant", "ent_type": "drug", "char_span": [15, 33], "tok_span": [2, 6]}, {"name": "18 D842V", "ent_type": "variant", "char_span": [60, 68], "tok_span": [15, 20]}, {"name": "to imatinib", "ent_type": "drug", "char_span": [253, 264], "tok_span": [56, 59]}], "relation_list": [{"subject": "18 D842V", "object": "imatinib-resistant", "sbj_char_span": [60, 68], "obj_char_span": [15, 33], "rel_type": "resistance or non-response", "sbj_tok_span": [15, 20], "obj_tok_span": [2, 6]}, {"subject": "18 D842V", "object": "to imatinib", "sbj_char_span": [60, 68], "obj_char_span": [253, 264], "rel_type": "resistance or non-response", "sbj_tok_span": [15, 20], "obj_tok_span": [56, 59]}], "umls_entity_list": []}, {"text": "Di Nicolantonio et al. ( ) also demonstrated that introduction of the BRAF V600E allele could confer resistance to either cetuximab or panitumumab in wild-type BRAF colorectal cancer cells .", "entity_list": [{"name": "panitumumab", "ent_type": "drug", "char_span": [135, 146], "tok_span": [32, 35]}, {"name": "V600E", "ent_type": "variant", "char_span": [75, 80], "tok_span": [18, 21]}], "relation_list": [{"subject": "V600E", "object": "panitumumab", "sbj_char_span": [75, 80], "obj_char_span": [135, 146], "rel_type": "resistance or non-response", "sbj_tok_span": [18, 21], "obj_tok_span": [32, 35]}], "umls_entity_list": []}, {"text": "The effect of BRAF V600E mutation on cetuximab or panitumumab response was also assessed using cellular models of CRC .", "entity_list": [{"name": "panitumumab", "ent_type": "drug", "char_span": [50, 61], "tok_span": [14, 17]}, {"name": "V600E", "ent_type": "variant", "char_span": [19, 24], "tok_span": [4, 7]}], "relation_list": [{"subject": "V600E", "object": "panitumumab", "sbj_char_span": [19, 24], "obj_char_span": [50, 61], "rel_type": "resistance or non-response", "sbj_tok_span": [4, 7], "obj_tok_span": [14, 17]}], "umls_entity_list": []}, {"text": "Targeting the oncogenic fusion protein echinoderm microtubule associated protein-like 4-anaplastic lymphoma kinase ( EML4-ALK ) with TKIs such as crizotinib has also been shown to be negatively affected by the development of secondary gate keeper residue mutations such as L1196M , and the emergence of fusion negative tumors that render the disease insensitive to the drug .", "entity_list": [{"name": "crizotinib", "ent_type": "drug", "char_span": [146, 156], "tok_span": [34, 38]}, {"name": "L1196M", "ent_type": "variant", "char_span": [273, 279], "tok_span": [58, 62]}], "relation_list": [{"subject": "L1196M", "object": "crizotinib", "sbj_char_span": [273, 279], "obj_char_span": [146, 156], "rel_type": "resistance", "sbj_tok_span": [58, 62], "obj_tok_span": [34, 38]}], "umls_entity_list": []}, {"text": "In vitro NSCLC cell lines selected for resistance to crizotinib also show amplification of the ALK fusion gene as well as kinase domain mutations such as L1196M ( ) .", "entity_list": [{"name": "crizotinib", "ent_type": "drug", "char_span": [53, 63], "tok_span": [9, 13]}, {"name": "L1196M", "ent_type": "variant", "char_span": [154, 160], "tok_span": [30, 34]}], "relation_list": [{"subject": "L1196M", "object": "crizotinib", "sbj_char_span": [154, 160], "obj_char_span": [53, 63], "rel_type": "resistance", "sbj_tok_span": [30, 34], "obj_tok_span": [9, 13]}], "umls_entity_list": []}, {"text": "In the Crizotinib-resistant DFCI076 cell line , a unique L1152R ALK secondary mutation and concurrent coactivation of epidermal growth factor receptor (EGFR) signaling imparted resistance .", "entity_list": [{"name": "Crizotinib-resistant", "ent_type": "drug", "char_span": [7, 27], "tok_span": [2, 8]}, {"name": "L1152R", "ent_type": "variant", "char_span": [57, 63], "tok_span": [17, 21]}], "relation_list": [{"subject": "L1152R", "object": "Crizotinib-resistant", "sbj_char_span": [57, 63], "obj_char_span": [7, 27], "rel_type": "resistance", "sbj_tok_span": [17, 21], "obj_tok_span": [2, 8]}], "umls_entity_list": []}, {"text": "Relapse of hypereosinophilia during treatment with imatinib has been reported in two F/P+ patients , and was associated with appearance of a T674I point mutation in the ATP binding site of the PDGFRA moiety , similar to the T315I mutation observed in patients with CML that become refractory to treatment .", "entity_list": [{"name": "imatinib", "ent_type": "drug", "char_span": [51, 59], "tok_span": [10, 12]}, {"name": "T674I", "ent_type": "variant", "char_span": [141, 146], "tok_span": [30, 34]}], "relation_list": [{"subject": "T674I", "object": "imatinib", "sbj_char_span": [141, 146], "obj_char_span": [51, 59], "rel_type": "resistance", "sbj_tok_span": [30, 34], "obj_tok_span": [10, 12]}], "umls_entity_list": []}, {"text": "Afatinib is an irreversible HER2/ErbB-family blocker that shows high affinity for EGFR T790M mutation .", "entity_list": [{"name": "Afatinib", "ent_type": "drug", "char_span": [0, 8], "tok_span": [0, 2]}, {"name": "T790M", "ent_type": "variant", "char_span": [87, 92], "tok_span": [19, 23]}], "relation_list": [{"subject": "T790M", "object": "Afatinib", "sbj_char_span": [87, 92], "obj_char_span": [0, 8], "rel_type": "response", "sbj_tok_span": [19, 23], "obj_tok_span": [0, 2]}], "umls_entity_list": []}, {"text": "Moreover , dual inhibition of EGFR with an irreversible EGFR inhibitor ( afatinib ) and the EGFR neutralizing antibody cetuximab has recently shown promising activity in EGFR mutant lung cancers with acquired EGFR TKI resistance that harbor an EGFR T790M mutation .", "entity_list": [{"name": "afatinib", "ent_type": "drug", "char_span": [73, 81], "tok_span": [12, 14]}, {"name": "T790M", "ent_type": "variant", "char_span": [249, 254], "tok_span": [44, 48]}], "relation_list": [{"subject": "T790M", "object": "afatinib", "sbj_char_span": [249, 254], "obj_char_span": [73, 81], "rel_type": "response", "sbj_tok_span": [44, 48], "obj_tok_span": [12, 14]}], "umls_entity_list": []}, {"text": "Second generation EGFR TKIs e.g. , BIBW 2992 ( afatinib ) and PF00299804 ( dacomitinib ) , and third generation EGFR TKIs e.g. , CO-1686 and AZD9291 are irreversible inhibitors that could overcome the AR caused by T790M .", "entity_list": [{"name": "BIBW 2992", "ent_type": "drug", "char_span": [35, 44], "tok_span": [10, 14]}, {"name": "T790M", "ent_type": "variant", "char_span": [214, 219], "tok_span": [61, 65]}, {"name": "afatinib", "ent_type": "drug", "char_span": [47, 55], "tok_span": [15, 17]}], "relation_list": [{"subject": "T790M", "object": "BIBW 2992", "sbj_char_span": [214, 219], "obj_char_span": [35, 44], "rel_type": "response", "sbj_tok_span": [61, 65], "obj_tok_span": [10, 14]}, {"subject": "T790M", "object": "afatinib", "sbj_char_span": [214, 219], "obj_char_span": [47, 55], "rel_type": "response", "sbj_tok_span": [61, 65], "obj_tok_span": [15, 17]}], "umls_entity_list": []}, {"text": "Verbeek and coworkers set out to compare the efficiency of four recently developed TK inhibitors , XL184 , Vandetanib , Sunitinib and Axitinib , using three cell lines : the first derived from sporadic MTC expressing a C634W RET mutation , the second derived from metastatic sporadic MTC expressing a M918T RET mutation .", "entity_list": [{"name": "Vandetanib", "ent_type": "drug", "char_span": [107, 117], "tok_span": [22, 26]}, {"name": "M918T", "ent_type": "variant", "char_span": [301, 306], "tok_span": [66, 70]}, {"name": "C634W", "ent_type": "variant", "char_span": [219, 224], "tok_span": [49, 53]}], "relation_list": [{"subject": "M918T", "object": "Vandetanib", "sbj_char_span": [301, 306], "obj_char_span": [107, 117], "rel_type": "response", "sbj_tok_span": [66, 70], "obj_tok_span": [22, 26]}, {"subject": "C634W", "object": "Vandetanib", "sbj_char_span": [219, 224], "obj_char_span": [107, 117], "rel_type": "response", "sbj_tok_span": [49, 53], "obj_tok_span": [22, 26]}], "umls_entity_list": []}, {"text": "Patients with mutations linked to resistance with dasatinib ( F317L ) and nilotinib ( Y253H and F359C/I/V ) were among those who responded to bosutinib ( Khoury et al. , 2012 ) .", "entity_list": [{"name": "bosutinib", "ent_type": "drug", "char_span": [142, 151], "tok_span": [40, 43]}, {"name": "Y253H", "ent_type": "variant", "char_span": [86, 91], "tok_span": [20, 24]}], "relation_list": [{"subject": "Y253H", "object": "bosutinib", "sbj_char_span": [86, 91], "obj_char_span": [142, 151], "rel_type": "response", "sbj_tok_span": [20, 24], "obj_tok_span": [40, 43]}], "umls_entity_list": []}, {"text": "In contrast , ponatinib was designed to avoid binding with the side chain of T315I in native BCR-ABL , and instead forms beneficial van der Waals interactions with the isoleucine side chain of the T315I mutant .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [14, 23], "tok_span": [3, 7]}, {"name": "T315I", "ent_type": "variant", "char_span": [77, 82], "tok_span": [17, 21]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [77, 82], "obj_char_span": [14, 23], "rel_type": "response", "sbj_tok_span": [17, 21], "obj_tok_span": [3, 7]}], "umls_entity_list": []}, {"text": "In vitro screening assay has demonstrated that ponatinib , the first TKI effective against T315I Bcr-Abl , is also a potent inhibitor of KIT , PDGFRα , Flt3 , Src , VEGFR and FGFR .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [47, 56], "tok_span": [7, 11]}, {"name": "T315I", "ent_type": "variant", "char_span": [91, 96], "tok_span": [18, 22]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [91, 96], "obj_char_span": [47, 56], "rel_type": "response", "sbj_tok_span": [18, 22], "obj_tok_span": [7, 11]}], "umls_entity_list": []}, {"text": "Ponatinib ( AP24534 ) is an orally administered TKI designed to inhibit BCR-ABL with mutations , especially T315I , which confers resistance to other TKI such as imatinib , dasatinib , nilotinib , and bosutinib ( reviewed in ) . ", "entity_list": [{"name": "Ponatinib", "ent_type": "drug", "char_span": [0, 9], "tok_span": [0, 2]}, {"name": "T315I", "ent_type": "variant", "char_span": [108, 113], "tok_span": [25, 29]}, {"name": "AP24534", "ent_type": "drug", "char_span": [12, 19], "tok_span": [3, 7]}], "relation_list": [{"subject": "T315I", "object": "Ponatinib", "sbj_char_span": [108, 113], "obj_char_span": [0, 9], "rel_type": "response", "sbj_tok_span": [25, 29], "obj_tok_span": [0, 2]}, {"subject": "T315I", "object": "AP24534", "sbj_char_span": [108, 113], "obj_char_span": [12, 19], "rel_type": "response", "sbj_tok_span": [25, 29], "obj_tok_span": [3, 7]}], "umls_entity_list": []}, {"text": "The PACE ( Ponatinib Ph+ ALL and CML Evaluation ) trial has been set up to evaluate the effect of Ponatinib on CML patients that were either resistant or intolerant to dasatinib or nilotinib or with T315I mutation .", "entity_list": [{"name": "Ponatinib", "ent_type": "drug", "char_span": [11, 20], "tok_span": [4, 6]}, {"name": "T315I", "ent_type": "variant", "char_span": [199, 204], "tok_span": [45, 49]}, {"name": "Ponatinib", "ent_type": "drug", "char_span": [98, 107], "tok_span": [23, 25]}], "relation_list": [{"subject": "T315I", "object": "Ponatinib", "sbj_char_span": [199, 204], "obj_char_span": [11, 20], "rel_type": "response", "sbj_tok_span": [45, 49], "obj_tok_span": [4, 6]}, {"subject": "T315I", "object": "Ponatinib", "sbj_char_span": [199, 204], "obj_char_span": [98, 107], "rel_type": "response", "sbj_tok_span": [45, 49], "obj_tok_span": [23, 25]}], "umls_entity_list": []}, {"text": "For example , patients with T315I mutation respond only on treatment with third generation TKI Ponatinib , which was specifically designed as a treatment option for these populations .", "entity_list": [{"name": "Ponatinib", "ent_type": "drug", "char_span": [95, 104], "tok_span": [19, 21]}, {"name": "T315I", "ent_type": "variant", "char_span": [28, 33], "tok_span": [5, 9]}], "relation_list": [{"subject": "T315I", "object": "Ponatinib", "sbj_char_span": [28, 33], "obj_char_span": [95, 104], "rel_type": "response", "sbj_tok_span": [5, 9], "obj_tok_span": [19, 21]}], "umls_entity_list": []}, {"text": "The choice of the second-line therapy is also dictated by whether the patient has a T315I mutation or not – ponatinib being the most promising agent in such a case .", "entity_list": [{"name": "– ponatinib", "ent_type": "drug", "char_span": [106, 117], "tok_span": [25, 30]}, {"name": "T315I", "ent_type": "variant", "char_span": [84, 89], "tok_span": [18, 22]}], "relation_list": [{"subject": "T315I", "object": "– ponatinib", "sbj_char_span": [84, 89], "obj_char_span": [106, 117], "rel_type": "response", "sbj_tok_span": [18, 22], "obj_tok_span": [25, 30]}], "umls_entity_list": []}, {"text": "The E884K mutation represents the first mutation reported to show an apparent differential response to the two EGFR kinase inhibitors erlotinib and gefitinib , while L858R was known to be sensitizing to both .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [148, 157], "tok_span": [28, 32]}, {"name": "L858R", "ent_type": "variant", "char_span": [166, 171], "tok_span": [34, 38]}, {"name": "erlotinib", "ent_type": "drug", "char_span": [134, 143], "tok_span": [23, 27]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [166, 171], "obj_char_span": [148, 157], "rel_type": "sensitivity", "sbj_tok_span": [34, 38], "obj_tok_span": [28, 32]}, {"subject": "L858R", "object": "erlotinib", "sbj_char_span": [166, 171], "obj_char_span": [134, 143], "rel_type": "sensitivity", "sbj_tok_span": [34, 38], "obj_tok_span": [23, 27]}], "umls_entity_list": []}, {"text": "( D ) COS-7 cells with stable transduced expression of L858R or L858R+E884K mutant EGFR were tested in cellular cytotoxicity assay in vitro under drug treatment with either erlotinib or gefitinib at indicated concentrations .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [186, 195], "tok_span": [46, 50]}, {"name": "L858R", "ent_type": "variant", "char_span": [55, 60], "tok_span": [12, 16]}, {"name": "erlotinib", "ent_type": "drug", "char_span": [173, 182], "tok_span": [41, 45]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [55, 60], "obj_char_span": [186, 195], "rel_type": "sensitivity", "sbj_tok_span": [12, 16], "obj_tok_span": [46, 50]}, {"subject": "L858R", "object": "erlotinib", "sbj_char_span": [55, 60], "obj_char_span": [173, 182], "rel_type": "sensitivity", "sbj_tok_span": [12, 16], "obj_tok_span": [41, 45]}], "umls_entity_list": []}, {"text": "( B ) Densitometric quantitation of the p-EGFR levels showing that R958D mutation differentially altered L858R mutant receptor sensitivity to erlotinib ( more resistant ) and gefitinib ( more sensitive ) .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [175, 184], "tok_span": [41, 45]}, {"name": "L858R", "ent_type": "variant", "char_span": [105, 110], "tok_span": [24, 28]}, {"name": "erlotinib", "ent_type": "drug", "char_span": [142, 151], "tok_span": [32, 36]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [105, 110], "obj_char_span": [175, 184], "rel_type": "sensitivity", "sbj_tok_span": [24, 28], "obj_tok_span": [41, 45]}, {"subject": "L858R", "object": "erlotinib", "sbj_char_span": [105, 110], "obj_char_span": [142, 151], "rel_type": "sensitivity", "sbj_tok_span": [24, 28], "obj_tok_span": [32, 36]}], "umls_entity_list": []}, {"text": "Further study could be the mono/combinations of chemotherapy with gefitinib or inhibitors of the AKT pathway which should be tested in vitro in cell lines and in vivo in tumor xenografts with EGFR L858R mutations to determine whether these may be additive or synergistic .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [66, 75], "tok_span": [11, 15]}, {"name": "L858R", "ent_type": "variant", "char_span": [197, 202], "tok_span": [39, 43]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [197, 202], "obj_char_span": [66, 75], "rel_type": "sensitivity", "sbj_tok_span": [39, 43], "obj_tok_span": [11, 15]}], "umls_entity_list": []}, {"text": "Cell culture IC50 Gefitinib μM Exon 19 Del L858R ( ex21 ) L861Q ( ex21 ) T790M", "entity_list": [{"name": "Gefitinib", "ent_type": "drug", "char_span": [18, 27], "tok_span": [4, 7]}, {"name": ") T790M", "ent_type": "variant", "char_span": [71, 78], "tok_span": [28, 33]}, {"name": "Del L858R", "ent_type": "variant", "char_span": [39, 48], "tok_span": [12, 17]}], "relation_list": [{"subject": ") T790M", "object": "Gefitinib", "sbj_char_span": [71, 78], "obj_char_span": [18, 27], "rel_type": "resistance or non-response", "sbj_tok_span": [28, 33], "obj_tok_span": [4, 7]}, {"subject": "Del L858R", "object": "Gefitinib", "sbj_char_span": [39, 48], "obj_char_span": [18, 27], "rel_type": "sensitivity", "sbj_tok_span": [12, 17], "obj_tok_span": [4, 7]}], "umls_entity_list": []}, {"text": "In order to address this aspect we focused our attention on one of the high surface expressing cells , Pe e/10 and as controls on two stable NSCLC cell lines , the gefitinib sensitive PC9 and its resistant counterpart PC9ZD bearing the T790M mutation .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [164, 173], "tok_span": [34, 38]}, {"name": "T790M", "ent_type": "variant", "char_span": [236, 241], "tok_span": [51, 55]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [236, 241], "obj_char_span": [164, 173], "rel_type": "resistance or non-response", "sbj_tok_span": [51, 55], "obj_tok_span": [34, 38]}], "umls_entity_list": []}, {"text": "EGFR L858R , one of the most common activating mutations , allows gefitinib to move deeper into the binding pocket , enhancing the interaction between gefitinib and the receptor . ", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [66, 75], "tok_span": [15, 19]}, {"name": "gefitinib", "ent_type": "drug", "char_span": [151, 160], "tok_span": [31, 35]}, {"name": "L858R", "ent_type": "variant", "char_span": [5, 10], "tok_span": [1, 5]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [5, 10], "obj_char_span": [66, 75], "rel_type": "sensitivity", "sbj_tok_span": [1, 5], "obj_tok_span": [15, 19]}, {"subject": "L858R", "object": "gefitinib", "sbj_char_span": [5, 10], "obj_char_span": [151, 160], "rel_type": "sensitivity", "sbj_tok_span": [1, 5], "obj_tok_span": [31, 35]}], "umls_entity_list": []}, {"text": "Doody and colleagues studied the activity of cetuximab with NSCLC lines bearing both wild-type EGFR and those with activating mutations in the intracellular kinase domain : not only those known to confer sensitivity to gefitinib and erlotinib ( L858R and delL747-T753insS ) but also the TKI-resistant mutation T790M .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [219, 228], "tok_span": [40, 44]}, {"name": "T790M", "ent_type": "variant", "char_span": [310, 315], "tok_span": [74, 78]}, {"name": "L858R", "ent_type": "variant", "char_span": [245, 250], "tok_span": [50, 54]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [310, 315], "obj_char_span": [219, 228], "rel_type": "resistance or non-response", "sbj_tok_span": [74, 78], "obj_tok_span": [40, 44]}, {"subject": "L858R", "object": "gefitinib", "sbj_char_span": [245, 250], "obj_char_span": [219, 228], "rel_type": "sensitivity", "sbj_tok_span": [50, 54], "obj_tok_span": [40, 44]}], "umls_entity_list": []}, {"text": "H1975 NSCLC , harboring T790M mutation in the EGFR which renders gefitinib ineffective , appeared to be sensitive to AMA treatment .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [65, 74], "tok_span": [16, 20]}, {"name": "T790M", "ent_type": "variant", "char_span": [24, 29], "tok_span": [6, 10]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [24, 29], "obj_char_span": [65, 74], "rel_type": "resistance or non-response", "sbj_tok_span": [6, 10], "obj_tok_span": [16, 20]}], "umls_entity_list": []}, {"text": "Activating mutations such as L858R or delL747-P753insS that have previously been reported to be associated with Iressa sensitivity were not found .", "entity_list": [{"name": "Iressa", "ent_type": "drug", "char_span": [112, 118], "tok_span": [29, 32]}, {"name": "L858R", "ent_type": "variant", "char_span": [29, 34], "tok_span": [5, 9]}], "relation_list": [{"subject": "L858R", "object": "Iressa", "sbj_char_span": [29, 34], "obj_char_span": [112, 118], "rel_type": "sensitivity", "sbj_tok_span": [5, 9], "obj_tok_span": [29, 32]}], "umls_entity_list": []}, {"text": "EGFR M+ NSCLC cells ( HCC-827 , PC-9 ) were markedly more sensitive to growth inhibition by an EGFR TKI ( gefitinib ) as well as the AKT inhibitor MK2206 , compared with EGFR wild-type cells ( A549 ) and EGFR T790M cells ( H1975 ) ( Table ) .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [106, 115], "tok_span": [28, 32]}, {"name": "T790M", "ent_type": "variant", "char_span": [209, 214], "tok_span": [56, 60]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [209, 214], "obj_char_span": [106, 115], "rel_type": "resistance or non-response", "sbj_tok_span": [56, 60], "obj_tok_span": [28, 32]}], "umls_entity_list": []}, {"text": "While drug-sensitive L858R bearing lungs showed degenerating tumor after erlotinib ( ) , EGFRL858R+T790M bearing tumors contained virtually all viable cells with no treatment effect ( and ) .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [73, 82], "tok_span": [15, 19]}, {"name": "L858R", "ent_type": "variant", "char_span": [21, 26], "tok_span": [4, 8]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [21, 26], "obj_char_span": [73, 82], "rel_type": "sensitivity", "sbj_tok_span": [4, 8], "obj_tok_span": [15, 19]}], "umls_entity_list": []}, {"text": "We further tested whether T790M expressing lung tumors would respond to the kinase inhibitor , erlotinib , or an hsp90 inhibitor , 17-allylamino-17-demethoxygeldanamycin ( 17-AAG ) .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [95, 104], "tok_span": [18, 22]}, {"name": "T790M", "ent_type": "variant", "char_span": [26, 31], "tok_span": [4, 8]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [26, 31], "obj_char_span": [95, 104], "rel_type": "resistance or non-response", "sbj_tok_span": [4, 8], "obj_tok_span": [18, 22]}], "umls_entity_list": []}, {"text": "TP53 : Not done Yes SD 11.5 erlotinib , dasatinib PD2 10 Adenocarcinoma L858R ( exon 21 ) Sensitive PIK3CA : Not done", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [28, 37], "tok_span": [10, 14]}, {"name": "L858R", "ent_type": "variant", "char_span": [72, 77], "tok_span": [22, 26]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [72, 77], "obj_char_span": [28, 37], "rel_type": "sensitivity", "sbj_tok_span": [22, 26], "obj_tok_span": [10, 14]}], "umls_entity_list": []}, {"text": "A second patient ( case # 5 , Table ) with two known EGFR-sensitive mutations ( L858R and G873E in exon 21 ) and a PIK3CA mutation ( E542K in exon 9 ) had a PR ( 55 % decrease ; duration=9+ months ) on erlotinib/cetuximab/bevacizumab .", "entity_list": [{"name": "erlotinib/cetuximab/bevacizumab", "ent_type": "drug", "char_span": [202, 233], "tok_span": [62, 74]}, {"name": "L858R", "ent_type": "variant", "char_span": [80, 85], "tok_span": [18, 22]}], "relation_list": [{"subject": "L858R", "object": "erlotinib/cetuximab/bevacizumab", "sbj_char_span": [80, 85], "obj_char_span": [202, 233], "rel_type": "sensitivity", "sbj_tok_span": [18, 22], "obj_tok_span": [62, 74]}], "umls_entity_list": []}, {"text": "A third patient ( case # 10 , Table ) with a known EGFR-sensitive mutation ( L858R ) in exon 21 attained SD for 10+ months on erlotinib/bortezomib .", "entity_list": [{"name": "erlotinib/bortezomib", "ent_type": "drug", "char_span": [126, 146], "tok_span": [33, 43]}, {"name": "L858R", "ent_type": "variant", "char_span": [77, 82], "tok_span": [18, 22]}], "relation_list": [{"subject": "L858R", "object": "erlotinib/bortezomib", "sbj_char_span": [77, 82], "obj_char_span": [126, 146], "rel_type": "sensitivity", "sbj_tok_span": [18, 22], "obj_tok_span": [33, 43]}], "umls_entity_list": []}, {"text": "Computed tomography ( CT ) scans of a NSCLC patient ( case # 5 , Table ) with two sensitive EGFR mutations ( L858R in exon 21 and G873E in exon 21 ) and a PIK3CA mutation ( E542K in exon 9 ) a ) CT at baseline , and b ) CT taken 5 months after treatment initiation with erlotinib/cetuximab/bevacizumab demonstrating a PR ( -55 % ) .", "entity_list": [{"name": "erlotinib/cetuximab/bevacizumab", "ent_type": "drug", "char_span": [270, 301], "tok_span": [73, 85]}, {"name": "L858R", "ent_type": "variant", "char_span": [109, 114], "tok_span": [24, 28]}], "relation_list": [{"subject": "L858R", "object": "erlotinib/cetuximab/bevacizumab", "sbj_char_span": [109, 114], "obj_char_span": [270, 301], "rel_type": "sensitivity", "sbj_tok_span": [24, 28], "obj_tok_span": [73, 85]}], "umls_entity_list": []}, {"text": "Most responses to erlotinib occur in patients with EGFR mutations , and both resistant ( e.g. , L861Q ) and sensitive ( e.g. , exon 18 G719S , exon 19 deletion or exon 21 L858R point mutation ) mutations have been identified .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [18, 27], "tok_span": [3, 7]}, {"name": "L858R", "ent_type": "variant", "char_span": [171, 176], "tok_span": [49, 53]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [171, 176], "obj_char_span": [18, 27], "rel_type": "sensitivity", "sbj_tok_span": [49, 53], "obj_tok_span": [3, 7]}], "umls_entity_list": []}, {"text": "However , the T790M variant was also found in some patients who were not treated with gefitinib , and the presence of the T790M mutation was reported to be significantly higher in advanced tumors than in early-stage tumors .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [86, 95], "tok_span": [19, 23]}, {"name": "T790M", "ent_type": "variant", "char_span": [14, 19], "tok_span": [3, 7]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [14, 19], "obj_char_span": [86, 95], "rel_type": "resistance or non-response", "sbj_tok_span": [3, 7], "obj_tok_span": [19, 23]}], "umls_entity_list": []}, {"text": "Thus , Inukai et al proposed that , although the detection of T790M positive tumor cells may be useful for predicting the clinical efficacy of gefitinib , gefitinib treatment might result in the selection of T790M mutant cells and that even a small fraction of T790M positive tumor cells at the beginning of treatment could lead to clinical resistance as a result of the selective proliferation of T790M mutant cells .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [143, 152], "tok_span": [30, 34]}, {"name": "T790M", "ent_type": "variant", "char_span": [62, 67], "tok_span": [14, 18]}, {"name": "gefitinib", "ent_type": "drug", "char_span": [155, 164], "tok_span": [35, 39]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [62, 67], "obj_char_span": [143, 152], "rel_type": "resistance or non-response", "sbj_tok_span": [14, 18], "obj_tok_span": [30, 34]}, {"subject": "T790M", "object": "gefitinib", "sbj_char_span": [62, 67], "obj_char_span": [155, 164], "rel_type": "resistance or non-response", "sbj_tok_span": [14, 18], "obj_tok_span": [35, 39]}], "umls_entity_list": []}, {"text": "However , analysis of DNA from cells in the pleural effusion that developed after treatment with gefitinib showed the C→T mutation at nucleotide 2369 in exon 20 ( C , lower panels ; ) , corresponding to the T790M mutation described above .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [97, 106], "tok_span": [16, 20]}, {"name": "the T790M", "ent_type": "variant", "char_span": [203, 212], "tok_span": [43, 48]}], "relation_list": [{"subject": "the T790M", "object": "gefitinib", "sbj_char_span": [203, 212], "obj_char_span": [97, 106], "rel_type": "resistance or non-response", "sbj_tok_span": [43, 48], "obj_tok_span": [16, 20]}], "umls_entity_list": []}, {"text": "The mutant 2369 T peak was small , possibly because gefitinib had been discontinued in this patient for 4 mo at the time pleural fluid tumor cells were collected ; thus , there was no selective advantage conferred upon cells bearing the T790M mutation .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [52, 61], "tok_span": [11, 15]}, {"name": "T790M", "ent_type": "variant", "char_span": [237, 242], "tok_span": [47, 51]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [237, 242], "obj_char_span": [52, 61], "rel_type": "resistance or non-response", "sbj_tok_span": [47, 51], "obj_tok_span": [11, 15]}], "umls_entity_list": []}, {"text": "Collectively , our results suggest that the T790M mutation is associated with lesions that progress while on gefitinib or erlotinib .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [109, 118], "tok_span": [20, 24]}, {"name": "T790M", "ent_type": "variant", "char_span": [44, 49], "tok_span": [7, 11]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [44, 49], "obj_char_span": [109, 118], "rel_type": "resistance or non-response", "sbj_tok_span": [7, 11], "obj_tok_span": [20, 24]}], "umls_entity_list": []}, {"text": "Gefitinib inhibited the activity of wild-type and L858R EGFRs progressively with increasing concentrations of drug , as demonstrated by a reduction of tyrosine phosphorylated proteins ( A ) and a decrease in p-EGFR : t-EGFR ratios ( B ) . ", "entity_list": [{"name": "Gefitinib", "ent_type": "drug", "char_span": [0, 9], "tok_span": [0, 3]}, {"name": "L858R", "ent_type": "variant", "char_span": [50, 55], "tok_span": [11, 15]}], "relation_list": [{"subject": "L858R", "object": "Gefitinib", "sbj_char_span": [50, 55], "obj_char_span": [0, 9], "rel_type": "sensitivity", "sbj_tok_span": [11, 15], "obj_tok_span": [0, 3]}], "umls_entity_list": []}, {"text": "We show here , through molecular analysis of tumor material from three patients and one NSCLC cell line , as well as additional biochemical studies , that acquired clinical drug resistance to gefitinib or erlotinib is indeed associated with the T790M mutation .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [192, 201], "tok_span": [32, 36]}, {"name": "T790M", "ent_type": "variant", "char_span": [245, 250], "tok_span": [46, 50]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [245, 250], "obj_char_span": [192, 201], "rel_type": "resistance or non-response", "sbj_tok_span": [46, 50], "obj_tok_span": [32, 36]}], "umls_entity_list": []}, {"text": "This study revealed that the quinazoline rings of erlotinib and lapatinib interact differently with the EGFR kinase domain , suggesting that while the T790M mutation may affect inhibition by erlotinib and gefitinib , it may not affect inhibition of EGFR by compounds similar to lapatinib .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [205, 214], "tok_span": [44, 48]}, {"name": "T790M", "ent_type": "variant", "char_span": [151, 156], "tok_span": [30, 34]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [151, 156], "obj_char_span": [205, 214], "rel_type": "resistance or non-response", "sbj_tok_span": [30, 34], "obj_tok_span": [44, 48]}], "umls_entity_list": []}, {"text": "Sequencing Chromatograms with the T790M EGFR Exon 20 Mutation in Various Clinical Specimens and the NSCLC Cell Line H1975 ( A–C ) In all three patients—patient 1 ( A ) , patient 2 ( B ) , and patient 3 ( C ) —the secondary T790M mutation was observed only in lesions obtained after progression on either gefitinib or erlotinib . ( D ) Cell line H1975 contains both an exon 21 L858R mutation ( upper panel ) and the exon 20 T790M mutation ( lower panel ) .", "entity_list": [{"name": "either gefitinib", "ent_type": "drug", "char_span": [297, 313], "tok_span": [73, 78]}, {"name": "T790M", "ent_type": "variant", "char_span": [34, 39], "tok_span": [5, 9]}, {"name": "L858R", "ent_type": "variant", "char_span": [376, 381], "tok_span": [97, 101]}], "relation_list": [{"subject": "T790M", "object": "either gefitinib", "sbj_char_span": [34, 39], "obj_char_span": [297, 313], "rel_type": "resistance or non-response", "sbj_tok_span": [5, 9], "obj_tok_span": [73, 78]}, {"subject": "L858R", "object": "either gefitinib", "sbj_char_span": [376, 381], "obj_char_span": [297, 313], "rel_type": "sensitivity", "sbj_tok_span": [97, 101], "obj_tok_span": [73, 78]}], "umls_entity_list": []}, {"text": "Actually , the response rate was 78 % and 59 % for patients carrying L858R mutation and exon 19 deletion , respectively , which are activating mutations , predictive for response to gefitinib , whereas it was 0 % in patients with atypical mutations .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [182, 191], "tok_span": [35, 39]}, {"name": "L858R", "ent_type": "variant", "char_span": [69, 74], "tok_span": [14, 18]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [69, 74], "obj_char_span": [182, 191], "rel_type": "sensitivity", "sbj_tok_span": [14, 18], "obj_tok_span": [35, 39]}], "umls_entity_list": []}, {"text": "Partial Loss of the Activating Mutant EGFR ( L858R ) Gene in Erlotinib- or Gefitinib-resistant Cell Lines from 11–18", "entity_list": [{"name": "Gefitinib-resistant", "ent_type": "drug", "char_span": [75, 94], "tok_span": [22, 27]}, {"name": "L858R", "ent_type": "variant", "char_span": [45, 50], "tok_span": [10, 14]}], "relation_list": [{"subject": "L858R", "object": "Gefitinib-resistant", "sbj_char_span": [45, 50], "obj_char_span": [75, 94], "rel_type": "sensitivity", "sbj_tok_span": [10, 14], "obj_tok_span": [22, 27]}], "umls_entity_list": []}, {"text": "Insertion mutant autophosphorylation is less sensitive to inhibition by gefitinib than that of L858R , but CL-387,785 is more effective than gefitinib at inhibiting insertion mutant ( and L858R ) autophosphorylation .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [72, 81], "tok_span": [12, 16]}, {"name": "L858R", "ent_type": "variant", "char_span": [95, 100], "tok_span": [19, 23]}, {"name": "gefitinib", "ent_type": "drug", "char_span": [141, 150], "tok_span": [36, 40]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [95, 100], "obj_char_span": [72, 81], "rel_type": "sensitivity", "sbj_tok_span": [19, 23], "obj_tok_span": [12, 16]}, {"subject": "L858R", "object": "gefitinib", "sbj_char_span": [95, 100], "obj_char_span": [141, 150], "rel_type": "sensitivity", "sbj_tok_span": [19, 23], "obj_tok_span": [36, 40]}], "umls_entity_list": []}, {"text": "An objective response rate of 25 % for gefitinib treatment was reported in 16 patients with exon 20 mutations , and it was much lower than the response rate of patients with deletions in exon 19 and L858R mutations .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [39, 48], "tok_span": [8, 12]}, {"name": "L858R", "ent_type": "variant", "char_span": [199, 204], "tok_span": [40, 44]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [199, 204], "obj_char_span": [39, 48], "rel_type": "sensitivity", "sbj_tok_span": [40, 44], "obj_tok_span": [8, 12]}], "umls_entity_list": []}, {"text": "However , treatment with gefitinib and erlotinib will eventually fail because of the development of acquired drug resistance resulting from amplification of the MET proto-oncogene or the threonine-to-methionine amino acid substitution at position 790 ( T790M ) of EGFR , which is detected in 50 % of clinically resistant patients , .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [25, 34], "tok_span": [4, 8]}, {"name": "T790M", "ent_type": "variant", "char_span": [253, 258], "tok_span": [50, 54]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [253, 258], "obj_char_span": [25, 34], "rel_type": "resistance or non-response", "sbj_tok_span": [50, 54], "obj_tok_span": [4, 8]}], "umls_entity_list": []}, {"text": "Compared with the parental compound gefitinib , V1801 is a relatively weak EGFR inhibitor which bears a much more potent cytotoxicity in T790M EGFR harboring NCI-H1975 cells ( ) .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [36, 45], "tok_span": [5, 9]}, {"name": "T790M", "ent_type": "variant", "char_span": [137, 142], "tok_span": [27, 31]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [137, 142], "obj_char_span": [36, 45], "rel_type": "resistance or non-response", "sbj_tok_span": [27, 31], "obj_tok_span": [5, 9]}], "umls_entity_list": []}, {"text": "One of the proposed mechanisms of resistance to gefitinib and erlotinib is the T790M mutation on exon 20 .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [48, 57], "tok_span": [8, 12]}, {"name": "T790M", "ent_type": "variant", "char_span": [79, 84], "tok_span": [19, 23]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [79, 84], "obj_char_span": [48, 57], "rel_type": "resistance or non-response", "sbj_tok_span": [19, 23], "obj_tok_span": [8, 12]}], "umls_entity_list": []}, {"text": "Emerging data suggest that patients with NSCLC and EGFR exon 19 deletion have a longer survival following treatment with gefitinib or erlotinib compared with those with L858R mutation .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [121, 130], "tok_span": [19, 23]}, {"name": "L858R", "ent_type": "variant", "char_span": [169, 174], "tok_span": [32, 36]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [169, 174], "obj_char_span": [121, 130], "rel_type": "sensitivity", "sbj_tok_span": [32, 36], "obj_tok_span": [19, 23]}], "umls_entity_list": []}, {"text": "Therefore , to elucidate the structural and dynamic consequences of the DM on the catalytic domain of EGFR and its affinity toward gefitinib , we performed molecular dynamic simulations ( 50 ns ) of the wild type ( WT ) -EGFR and three oncogenic mutants : G719S , T790M , and DM in complex with gefitinib .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [131, 140], "tok_span": [22, 26]}, {"name": "T790M", "ent_type": "variant", "char_span": [264, 269], "tok_span": [55, 59]}, {"name": "gefitinib", "ent_type": "drug", "char_span": [295, 304], "tok_span": [65, 69]}, {"name": "G719S", "ent_type": "variant", "char_span": [256, 261], "tok_span": [50, 54]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [264, 269], "obj_char_span": [131, 140], "rel_type": "resistance or non-response", "sbj_tok_span": [55, 59], "obj_tok_span": [22, 26]}, {"subject": "T790M", "object": "gefitinib", "sbj_char_span": [264, 269], "obj_char_span": [295, 304], "rel_type": "resistance or non-response", "sbj_tok_span": [55, 59], "obj_tok_span": [65, 69]}, {"subject": "G719S", "object": "gefitinib", "sbj_char_span": [256, 261], "obj_char_span": [131, 140], "rel_type": "sensitivity", "sbj_tok_span": [50, 54], "obj_tok_span": [22, 26]}, {"subject": "G719S", "object": "gefitinib", "sbj_char_span": [256, 261], "obj_char_span": [295, 304], "rel_type": "sensitivity", "sbj_tok_span": [50, 54], "obj_tok_span": [65, 69]}], "umls_entity_list": []}, {"text": "To further characterize the effect of the T790M mutation on the conformational distribution of structural elements , we calculated the time dependent distance between the mass centers of gefitinib and the active site residue M793 for the WT and the mutant proteins .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [187, 196], "tok_span": [31, 35]}, {"name": "T790M", "ent_type": "variant", "char_span": [42, 47], "tok_span": [7, 11]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [42, 47], "obj_char_span": [187, 196], "rel_type": "resistance or non-response", "sbj_tok_span": [7, 11], "obj_tok_span": [31, 35]}], "umls_entity_list": []}, {"text": "( C ) EGFR T790M mutant does not resemble pEGFR unlike the EGFR L858R mutant shown in B. ( D–F ) increased inhibition potency for Erlotinib against EGFR L858R mutant compared to EGFR WT protein and subsequent decrease in potency for Erlotinib against EGFR L858R + E884K double mutant . ( G–I ) increased inhibition potency for Gefitinib against EGFR L858R mutant compared to EGFR WT protein and subsequent further increase in potency for Gefitinib against EGFR L858R + E884K double mutant .", "entity_list": [{"name": "for Gefitinib", "ent_type": "drug", "char_span": [323, 336], "tok_span": [82, 86]}, {"name": "T790M", "ent_type": "variant", "char_span": [11, 16], "tok_span": [4, 8]}, {"name": "for Gefitinib", "ent_type": "drug", "char_span": [434, 447], "tok_span": [104, 108]}, {"name": "for Erlotinib", "ent_type": "drug", "char_span": [126, 139], "tok_span": [35, 39]}, {"name": "L858R", "ent_type": "variant", "char_span": [64, 69], "tok_span": [18, 22]}, {"name": "for Erlotinib", "ent_type": "drug", "char_span": [229, 242], "tok_span": [56, 60]}], "relation_list": [{"subject": "T790M", "object": "for Gefitinib", "sbj_char_span": [11, 16], "obj_char_span": [323, 336], "rel_type": "resistance or non-response", "sbj_tok_span": [4, 8], "obj_tok_span": [82, 86]}, {"subject": "T790M", "object": "for Gefitinib", "sbj_char_span": [11, 16], "obj_char_span": [434, 447], "rel_type": "resistance or non-response", "sbj_tok_span": [4, 8], "obj_tok_span": [104, 108]}, {"subject": "L858R", "object": "for Erlotinib", "sbj_char_span": [64, 69], "obj_char_span": [126, 139], "rel_type": "sensitivity", "sbj_tok_span": [18, 22], "obj_tok_span": [35, 39]}, {"subject": "L858R", "object": "for Erlotinib", "sbj_char_span": [64, 69], "obj_char_span": [229, 242], "rel_type": "sensitivity", "sbj_tok_span": [18, 22], "obj_tok_span": [56, 60]}, {"subject": "T790M", "object": "for Erlotinib", "sbj_char_span": [11, 16], "obj_char_span": [126, 139], "rel_type": "resistance or non-response", "sbj_tok_span": [4, 8], "obj_tok_span": [35, 39]}, {"subject": "T790M", "object": "for Erlotinib", "sbj_char_span": [11, 16], "obj_char_span": [229, 242], "rel_type": "resistance or non-response", "sbj_tok_span": [4, 8], "obj_tok_span": [56, 60]}], "umls_entity_list": []}, {"text": "The mechanism of resistance in three patients was acquisition of a T790M substitution in EGFR that was not present at time of diagnosis , but was detected with progression of disease after initial response to gefitinib or erlotinib .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [209, 218], "tok_span": [38, 42]}, {"name": "T790M", "ent_type": "variant", "char_span": [67, 72], "tok_span": [11, 15]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [67, 72], "obj_char_span": [209, 218], "rel_type": "resistance or non-response", "sbj_tok_span": [11, 15], "obj_tok_span": [38, 42]}], "umls_entity_list": []}, {"text": "Furthermore , the NSCLC cell line H1975 harbors both the L858R and T790M mutations , and is resistant to inhibition by gefitinib or erlotinib , unlike cell lines that express the L858R allele alone .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [119, 128], "tok_span": [30, 34]}, {"name": "T790M", "ent_type": "variant", "char_span": [67, 72], "tok_span": [18, 22]}, {"name": "L858R", "ent_type": "variant", "char_span": [57, 62], "tok_span": [13, 17]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [67, 72], "obj_char_span": [119, 128], "rel_type": "resistance or non-response", "sbj_tok_span": [18, 22], "obj_tok_span": [30, 34]}, {"subject": "L858R", "object": "gefitinib", "sbj_char_span": [57, 62], "obj_char_span": [119, 128], "rel_type": "sensitivity", "sbj_tok_span": [13, 17], "obj_tok_span": [30, 34]}], "umls_entity_list": []}, {"text": "These observations provide convincing evidence that , at least in some patients with NSCLC , resistance to gefitinib or erlotinib can be attributed to acquisition of a T790M mutation in the context of EGFR .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [107, 116], "tok_span": [17, 21]}, {"name": "T790M", "ent_type": "variant", "char_span": [168, 173], "tok_span": [33, 37]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [168, 173], "obj_char_span": [107, 116], "rel_type": "resistance or non-response", "sbj_tok_span": [33, 37], "obj_tok_span": [17, 21]}], "umls_entity_list": []}, {"text": "H1975 cell line was chosen because it expresses the ‘gatekeeper'-resistant T790M-EGFR mutation ( in-cis with L858R ) in the receptor kinase domain hydrophobic pocket , representing a major mechanism of resistance to reversible EGFR-TKI ( erlotinib/gefitinib ) ( ; ) .", "entity_list": [{"name": "erlotinib/gefitinib", "ent_type": "drug", "char_span": [238, 257], "tok_span": [56, 65]}, {"name": "with L858R", "ent_type": "variant", "char_span": [104, 114], "tok_span": [29, 34]}, {"name": "( erlotinib/gefitinib", "ent_type": "drug", "char_span": [236, 257], "tok_span": [55, 65]}], "relation_list": [{"subject": "with L858R", "object": "erlotinib/gefitinib", "sbj_char_span": [104, 114], "obj_char_span": [238, 257], "rel_type": "sensitivity", "sbj_tok_span": [29, 34], "obj_tok_span": [56, 65]}, {"subject": "with L858R", "object": "( erlotinib/gefitinib", "sbj_char_span": [104, 114], "obj_char_span": [236, 257], "rel_type": "sensitivity", "sbj_tok_span": [29, 34], "obj_tok_span": [55, 65]}], "umls_entity_list": []}, {"text": "The research article by Pao et al. provides important new information addressing three patients with acquired resistance to gefitinib or erlotinib in progressing tumors containing a secondary mutation , leading to the substitution of methionine for threonine at position 790 ( T790M ) in exon 20 .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [124, 133], "tok_span": [20, 24]}, {"name": "T790M", "ent_type": "variant", "char_span": [277, 282], "tok_span": [52, 56]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [277, 282], "obj_char_span": [124, 133], "rel_type": "resistance or non-response", "sbj_tok_span": [52, 56], "obj_tok_span": [20, 24]}], "umls_entity_list": []}, {"text": "The tumor progressed and developed an additional T790M mutation after nine months of gefitinib treatment .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [85, 94], "tok_span": [16, 20]}, {"name": "T790M", "ent_type": "variant", "char_span": [49, 54], "tok_span": [7, 11]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [49, 54], "obj_char_span": [85, 94], "rel_type": "resistance or non-response", "sbj_tok_span": [7, 11], "obj_tok_span": [16, 20]}], "umls_entity_list": []}, {"text": "The T790M mutation is rarely found in tumors from patients not treated with either gefitinib or erlotinib , and could be discovered only in progressing tumors , in addition to a primary drug-sensitive mutation in EGFR .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [83, 92], "tok_span": [17, 21]}, {"name": "T790M", "ent_type": "variant", "char_span": [4, 9], "tok_span": [1, 5]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [4, 9], "obj_char_span": [83, 92], "rel_type": "resistance or non-response", "sbj_tok_span": [1, 5], "obj_tok_span": [17, 21]}], "umls_entity_list": []}, {"text": "In the case of our patient , the patient received no prior systemic chemotherapy , and we identified an initial gefitinib sensitizing L858R EGFR mutation , followed by a T790M mutation concomitantly with L858R in the biopsy taken from the growing tumor nine months after gefitinib use .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [112, 121], "tok_span": [20, 24]}, {"name": "T790M", "ent_type": "variant", "char_span": [170, 175], "tok_span": [36, 40]}, {"name": "gefitinib", "ent_type": "drug", "char_span": [271, 280], "tok_span": [59, 63]}, {"name": "L858R", "ent_type": "variant", "char_span": [134, 139], "tok_span": [26, 30]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [170, 175], "obj_char_span": [112, 121], "rel_type": "resistance or non-response", "sbj_tok_span": [36, 40], "obj_tok_span": [20, 24]}, {"subject": "T790M", "object": "gefitinib", "sbj_char_span": [170, 175], "obj_char_span": [271, 280], "rel_type": "resistance or non-response", "sbj_tok_span": [36, 40], "obj_tok_span": [59, 63]}, {"subject": "L858R", "object": "gefitinib", "sbj_char_span": [134, 139], "obj_char_span": [112, 121], "rel_type": "sensitivity", "sbj_tok_span": [26, 30], "obj_tok_span": [20, 24]}, {"subject": "L858R", "object": "gefitinib", "sbj_char_span": [134, 139], "obj_char_span": [271, 280], "rel_type": "sensitivity", "sbj_tok_span": [26, 30], "obj_tok_span": [59, 63]}], "umls_entity_list": []}, {"text": "We describe a chemonaive patient with gefitinib-sensitive lung adenocarcinoma harboring L858R .", "entity_list": [{"name": "gefitinib-sensitive", "ent_type": "drug", "char_span": [38, 57], "tok_span": [8, 14]}, {"name": "L858R", "ent_type": "variant", "char_span": [88, 93], "tok_span": [17, 21]}], "relation_list": [{"subject": "L858R", "object": "gefitinib-sensitive", "sbj_char_span": [88, 93], "obj_char_span": [38, 57], "rel_type": "sensitivity", "sbj_tok_span": [17, 21], "obj_tok_span": [8, 14]}], "umls_entity_list": []}, {"text": "Gefitinib responsiveness results in large part from the drug 's effective inhibition of essential antiapoptotic signals transduced by the mutant receptor , and L858R is the most commonly detected mutation .", "entity_list": [{"name": "Gefitinib", "ent_type": "drug", "char_span": [0, 9], "tok_span": [0, 3]}, {"name": "L858R", "ent_type": "variant", "char_span": [160, 165], "tok_span": [27, 31]}], "relation_list": [{"subject": "L858R", "object": "Gefitinib", "sbj_char_span": [160, 165], "obj_char_span": [0, 9], "rel_type": "sensitivity", "sbj_tok_span": [27, 31], "obj_tok_span": [0, 3]}], "umls_entity_list": []}, {"text": "Citation : Gow CH , Shih JY , Chang YL , Yu CJ ( 2005 ) Acquired gefitinib-resistant mutation of epidermal growth factor receptor in a chemonaive lung adenocarcinoma harboring gefitinib-sensitive mutation L858R .", "entity_list": [{"name": "gefitinib-resistant", "ent_type": "drug", "char_span": [65, 84], "tok_span": [22, 28]}, {"name": "L858R", "ent_type": "variant", "char_span": [205, 210], "tok_span": [49, 53]}, {"name": "gefitinib-sensitive", "ent_type": "drug", "char_span": [176, 195], "tok_span": [42, 48]}], "relation_list": [{"subject": "L858R", "object": "gefitinib-resistant", "sbj_char_span": [205, 210], "obj_char_span": [65, 84], "rel_type": "sensitivity", "sbj_tok_span": [49, 53], "obj_tok_span": [22, 28]}, {"subject": "L858R", "object": "gefitinib-sensitive", "sbj_char_span": [205, 210], "obj_char_span": [176, 195], "rel_type": "sensitivity", "sbj_tok_span": [49, 53], "obj_tok_span": [42, 48]}], "umls_entity_list": []}, {"text": "Another second-generation irreversible EGFR TKI , dacomitinib , demonstrated preclinical efficacy in NSCLC tumours harbouring the T790M gatekeeper mutation , , which is present in ∼50 % of NSCLCs that have acquired resistance to erlotinib or gefitinib , .", "entity_list": [{"name": "or gefitinib", "ent_type": "drug", "char_span": [239, 251], "tok_span": [53, 58]}, {"name": "T790M", "ent_type": "variant", "char_span": [130, 135], "tok_span": [24, 28]}, {"name": "to erlotinib", "ent_type": "drug", "char_span": [226, 238], "tok_span": [48, 53]}], "relation_list": [{"subject": "T790M", "object": "or gefitinib", "sbj_char_span": [130, 135], "obj_char_span": [239, 251], "rel_type": "resistance or non-response", "sbj_tok_span": [24, 28], "obj_tok_span": [53, 58]}, {"subject": "T790M", "object": "to erlotinib", "sbj_char_span": [130, 135], "obj_char_span": [226, 238], "rel_type": "resistance or non-response", "sbj_tok_span": [24, 28], "obj_tok_span": [48, 53]}], "umls_entity_list": []}, {"text": "For example , gefitinib resistance in patients with EGFR mutant non-small cell lung cancers has been shown to be mediated in some cases by the selection of cancer cells harboring the EGFR ( T790M ) gatekeeper mutation and/or MET gene amplification .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [14, 23], "tok_span": [3, 7]}, {"name": "T790M", "ent_type": "variant", "char_span": [190, 195], "tok_span": [38, 42]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [190, 195], "obj_char_span": [14, 23], "rel_type": "resistance or non-response", "sbj_tok_span": [38, 42], "obj_tok_span": [3, 7]}], "umls_entity_list": []}, {"text": "As previously demonstrated , cells with the deletion mutant and the point mutation L858R were inhibited by the TKIs gefitinib and erlotinib , while the exon 20 insertion mutation was resistant . ", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [116, 125], "tok_span": [23, 27]}, {"name": "L858R", "ent_type": "variant", "char_span": [83, 88], "tok_span": [13, 17]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [83, 88], "obj_char_span": [116, 125], "rel_type": "sensitivity", "sbj_tok_span": [13, 17], "obj_tok_span": [23, 27]}], "umls_entity_list": []}, {"text": "Female 47 Moderately differentiated papilla adenocarcinoma 10 Gefitinib SD 21 39 P753S , L858R", "entity_list": [{"name": "Gefitinib", "ent_type": "drug", "char_span": [62, 71], "tok_span": [9, 12]}, {"name": "L858R", "ent_type": "variant", "char_span": [89, 94], "tok_span": [20, 24]}], "relation_list": [{"subject": "L858R", "object": "Gefitinib", "sbj_char_span": [89, 94], "obj_char_span": [62, 71], "rel_type": "sensitivity", "sbj_tok_span": [20, 24], "obj_tok_span": [9, 12]}], "umls_entity_list": []}, {"text": "Female 53 Moderately differentiated squamous carcinoma adenosquamous carcinoma and fine counts 0 Gefitinib PR 15 58+ delE746-A750 , L858R", "entity_list": [{"name": "Gefitinib", "ent_type": "drug", "char_span": [97, 106], "tok_span": [16, 19]}, {"name": "L858R", "ent_type": "variant", "char_span": [132, 137], "tok_span": [32, 36]}], "relation_list": [{"subject": "L858R", "object": "Gefitinib", "sbj_char_span": [132, 137], "obj_char_span": [97, 106], "rel_type": "sensitivity", "sbj_tok_span": [32, 36], "obj_tok_span": [16, 19]}], "umls_entity_list": []}, {"text": "Male 70 Moderately and poorly differentiated adenocarcinoma 20 Gefitinib SD 6 6.5 S768I , L858R", "entity_list": [{"name": "Gefitinib", "ent_type": "drug", "char_span": [63, 72], "tok_span": [9, 12]}, {"name": "L858R", "ent_type": "variant", "char_span": [90, 95], "tok_span": [22, 26]}], "relation_list": [{"subject": "L858R", "object": "Gefitinib", "sbj_char_span": [90, 95], "obj_char_span": [63, 72], "rel_type": "sensitivity", "sbj_tok_span": [22, 26], "obj_tok_span": [9, 12]}], "umls_entity_list": []}, {"text": "Examples include the T790M mutation in the gefitinib binding pocket of EGFR ; the T164I mutation within the epinephrine binding pocket of β2-adrenergic receptor ; and the polymorphism within binding pocket of STI-571 to c-Abl .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [43, 52], "tok_span": [10, 14]}, {"name": "T790M", "ent_type": "variant", "char_span": [21, 26], "tok_span": [3, 7]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [21, 26], "obj_char_span": [43, 52], "rel_type": "resistance or non-response", "sbj_tok_span": [3, 7], "obj_tok_span": [10, 14]}], "umls_entity_list": []}, {"text": "Furthermore , the association of cetuximab with afatinib has been shown to be effective to overcome T790M mediated drug resistance . ", "entity_list": [{"name": "T790M", "ent_type": "variant", "char_span": [100, 105], "tok_span": [20, 24]}, {"name": "afatinib", "ent_type": "drug", "char_span": [48, 56], "tok_span": [10, 12]}], "relation_list": [{"subject": "T790M", "object": "afatinib", "sbj_char_span": [100, 105], "obj_char_span": [48, 56], "rel_type": "response", "sbj_tok_span": [20, 24], "obj_tok_span": [10, 12]}], "umls_entity_list": []}, {"text": "While T790M is found in about half of patients with acquired resistance to erlotinib and gefitinib , the other mechanism of resistance – MET amplification – makes up about 5 % –10 % of these patients .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [75, 84], "tok_span": [16, 20]}, {"name": "T790M", "ent_type": "variant", "char_span": [6, 11], "tok_span": [1, 5]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [6, 11], "obj_char_span": [75, 84], "rel_type": "resistance or non-response", "sbj_tok_span": [1, 5], "obj_tok_span": [16, 20]}], "umls_entity_list": []}, {"text": "Three of the 4 patients with T790M status ascertained from an archival biopsy initiated dacomitinib more than 90 days after discontinuing from erlotinib .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [143, 152], "tok_span": [31, 35]}, {"name": "T790M", "ent_type": "variant", "char_span": [29, 34], "tok_span": [6, 10]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [29, 34], "obj_char_span": [143, 152], "rel_type": "resistance or non-response", "sbj_tok_span": [6, 10], "obj_tok_span": [31, 35]}], "umls_entity_list": []}, {"text": "The increased inhibition potency for Erlotinib against the oncogenic EGFR L858R mutant ( over the EGFR WT protein ) correlates with decreased global connectivity of the hub residues ( Arg-958 , Glu-884 , Gln-894 and Asp-896 ) in the mutant ( – wild type , – L858R mutant ) .", "entity_list": [{"name": "Erlotinib", "ent_type": "drug", "char_span": [37, 46], "tok_span": [5, 8]}, {"name": "L858R", "ent_type": "variant", "char_span": [74, 79], "tok_span": [12, 16]}], "relation_list": [{"subject": "L858R", "object": "Erlotinib", "sbj_char_span": [74, 79], "obj_char_span": [37, 46], "rel_type": "sensitivity", "sbj_tok_span": [12, 16], "obj_tok_span": [5, 8]}], "umls_entity_list": []}, {"text": "These results suggest that the addition of CX-4945 to EGFR-TKI may overcome T790M mediated resistance through the increased activity of EGFR-TKI to suppress EGFR signals by the down-regulation of EGFR . 10.1371/journal.pone.0114000.g004Addition of CX-4945 to EGFR-TKIs substantially suppressed the EGFR signaling pathway in gefitinib/erlotinib-resistant , PC-9 cells .", "entity_list": [{"name": "gefitinib/erlotinib-resistant", "ent_type": "drug", "char_span": [324, 353], "tok_span": [80, 91]}, {"name": "T790M", "ent_type": "variant", "char_span": [76, 81], "tok_span": [18, 22]}], "relation_list": [{"subject": "T790M", "object": "gefitinib/erlotinib-resistant", "sbj_char_span": [76, 81], "obj_char_span": [324, 353], "rel_type": "resistance or non-response", "sbj_tok_span": [18, 22], "obj_tok_span": [80, 91]}], "umls_entity_list": []}, {"text": "The L858R EGFR kinase domain is , however , sensitive to erlotinib and MIG6 inhibition , .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [57, 66], "tok_span": [14, 18]}, {"name": "L858R", "ent_type": "variant", "char_span": [4, 9], "tok_span": [1, 5]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [4, 9], "obj_char_span": [57, 66], "rel_type": "sensitivity", "sbj_tok_span": [1, 5], "obj_tok_span": [14, 18]}], "umls_entity_list": []}, {"text": "The L858R and Δ746–750 tEGFR forms were potently inhibited by erlotinib with apparent Kis in the range of 0.1–0.4 µM , about equal to the apparent Ki of erlotinib for WT tEGFR complexed with EGF .", "entity_list": [{"name": "by erlotinib", "ent_type": "drug", "char_span": [59, 71], "tok_span": [19, 24]}, {"name": "L858R", "ent_type": "variant", "char_span": [4, 9], "tok_span": [1, 5]}, {"name": "Ki of erlotinib", "ent_type": "drug", "char_span": [147, 162], "tok_span": [46, 52]}], "relation_list": [{"subject": "L858R", "object": "by erlotinib", "sbj_char_span": [4, 9], "obj_char_span": [59, 71], "rel_type": "sensitivity", "sbj_tok_span": [1, 5], "obj_tok_span": [19, 24]}, {"subject": "L858R", "object": "Ki of erlotinib", "sbj_char_span": [4, 9], "obj_char_span": [147, 162], "rel_type": "sensitivity", "sbj_tok_span": [1, 5], "obj_tok_span": [46, 52]}], "umls_entity_list": []}, {"text": "( c ) Western blot analysis of the expression levels of WT , L858R , and Δ746–750 tEGFRs in the presence and absence of the EGFR inhibitor erlotinib .", "entity_list": [{"name": "inhibitor erlotinib", "ent_type": "drug", "char_span": [129, 148], "tok_span": [35, 40]}, {"name": "L858R", "ent_type": "variant", "char_span": [61, 66], "tok_span": [13, 17]}], "relation_list": [{"subject": "L858R", "object": "inhibitor erlotinib", "sbj_char_span": [61, 66], "obj_char_span": [129, 148], "rel_type": "sensitivity", "sbj_tok_span": [13, 17], "obj_tok_span": [35, 40]}], "umls_entity_list": []}, {"text": "HEK293 GnTi− cells were transfected with the plasmid DNA encoding tEGFR , and cultured in the presence and absence of 50 nM erlotinib . ( d ) Coomassie blue stained SDS-PAGE analysis of the purified L858R tEGFR and Δ746–750 tEGFR with either EGF or Cetuximab ( Cetux ) as ligand .", "entity_list": [{"name": "nM erlotinib", "ent_type": "drug", "char_span": [121, 133], "tok_span": [26, 31]}, {"name": "L858R", "ent_type": "variant", "char_span": [199, 204], "tok_span": [48, 52]}], "relation_list": [{"subject": "L858R", "object": "nM erlotinib", "sbj_char_span": [199, 204], "obj_char_span": [121, 133], "rel_type": "sensitivity", "sbj_tok_span": [48, 52], "obj_tok_span": [26, 31]}], "umls_entity_list": []}, {"text": "( A ) The T790M secondary mutation in exon 20 of EGFR is present in 50 % –70 % of NSCLC patients who acquire resistance to EGFR-TKIs , such as gefitinib or erlotinib .", "entity_list": [{"name": "or erlotinib", "ent_type": "drug", "char_span": [153, 165], "tok_span": [41, 46]}, {"name": "T790M", "ent_type": "variant", "char_span": [10, 15], "tok_span": [4, 8]}], "relation_list": [{"subject": "T790M", "object": "or erlotinib", "sbj_char_span": [10, 15], "obj_char_span": [153, 165], "rel_type": "resistance or non-response", "sbj_tok_span": [4, 8], "obj_tok_span": [41, 46]}], "umls_entity_list": []}, {"text": "A final mechanism of resistance in gastric cancer cell lines has been demonstrated when MET amplified SNU6838 gastric cancer cell lines were treated with the MET inhibitors PHA-665752 and PF2341066 ; a novel mutation occurred in the activation loop of MET , causing a conformal change that blocked inhibitor binding analogous to the gatekeeper mutations seen in EGFR ( T790M ) following erlotinib treatment and in ABL ( T315I ) following imatinib .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [387, 396], "tok_span": [79, 83]}, {"name": "T790M", "ent_type": "variant", "char_span": [369, 374], "tok_span": [73, 77]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [369, 374], "obj_char_span": [387, 396], "rel_type": "resistance or non-response", "sbj_tok_span": [73, 77], "obj_tok_span": [79, 83]}], "umls_entity_list": []}, {"text": "However , in patients with acquired resistance , tumor cells bearing EGFR T790M represented a minority of cells , and as such , part of the tumor may remain responsive to erlotinib or gefitinib. , The other signal pathway related EGFR followed the same principles .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [171, 180], "tok_span": [34, 38]}, {"name": "T790M", "ent_type": "variant", "char_span": [74, 79], "tok_span": [12, 16]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [74, 79], "obj_char_span": [171, 180], "rel_type": "resistance or non-response", "sbj_tok_span": [12, 16], "obj_tok_span": [34, 38]}], "umls_entity_list": []}, {"text": "Changes in dasatinib and erlotinib ( 2 ) induced cell viability were assessed in PC9 cells stably expressing either a mutant drug sensitive EGFR allele ( L858R ) or a drug resistant allele ( L858R/T790M ) ( ) .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [25, 34], "tok_span": [5, 9]}, {"name": "L858R", "ent_type": "variant", "char_span": [154, 159], "tok_span": [31, 35]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [154, 159], "obj_char_span": [25, 34], "rel_type": "sensitivity", "sbj_tok_span": [31, 35], "obj_tok_span": [5, 9]}], "umls_entity_list": []}, {"text": "PC9 cells expressing either L858R EGFR or L858R/T790M EGFR were exposed to indicated concentrations of dasatinib ( D ) or erlotinib ( E ) for 120 hr and cell viability was accessed .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [122, 131], "tok_span": [33, 37]}, {"name": "L858R", "ent_type": "variant", "char_span": [28, 33], "tok_span": [5, 9]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [28, 33], "obj_char_span": [122, 131], "rel_type": "sensitivity", "sbj_tok_span": [5, 9], "obj_tok_span": [33, 37]}], "umls_entity_list": []}, {"text": "B PC9 cells expressing either L858R EGFR ( left panel ) or L858R/T790M EGFR ( right panel ) were exposed to indicated concentrations of erlotinib ( E ) or dasatinib ( D ) for 24 hr. ", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [136, 145], "tok_span": [36, 40]}, {"name": "L858R", "ent_type": "variant", "char_span": [30, 35], "tok_span": [6, 10]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [30, 35], "obj_char_span": [136, 145], "rel_type": "sensitivity", "sbj_tok_span": [6, 10], "obj_tok_span": [36, 40]}], "umls_entity_list": []}, {"text": "Erlotinib EGFR EGFR protein expression positive EGFR exon 19 deletion or exon 21 substitution ( L858R ) positive Clinical pharmacology Indications and usage , dosage and administration , clinical pharmacology , clinical studies Everolimus ERBB2 HER2 protein overexpression negative Indications and usage , boxed warning , adverse reactions , use in specific populations , clinical pharmacology , clinical studies", "entity_list": [{"name": "Erlotinib", "ent_type": "drug", "char_span": [0, 9], "tok_span": [0, 3]}, {"name": "L858R", "ent_type": "variant", "char_span": [96, 101], "tok_span": [17, 21]}], "relation_list": [{"subject": "L858R", "object": "Erlotinib", "sbj_char_span": [96, 101], "obj_char_span": [0, 9], "rel_type": "sensitivity", "sbj_tok_span": [17, 21], "obj_tok_span": [0, 3]}], "umls_entity_list": []}, {"text": "Inhibition of epidermal growth factor receptor (EGFR) kinase activity by EGFR tyrosine kinase inhibitors ( EGFR-TKIs ) , such as gefitinib and erlotinib , can result in improved response and prolonged progression-free survival ( PFS ) in selected non-small cell lung cancer ( NSCLC ) patients harboring sensitizing EGFR mutations , especially the exon 19del and exon 21 L858R mutations – . ", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [143, 152], "tok_span": [30, 34]}, {"name": "L858R", "ent_type": "variant", "char_span": [370, 375], "tok_span": [75, 79]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [370, 375], "obj_char_span": [143, 152], "rel_type": "sensitivity", "sbj_tok_span": [75, 79], "obj_tok_span": [30, 34]}], "umls_entity_list": []}, {"text": "Poziotinib ( also known as HM781-36B ) , a new potent irreversible inhibitor of EGFR , HER2 , HER4 , and transient erythroblastopenia of childhood family of kinases inhibitor ( BTK , BLK , and BMX ) , demonstrated preclinical efficacy against T790M mutant at eightfold lower doses compared to afatinib . ", "entity_list": [{"name": "T790M", "ent_type": "variant", "char_span": [243, 248], "tok_span": [58, 62]}, {"name": "afatinib", "ent_type": "drug", "char_span": [293, 301], "tok_span": [70, 72]}], "relation_list": [{"subject": "T790M", "object": "afatinib", "sbj_char_span": [243, 248], "obj_char_span": [293, 301], "rel_type": "response", "sbj_tok_span": [58, 62], "obj_tok_span": [70, 72]}], "umls_entity_list": []}, {"text": "Tyrosine kinase inhibitors ( TKIs ) targeting the epidermal growth factor receptor (EGFR) , such as gefitinib and erlotinib , have shown remarkable activity in the patients with NSCLC , and particularly these TKIs are more effective to NSCLC with EGFR mutations in 19 exon ( in-frame deletions ) and exon 21 ( L858R point mutation ) , which are found to be more prevalent in Asian patients .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [114, 123], "tok_span": [25, 29]}, {"name": "L858R", "ent_type": "variant", "char_span": [310, 315], "tok_span": [66, 70]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [310, 315], "obj_char_span": [114, 123], "rel_type": "sensitivity", "sbj_tok_span": [66, 70], "obj_tok_span": [25, 29]}], "umls_entity_list": []}, {"text": "Although the sequence analysis of EGFR might be necessary for clinical trials using TKI such as gefitinib or erlotinib , these simple methods established in this study for detection of exon 19 deletion and exon 21 L858R mutation are very useful for screening .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [109, 118], "tok_span": [22, 26]}, {"name": "L858R", "ent_type": "variant", "char_span": [214, 219], "tok_span": [43, 47]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [214, 219], "obj_char_span": [109, 118], "rel_type": "sensitivity", "sbj_tok_span": [43, 47], "obj_tok_span": [22, 26]}], "umls_entity_list": []}, {"text": "Non-small cell lung cancer Kinase domain deletions ( exon 19 ) , point mutations ( exon 21 ) Gene amplification Erlotinib , Gefitinib T790M gatekeeper mutation ( 50 % ) , , elevated c-Met/HGF expression ( 20 % ) – Colorectal cancer ( metastatic ) Rare , Overexpression , copy number increase Cetuximab , Panitumumab K-ras– , B-raf , PIK3CA , PTEN mutations", "entity_list": [{"name": "Cetuximab", "ent_type": "drug", "char_span": [292, 301], "tok_span": [72, 75]}, {"name": "T790M", "ent_type": "variant", "char_span": [134, 139], "tok_span": [30, 34]}], "relation_list": [{"subject": "T790M", "object": "Cetuximab", "sbj_char_span": [134, 139], "obj_char_span": [292, 301], "rel_type": "response", "sbj_tok_span": [30, 34], "obj_tok_span": [72, 75]}], "umls_entity_list": []}, {"text": "These second-generation EGFR inhibitors have also been shown to drive drug resistance through the acquisition of T790M in both preclinical and clinical settings , suggesting low potency against T790M. , As a potential solution , afatinib was combined with the EGFR antibody cetuximab in a Phase IIB study , which demonstrated an impressive response rate of 32 % in patients with EGFR mutant lung cancers resistant to first-generation EGFR inhibitors .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [274, 283], "tok_span": [52, 56]}, {"name": "T790M", "ent_type": "variant", "char_span": [113, 118], "tok_span": [18, 22]}], "relation_list": [{"subject": "T790M", "object": "cetuximab", "sbj_char_span": [113, 118], "obj_char_span": [274, 283], "rel_type": "response", "sbj_tok_span": [18, 22], "obj_tok_span": [52, 56]}], "umls_entity_list": []}, {"text": "As the second-generation , irreversible EGFR-TKIs , such as afatinib and dacomitinib , failed to overcome the resistance caused by T790M , , other measures , such as EGFR dual targeting with cetuximab and afatinib and third-geneneration , mutant-selective EGFR-TKIs – are being actively evaluated .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [191, 200], "tok_span": [44, 48]}, {"name": "T790M", "ent_type": "variant", "char_span": [131, 136], "tok_span": [29, 33]}, {"name": "afatinib", "ent_type": "drug", "char_span": [60, 68], "tok_span": [14, 16]}, {"name": "afatinib", "ent_type": "drug", "char_span": [205, 213], "tok_span": [49, 51]}], "relation_list": [{"subject": "T790M", "object": "cetuximab", "sbj_char_span": [131, 136], "obj_char_span": [191, 200], "rel_type": "response", "sbj_tok_span": [29, 33], "obj_tok_span": [44, 48]}, {"subject": "T790M", "object": "afatinib", "sbj_char_span": [131, 136], "obj_char_span": [60, 68], "rel_type": "response", "sbj_tok_span": [29, 33], "obj_tok_span": [14, 16]}, {"subject": "T790M", "object": "afatinib", "sbj_char_span": [131, 136], "obj_char_span": [205, 213], "rel_type": "response", "sbj_tok_span": [29, 33], "obj_tok_span": [49, 51]}], "umls_entity_list": []}, {"text": "Several preclinical reports showed that other agents , such as the anti-EGFR monoclonal Ab cetuximab or PI3K/mTOR inhibitors combined with irreversible EGFR inhibitors hold promise to overcome resistance mediated by T790M .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [91, 100], "tok_span": [16, 20]}, {"name": "T790M", "ent_type": "variant", "char_span": [216, 221], "tok_span": [39, 43]}], "relation_list": [{"subject": "T790M", "object": "cetuximab", "sbj_char_span": [216, 221], "obj_char_span": [91, 100], "rel_type": "response", "sbj_tok_span": [39, 43], "obj_tok_span": [16, 20]}], "umls_entity_list": []}, {"text": "Pan J et al reported that EXEL-0862 is effective against Gleevec-resistant D816V KIT and T674I PDGFRα ( 2007 ) .", "entity_list": [{"name": "Gleevec-resistant", "ent_type": "drug", "char_span": [57, 74], "tok_span": [14, 19]}, {"name": "T674I", "ent_type": "variant", "char_span": [89, 94], "tok_span": [26, 30]}], "relation_list": [{"subject": "T674I", "object": "Gleevec-resistant", "sbj_char_span": [89, 94], "obj_char_span": [57, 74], "rel_type": "resistance", "sbj_tok_span": [26, 30], "obj_tok_span": [14, 19]}], "umls_entity_list": []}, {"text": "However , the secondary mutation T674I FIP1L1-PDGFRα in its kinase domain has been found in imatinib-refractory HES or CEL .", "entity_list": [{"name": "in imatinib-refractory", "ent_type": "drug", "char_span": [89, 111], "tok_span": [25, 30]}, {"name": "T674I", "ent_type": "variant", "char_span": [33, 38], "tok_span": [5, 9]}], "relation_list": [{"subject": "T674I", "object": "in imatinib-refractory", "sbj_char_span": [33, 38], "obj_char_span": [89, 111], "rel_type": "resistance", "sbj_tok_span": [5, 9], "obj_tok_span": [25, 30]}], "umls_entity_list": []}, {"text": "Because tyrosine kinase inhibitor sorafenib was effective for imatinib-resistant FIP1L1-PDGFRα T674I mutation cells , we also compared the inhibitory effect of DCC-2036 with sorafenib in the BaF3-T674I cells .", "entity_list": [{"name": "imatinib-resistant", "ent_type": "drug", "char_span": [62, 80], "tok_span": [9, 13]}, {"name": "FIP1L1-PDGFRα T674I", "ent_type": "variant", "char_span": [81, 100], "tok_span": [13, 26]}], "relation_list": [{"subject": "FIP1L1-PDGFRα T674I", "object": "imatinib-resistant", "sbj_char_span": [81, 100], "obj_char_span": [62, 80], "rel_type": "resistance", "sbj_tok_span": [13, 26], "obj_tok_span": [9, 13]}], "umls_entity_list": []}, {"text": "BT474 lapatinib-resistant cells acquire E542K PIK3CA mutation .", "entity_list": [{"name": "lapatinib-resistant", "ent_type": "drug", "char_span": [6, 25], "tok_span": [3, 8]}, {"name": "E542K", "ent_type": "variant", "char_span": [40, 45], "tok_span": [10, 14]}], "relation_list": [{"subject": "E542K", "object": "lapatinib-resistant", "sbj_char_span": [40, 45], "obj_char_span": [6, 25], "rel_type": "sensitivity", "sbj_tok_span": [10, 14], "obj_tok_span": [3, 8]}], "umls_entity_list": []}, {"text": "Similarly to BT474 LR cells with acquired E542K mutation , cells with the other hotspot mutations showed a blunted inhibitor response of PI3K signaling to lapatinib with persistent PI3K-Akt signaling ( Figure A ) .", "entity_list": [{"name": "lapatinib", "ent_type": "drug", "char_span": [155, 164], "tok_span": [35, 38]}, {"name": "E542K", "ent_type": "variant", "char_span": [42, 47], "tok_span": [9, 13]}], "relation_list": [{"subject": "E542K", "object": "lapatinib", "sbj_char_span": [42, 47], "obj_char_span": [155, 164], "rel_type": "sensitivity", "sbj_tok_span": [9, 13], "obj_tok_span": [35, 38]}], "umls_entity_list": []}, {"text": "Acquired E542K mutation in BT474 lapatinib resistant cells shifts the lapatinib half-maximal inhibitory concentration ( IC50 ) for phosphoinositide 3-kinase signaling .", "entity_list": [{"name": "lapatinib", "ent_type": "drug", "char_span": [33, 42], "tok_span": [11, 14]}, {"name": "E542K", "ent_type": "variant", "char_span": [9, 14], "tok_span": [2, 6]}, {"name": "lapatinib", "ent_type": "drug", "char_span": [70, 79], "tok_span": [18, 21]}], "relation_list": [{"subject": "E542K", "object": "lapatinib", "sbj_char_span": [9, 14], "obj_char_span": [33, 42], "rel_type": "sensitivity", "sbj_tok_span": [2, 6], "obj_tok_span": [11, 14]}, {"subject": "E542K", "object": "lapatinib", "sbj_char_span": [9, 14], "obj_char_span": [70, 79], "rel_type": "sensitivity", "sbj_tok_span": [2, 6], "obj_tok_span": [18, 21]}], "umls_entity_list": []}, {"text": "We used the T670I mutant c-Kit unable to bind imatinib and responsible for myeloproliferative disorder in mice and imatinib-resistant GIST in humans , .", "entity_list": [{"name": "imatinib", "ent_type": "drug", "char_span": [46, 54], "tok_span": [14, 16]}, {"name": "T670I", "ent_type": "variant", "char_span": [12, 17], "tok_span": [3, 7]}, {"name": "imatinib-resistant", "ent_type": "drug", "char_span": [115, 133], "tok_span": [26, 30]}], "relation_list": [{"subject": "T670I", "object": "imatinib", "sbj_char_span": [12, 17], "obj_char_span": [46, 54], "rel_type": "resistance", "sbj_tok_span": [3, 7], "obj_tok_span": [14, 16]}, {"subject": "T670I", "object": "imatinib-resistant", "sbj_char_span": [12, 17], "obj_char_span": [115, 133], "rel_type": "resistance", "sbj_tok_span": [3, 7], "obj_tok_span": [26, 30]}], "umls_entity_list": []}, {"text": "Indeed , up to 10 µM imatinib was ineffective to block T670I mutant –driven cell proliferation , while kinase inhibitor sorafenib , which inhibits wt c-Kit at a concentration of 5 µM efficiently reduced this proliferation .", "entity_list": [{"name": "µM imatinib", "ent_type": "drug", "char_span": [18, 29], "tok_span": [5, 8]}, {"name": "block T670I", "ent_type": "variant", "char_span": [49, 60], "tok_span": [11, 16]}], "relation_list": [{"subject": "block T670I", "object": "µM imatinib", "sbj_char_span": [49, 60], "obj_char_span": [18, 29], "rel_type": "resistance", "sbj_tok_span": [11, 16], "obj_tok_span": [5, 8]}], "umls_entity_list": []}, {"text": "In a recent report , the c-KIT mutation L576P was associated with resistance to multiple KIT inhibitors including imatinib , nilotinib , and sorafenib , but objective tumor responses could be induced in 2 patients bearing the KIT L576P mutation after treatment with dasatinib .", "entity_list": [{"name": "imatinib", "ent_type": "drug", "char_span": [114, 122], "tok_span": [25, 27]}, {"name": "L576P", "ent_type": "variant", "char_span": [40, 45], "tok_span": [11, 15]}, {"name": "nilotinib", "ent_type": "drug", "char_span": [125, 134], "tok_span": [28, 31]}], "relation_list": [{"subject": "L576P", "object": "imatinib", "sbj_char_span": [40, 45], "obj_char_span": [114, 122], "rel_type": "resistance or non-response", "sbj_tok_span": [11, 15], "obj_tok_span": [25, 27]}, {"subject": "L576P", "object": "nilotinib", "sbj_char_span": [40, 45], "obj_char_span": [125, 134], "rel_type": "resistance or non-response", "sbj_tok_span": [11, 15], "obj_tok_span": [28, 31]}], "umls_entity_list": []}, {"text": "Indeed , Montagut et al. identified the S492R mutation in 2 out of 10 tumors from patients with cetuximab resistance , and those 2 tumors showed good response to panitumumab .", "entity_list": [{"name": "panitumumab", "ent_type": "drug", "char_span": [162, 173], "tok_span": [38, 41]}, {"name": "S492R", "ent_type": "variant", "char_span": [40, 45], "tok_span": [10, 14]}], "relation_list": [{"subject": "S492R", "object": "panitumumab", "sbj_char_span": [40, 45], "obj_char_span": [162, 173], "rel_type": "response", "sbj_tok_span": [10, 14], "obj_tok_span": [38, 41]}], "umls_entity_list": []}, {"text": "G1202R EML-ALKpm A mutation-specific strong H-bond pulls crizotinib out of the position found in the non-crizotinib resistant EML-ALK fusion gene 1151Tins Thr insertion is predicted to alter ATP binding to ALK", "entity_list": [{"name": "crizotinib", "ent_type": "drug", "char_span": [57, 67], "tok_span": [20, 24]}, {"name": "G1202R", "ent_type": "variant", "char_span": [0, 6], "tok_span": [0, 4]}, {"name": "non-crizotinib", "ent_type": "drug", "char_span": [101, 115], "tok_span": [31, 37]}], "relation_list": [{"subject": "G1202R", "object": "crizotinib", "sbj_char_span": [0, 6], "obj_char_span": [57, 67], "rel_type": "resistance", "sbj_tok_span": [0, 4], "obj_tok_span": [20, 24]}, {"subject": "G1202R", "object": "non-crizotinib", "sbj_char_span": [0, 6], "obj_char_span": [101, 115], "rel_type": "resistance", "sbj_tok_span": [0, 4], "obj_tok_span": [31, 37]}], "umls_entity_list": []}, {"text": "L1152R EML-ALKpm Mutation resistant to crizotinib and the structurally unrelated compound TAE684", "entity_list": [{"name": "crizotinib", "ent_type": "drug", "char_span": [39, 49], "tok_span": [13, 17]}, {"name": "L1152R", "ent_type": "variant", "char_span": [0, 6], "tok_span": [0, 4]}], "relation_list": [{"subject": "L1152R", "object": "crizotinib", "sbj_char_span": [0, 6], "obj_char_span": [39, 49], "rel_type": "resistance", "sbj_tok_span": [0, 4], "obj_tok_span": [13, 17]}], "umls_entity_list": []}, {"text": "The two mutations were shown to independently induce crizotinib resistance in Ba/F3 cells engineered to express the L1196M and C1156Y mutations . ", "entity_list": [{"name": "crizotinib", "ent_type": "drug", "char_span": [53, 63], "tok_span": [8, 12]}, {"name": "L1196M", "ent_type": "variant", "char_span": [116, 122], "tok_span": [23, 27]}, {"name": "C1156Y", "ent_type": "variant", "char_span": [127, 133], "tok_span": [28, 32]}], "relation_list": [{"subject": "L1196M", "object": "crizotinib", "sbj_char_span": [116, 122], "obj_char_span": [53, 63], "rel_type": "resistance", "sbj_tok_span": [23, 27], "obj_tok_span": [8, 12]}, {"subject": "C1156Y", "object": "crizotinib", "sbj_char_span": [127, 133], "obj_char_span": [53, 63], "rel_type": "resistance", "sbj_tok_span": [28, 32], "obj_tok_span": [8, 12]}], "umls_entity_list": []}, {"text": "Sasaki et al. reported that cells derived from pleural effusions of patients with EML4-ALK lung cancer who developed acquired resistance to crizotinib displayed the gatekeeper L1196M mutation and high levels of expression of EGFR ligands ( EGF and amphiregulin ) .", "entity_list": [{"name": "crizotinib", "ent_type": "drug", "char_span": [140, 150], "tok_span": [30, 34]}, {"name": "L1196M", "ent_type": "variant", "char_span": [176, 182], "tok_span": [39, 43]}], "relation_list": [{"subject": "L1196M", "object": "crizotinib", "sbj_char_span": [176, 182], "obj_char_span": [140, 150], "rel_type": "resistance", "sbj_tok_span": [39, 43], "obj_tok_span": [30, 34]}], "umls_entity_list": []}, {"text": "L1196M mutant cells were more resistant to crizotinib than C1156Y mutant cells .", "entity_list": [{"name": "crizotinib", "ent_type": "drug", "char_span": [43, 53], "tok_span": [10, 14]}, {"name": "L1196M", "ent_type": "variant", "char_span": [0, 6], "tok_span": [0, 4]}, {"name": "C1156Y", "ent_type": "variant", "char_span": [59, 65], "tok_span": [15, 19]}], "relation_list": [{"subject": "L1196M", "object": "crizotinib", "sbj_char_span": [0, 6], "obj_char_span": [43, 53], "rel_type": "resistance", "sbj_tok_span": [0, 4], "obj_tok_span": [10, 14]}, {"subject": "C1156Y", "object": "crizotinib", "sbj_char_span": [59, 65], "obj_char_span": [43, 53], "rel_type": "resistance", "sbj_tok_span": [15, 19], "obj_tok_span": [10, 14]}], "umls_entity_list": []}, {"text": "In the xenograft model of mice , the combination of cetuximab and afatinib can lead to a significant reduction of erlotinib-resistant tumor harboring T790M , compared to gefitinib plus cetuximab .", "entity_list": [{"name": "afatinib", "ent_type": "drug", "char_span": [66, 74], "tok_span": [16, 18]}, {"name": "T790M", "ent_type": "variant", "char_span": [150, 155], "tok_span": [33, 37]}], "relation_list": [{"subject": "T790M", "object": "afatinib", "sbj_char_span": [150, 155], "obj_char_span": [66, 74], "rel_type": "response", "sbj_tok_span": [33, 37], "obj_tok_span": [16, 18]}], "umls_entity_list": []}, {"text": "In a subset of patients with exon 19 and L858R mutations , the median PFS was 13.6 months for afatinib , compared with 6.9 months for chemotherapy ( HR = 0.47 , 95 % CI 0.34–0.65 , P & lt ; 0.0001 ) .", "entity_list": [{"name": "afatinib", "ent_type": "drug", "char_span": [94, 102], "tok_span": [24, 26]}, {"name": "L858R", "ent_type": "variant", "char_span": [41, 46], "tok_span": [9, 13]}], "relation_list": [{"subject": "L858R", "object": "afatinib", "sbj_char_span": [41, 46], "obj_char_span": [94, 102], "rel_type": "sensitivity", "sbj_tok_span": [9, 13], "obj_tok_span": [24, 26]}], "umls_entity_list": []}, {"text": "Overall survival of patients with common EGFR mutations ( defined as exon 19 deletion and exon 21 L858R point mutation ) in LUX-3 , LUX-6 , and combined cohorts Patient cohort Afatinib ( median OS ) Platinum based chemotherapy ( median OS ) Hazard ratio ( 95 % confidence interval )", "entity_list": [{"name": "Afatinib", "ent_type": "drug", "char_span": [176, 184], "tok_span": [40, 42]}, {"name": "L858R", "ent_type": "variant", "char_span": [98, 103], "tok_span": [17, 21]}], "relation_list": [{"subject": "L858R", "object": "Afatinib", "sbj_char_span": [98, 103], "obj_char_span": [176, 184], "rel_type": "sensitivity", "sbj_tok_span": [17, 21], "obj_tok_span": [40, 42]}], "umls_entity_list": []}, {"text": "Afatinib EGFR EGFR exon 19 deletion or exon 21 substitution ( L858R ) mutation positive Indications and usage , dosage and administration , adverse reactions , clinical pharmacology , clinical studies , patient counseling information", "entity_list": [{"name": "Afatinib", "ent_type": "drug", "char_span": [0, 8], "tok_span": [0, 2]}, {"name": "L858R", "ent_type": "variant", "char_span": [62, 67], "tok_span": [12, 16]}], "relation_list": [{"subject": "L858R", "object": "Afatinib", "sbj_char_span": [62, 67], "obj_char_span": [0, 8], "rel_type": "sensitivity", "sbj_tok_span": [12, 16], "obj_tok_span": [0, 2]}], "umls_entity_list": []}, {"text": "However , for some patients , especially those possessing the T315I kinase domain mutation , ponatinib ( Iclusig® ) will be the ideal TKI .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [93, 102], "tok_span": [18, 22]}, {"name": "T315I", "ent_type": "variant", "char_span": [62, 67], "tok_span": [10, 14]}, {"name": "Iclusig®", "ent_type": "drug", "char_span": [105, 113], "tok_span": [23, 28]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [62, 67], "obj_char_span": [93, 102], "rel_type": "response", "sbj_tok_span": [10, 14], "obj_tok_span": [18, 22]}, {"subject": "T315I", "object": "Iclusig®", "sbj_char_span": [62, 67], "obj_char_span": [105, 113], "rel_type": "response", "sbj_tok_span": [10, 14], "obj_tok_span": [23, 28]}], "umls_entity_list": []}, {"text": "Overcoming both losses of an active-site hydrogen bond and the steric hindrance caused by the T315I mutation were the main focus during the design process of ponatinib . ", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [158, 167], "tok_span": [34, 38]}, {"name": "T315I", "ent_type": "variant", "char_span": [94, 99], "tok_span": [20, 24]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [94, 99], "obj_char_span": [158, 167], "rel_type": "response", "sbj_tok_span": [20, 24], "obj_tok_span": [34, 38]}], "umls_entity_list": []}, {"text": "Ponatinib is currently FDA approved for T315I positive CML ( in any phase ) and T315I positive Ph+ALL , or any phase of CML or Ph+ALL for which no other TKIs are indicated .", "entity_list": [{"name": "Ponatinib", "ent_type": "drug", "char_span": [0, 9], "tok_span": [0, 2]}, {"name": "T315I", "ent_type": "variant", "char_span": [40, 45], "tok_span": [7, 11]}], "relation_list": [{"subject": "T315I", "object": "Ponatinib", "sbj_char_span": [40, 45], "obj_char_span": [0, 9], "rel_type": "response", "sbj_tok_span": [7, 11], "obj_tok_span": [0, 2]}], "umls_entity_list": []}, {"text": "A third generation inhibitor was recently tested in resistant/intolerant CML patients : ponatinib is a potent , synthetic , oral multi-target pan-BCR/ABL inhibitor able to block native and mutated BCR/ABL , including T315I mutation , resistant to dasatinib and nilotinib .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [88, 97], "tok_span": [16, 20]}, {"name": "T315I", "ent_type": "variant", "char_span": [217, 222], "tok_span": [49, 53]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [217, 222], "obj_char_span": [88, 97], "rel_type": "response", "sbj_tok_span": [49, 53], "obj_tok_span": [16, 20]}], "umls_entity_list": []}, {"text": "The PACE trial ( Ponatinib Ph+ ALL and CML Evaluation ) , a phase 2 open-label trial , tested ponatinib 45 mg QD in 449 patients resistant or intolerant to dasatinib or nilotinib or with T315I mutation in different phases of the disease .", "entity_list": [{"name": "Ponatinib", "ent_type": "drug", "char_span": [17, 26], "tok_span": [5, 7]}, {"name": "T315I", "ent_type": "variant", "char_span": [187, 192], "tok_span": [49, 53]}, {"name": "ponatinib", "ent_type": "drug", "char_span": [94, 103], "tok_span": [24, 28]}], "relation_list": [{"subject": "T315I", "object": "Ponatinib", "sbj_char_span": [187, 192], "obj_char_span": [17, 26], "rel_type": "response", "sbj_tok_span": [49, 53], "obj_tok_span": [5, 7]}, {"subject": "T315I", "object": "ponatinib", "sbj_char_span": [187, 192], "obj_char_span": [94, 103], "rel_type": "response", "sbj_tok_span": [49, 53], "obj_tok_span": [24, 28]}], "umls_entity_list": []}, {"text": "Targeting the T315I mutation : Ponatinib", "entity_list": [{"name": "Ponatinib", "ent_type": "drug", "char_span": [31, 40], "tok_span": [9, 11]}, {"name": "T315I", "ent_type": "variant", "char_span": [14, 19], "tok_span": [3, 7]}], "relation_list": [{"subject": "T315I", "object": "Ponatinib", "sbj_char_span": [14, 19], "obj_char_span": [31, 40], "rel_type": "response", "sbj_tok_span": [3, 7], "obj_tok_span": [9, 11]}], "umls_entity_list": []}, {"text": "Irrespective of its potential use in TKI-naïve CML and Ph+ ALL patients , the impressive activity against the T315I BCR–ABL1 will likely make ponatinib a crucial second line agent for patients with this mutation .", "entity_list": [{"name": "make ponatinib", "ent_type": "drug", "char_span": [137, 151], "tok_span": [34, 39]}, {"name": "the T315I", "ent_type": "variant", "char_span": [106, 115], "tok_span": [22, 27]}], "relation_list": [{"subject": "the T315I", "object": "make ponatinib", "sbj_char_span": [106, 115], "obj_char_span": [137, 151], "rel_type": "response", "sbj_tok_span": [22, 27], "obj_tok_span": [34, 39]}], "umls_entity_list": []}, {"text": "For instance , median survival of patients with blast phase ( BP ) CML who are refractory or intolerant to imatinib is 3 to 9 months. , Of particular concern is the ABL T315I ‘gatekeeper ' mutation , which renders leukemia cells resistant to all commercially available tyrosine kinase inhibitors other than ponatinib. ,", "entity_list": [{"name": "than ponatinib.", "ent_type": "drug", "char_span": [302, 317], "tok_span": [62, 68]}, {"name": "T315I", "ent_type": "variant", "char_span": [169, 174], "tok_span": [38, 42]}], "relation_list": [{"subject": "T315I", "object": "than ponatinib.", "sbj_char_span": [169, 174], "obj_char_span": [302, 317], "rel_type": "response", "sbj_tok_span": [38, 42], "obj_tok_span": [62, 68]}], "umls_entity_list": []}, {"text": "Finally , the third line inhibitor ponatinib has been developed and shown to exhibit substantial efficacy in patients with CML in whom the polyresistant BCR-ABL1 T315I mutation is expressed in leukemic cells .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [35, 44], "tok_span": [6, 10]}, {"name": "T315I", "ent_type": "variant", "char_span": [162, 167], "tok_span": [33, 37]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [162, 167], "obj_char_span": [35, 44], "rel_type": "response", "sbj_tok_span": [33, 37], "obj_tok_span": [6, 10]}], "umls_entity_list": []}, {"text": "Lung cancers caused by activating mutations in the epidermal growth factor receptor (EGFR) – mainly either deletion at exon 19 or L858R mutation at exon 21 – respond to small molecule tyrosine kinase inhibitors ( gefitinib and erlotinib ) , , , with a recently reported median survival to gefitinib of 17.5 months .", "entity_list": [{"name": "and erlotinib", "ent_type": "drug", "char_span": [223, 236], "tok_span": [44, 49]}, {"name": "or L858R", "ent_type": "variant", "char_span": [127, 135], "tok_span": [22, 27]}], "relation_list": [{"subject": "or L858R", "object": "and erlotinib", "sbj_char_span": [127, 135], "obj_char_span": [223, 236], "rel_type": "sensitivity", "sbj_tok_span": [22, 27], "obj_tok_span": [44, 49]}], "umls_entity_list": []}, {"text": "In the EGFR gene , for example , we detected L858R ( in II-18 and H1975 ) and E746_A750del mutations ( in PC-9 and H1650 ) , which are known to be sensitive to the anti-cancer drugs , gefitinib and erlotinib . ", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [198, 207], "tok_span": [63, 67]}, {"name": "L858R", "ent_type": "variant", "char_span": [45, 50], "tok_span": [10, 14]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [45, 50], "obj_char_span": [198, 207], "rel_type": "sensitivity", "sbj_tok_span": [10, 14], "obj_tok_span": [63, 67]}], "umls_entity_list": []}, {"text": "Our assay was based on human UT-7 cell lines ( expressing non mutated or T315I mutated BCR-ABL1 ) , mutagenized with ENU ( N-ethyl-N-nitrosourea ) and cultured with or without murine MS-5 stromal cells in the presence of imatinib , dasatinib , nilotinib , or ponatinib ( ) .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [259, 268], "tok_span": [70, 74]}, {"name": "T315I", "ent_type": "variant", "char_span": [73, 78], "tok_span": [16, 20]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [73, 78], "obj_char_span": [259, 268], "rel_type": "response", "sbj_tok_span": [16, 20], "obj_tok_span": [70, 74]}], "umls_entity_list": []}, {"text": "The constant detection of T315I mutation in the UT-7-11/ponatinib/with MS-5 screening strengthened this hypothesis ( Table , exp. 5 ) .", "entity_list": [{"name": "UT-7-11/ponatinib/with", "ent_type": "drug", "char_span": [48, 70], "tok_span": [11, 23]}, {"name": "T315I", "ent_type": "variant", "char_span": [26, 31], "tok_span": [4, 8]}], "relation_list": [{"subject": "T315I", "object": "UT-7-11/ponatinib/with", "sbj_char_span": [26, 31], "obj_char_span": [48, 70], "rel_type": "response", "sbj_tok_span": [4, 8], "obj_tok_span": [11, 23]}], "umls_entity_list": []}, {"text": "To examine the role of the MS-5 niche , we first analyzed by array-CGH ( 1 ) two imatinib-resistant UT-7-11 clones harboring the E255K mutation compared with UT-7-11 control that did not undergo ENU mutagenesis , and ( 2 ) two ponatinib-resistant UT-7-315 clones with the T315I mutation alone compared with non mutagenized UT-7-315 control ( Fig. ) .", "entity_list": [{"name": "ponatinib-resistant", "ent_type": "drug", "char_span": [227, 246], "tok_span": [60, 66]}, {"name": "T315I", "ent_type": "variant", "char_span": [272, 277], "tok_span": [74, 78]}], "relation_list": [{"subject": "T315I", "object": "ponatinib-resistant", "sbj_char_span": [272, 277], "obj_char_span": [227, 246], "rel_type": "response", "sbj_tok_span": [74, 78], "obj_tok_span": [60, 66]}], "umls_entity_list": []}, {"text": "Potential MS-5 effects were analyzed in ( 1 ) two imatinib-resistant UT-7-11 clones harboring the E255K mutation compared with non mutagenized UT-7-11 control and in ( 2 ) two ponatinib-resistant UT-7-315 clones harboring the T315I mutation alone compared with non mutagenized UT-7-315 control .", "entity_list": [{"name": "ponatinib-resistant", "ent_type": "drug", "char_span": [176, 195], "tok_span": [45, 51]}, {"name": "T315I", "ent_type": "variant", "char_span": [226, 231], "tok_span": [59, 63]}], "relation_list": [{"subject": "T315I", "object": "ponatinib-resistant", "sbj_char_span": [226, 231], "obj_char_span": [176, 195], "rel_type": "response", "sbj_tok_span": [59, 63], "obj_tok_span": [45, 51]}], "umls_entity_list": []}, {"text": "Second , in the presence of the MS-5 microenvironment , UT-7 cells harboring the T315I mutation alone could survive ponatinib .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [116, 125], "tok_span": [27, 31]}, {"name": "T315I", "ent_type": "variant", "char_span": [81, 86], "tok_span": [19, 23]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [81, 86], "obj_char_span": [116, 125], "rel_type": "response", "sbj_tok_span": [19, 23], "obj_tok_span": [27, 31]}], "umls_entity_list": []}, {"text": "In this model , T315I mutation and stromal niche could jointly play a crucial role in the acquisition of ponatinib resistance .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [105, 114], "tok_span": [22, 26]}, {"name": "T315I", "ent_type": "variant", "char_span": [16, 21], "tok_span": [4, 8]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [16, 21], "obj_char_span": [105, 114], "rel_type": "response", "sbj_tok_span": [4, 8], "obj_tok_span": [22, 26]}], "umls_entity_list": []}, {"text": "Overall , these data suggest that T315I mutants , supported by a stromal niche , could survive ponatinib through interactions mediated by direct contact or soluble factors .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [95, 104], "tok_span": [20, 24]}, {"name": "T315I", "ent_type": "variant", "char_span": [34, 39], "tok_span": [6, 10]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [34, 39], "obj_char_span": [95, 104], "rel_type": "response", "sbj_tok_span": [6, 10], "obj_tok_span": [20, 24]}], "umls_entity_list": []}, {"text": "In WJTOG3405 , 177 chemotherapy-naïve patients diagnosed with advanced NSCLC harboring sensitive EGFR mutations ( either deletion in the exon 19 or L858R point mutation in exon 21 ) were randomly assigned to receive either oral gefitinib or intravenous cisplatin plus docetaxel chemotherapy .", "entity_list": [{"name": "oral gefitinib", "ent_type": "drug", "char_span": [223, 237], "tok_span": [44, 49]}, {"name": "or L858R", "ent_type": "variant", "char_span": [145, 153], "tok_span": [27, 32]}], "relation_list": [{"subject": "or L858R", "object": "oral gefitinib", "sbj_char_span": [145, 153], "obj_char_span": [223, 237], "rel_type": "sensitivity", "sbj_tok_span": [27, 32], "obj_tok_span": [44, 49]}], "umls_entity_list": []}, {"text": "However , we found that gefitinib treatment of these cells did not result in dephosphorylation of ERK1/2 (A) or substantial apoptosis ( B ) , presumably due to the presence of the additional ( T790M ) mutation , known to reduce the kinase activity of EGFR , rendering it effectively wild type .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [24, 33], "tok_span": [5, 9]}, {"name": "T790M", "ent_type": "variant", "char_span": [193, 198], "tok_span": [46, 50]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [193, 198], "obj_char_span": [24, 33], "rel_type": "resistance or non-response", "sbj_tok_span": [46, 50], "obj_tok_span": [5, 9]}], "umls_entity_list": []}, {"text": "The NSCLC cell lines H358 ( WT EGFR ) , H1650 , HCC827 ( Del E746A750 deletions ) and H3255 ( L858R mutation ) were chosen for initial studies on the effects of gefitinib .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [161, 170], "tok_span": [49, 53]}, {"name": "L858R", "ent_type": "variant", "char_span": [94, 99], "tok_span": [34, 38]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [94, 99], "obj_char_span": [161, 170], "rel_type": "sensitivity", "sbj_tok_span": [34, 38], "obj_tok_span": [49, 53]}], "umls_entity_list": []}, {"text": "In addition , acquired resistance caused by a second site substitution , T790M in exon 20 , results in poorly gefitinib activity , .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [110, 119], "tok_span": [23, 27]}, {"name": "T790M", "ent_type": "variant", "char_span": [73, 78], "tok_span": [12, 16]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [73, 78], "obj_char_span": [110, 119], "rel_type": "resistance or non-response", "sbj_tok_span": [12, 16], "obj_tok_span": [23, 27]}], "umls_entity_list": []}, {"text": "In addition , recent studies showed the pharmacogenomic issues in EGFR determine the limitation of gefitinib in clinical applications : Activating mutations of the in-frame deletions ( ΔE746-A750 ) in exon 19 and the L858R point mutation in exon 21 of the EGFR tyrosine kinase domain in NSCLC are highly correlated with gefitinib sensitivity , , .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [99, 108], "tok_span": [17, 21]}, {"name": "the L858R", "ent_type": "variant", "char_span": [213, 222], "tok_span": [48, 53]}, {"name": "with gefitinib", "ent_type": "drug", "char_span": [315, 329], "tok_span": [69, 74]}], "relation_list": [{"subject": "the L858R", "object": "gefitinib", "sbj_char_span": [213, 222], "obj_char_span": [99, 108], "rel_type": "sensitivity", "sbj_tok_span": [48, 53], "obj_tok_span": [17, 21]}, {"subject": "the L858R", "object": "with gefitinib", "sbj_char_span": [213, 222], "obj_char_span": [315, 329], "rel_type": "sensitivity", "sbj_tok_span": [48, 53], "obj_tok_span": [69, 74]}], "umls_entity_list": []}, {"text": "These results confirm that up-regulation of BIM correlates with effective TKI induced apoptosis and that T790M suppresses this process in gefitinib treated cells .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [138, 147], "tok_span": [27, 31]}, {"name": "T790M", "ent_type": "variant", "char_span": [105, 110], "tok_span": [19, 23]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [105, 110], "obj_char_span": [138, 147], "rel_type": "resistance or non-response", "sbj_tok_span": [19, 23], "obj_tok_span": [27, 31]}], "umls_entity_list": []}, {"text": "Our in vitro studies demonstrated that both of the secondary mutations initially identified in our lab ( T790M and L747S ) confer varying degrees of resistance to the apoptotic signals initiated by gefitinib .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [198, 207], "tok_span": [38, 42]}, {"name": "T790M", "ent_type": "variant", "char_span": [105, 110], "tok_span": [17, 21]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [105, 110], "obj_char_span": [198, 207], "rel_type": "resistance or non-response", "sbj_tok_span": [17, 21], "obj_tok_span": [38, 42]}], "umls_entity_list": []}, {"text": "EGFR , AKT , and ERK1/2 were not inhibited in our T790M gefitinib treated models .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [56, 65], "tok_span": [18, 22]}, {"name": "T790M", "ent_type": "variant", "char_span": [50, 55], "tok_span": [14, 18]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [50, 55], "obj_char_span": [56, 65], "rel_type": "resistance or non-response", "sbj_tok_span": [14, 18], "obj_tok_span": [18, 22]}], "umls_entity_list": []}, {"text": "At the time of this writing , phase II trials in which patients with advanced NSCLC are included on the basis of presence of the two most common EGFR mutations ( either exon 19 deletions or the exon 21 arginine-for-leucine substitution at amino acid 858 , or L858R ) and are given gefitinib as first-line treatment show radiographic response rates that exceed 75 % .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [281, 290], "tok_span": [60, 64]}, {"name": "L858R", "ent_type": "variant", "char_span": [259, 264], "tok_span": [52, 56]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [259, 264], "obj_char_span": [281, 290], "rel_type": "sensitivity", "sbj_tok_span": [52, 56], "obj_tok_span": [60, 64]}], "umls_entity_list": []}, {"text": "BIM expression correlated with the amount of apoptosis in L858R , L858R-L747S , and L858R-T790M cells . ( B ) Modulation of signaling following gefitinib treatment in Ba/F3 cells expressing EGFR mutants .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [144, 153], "tok_span": [45, 49]}, {"name": "L858R", "ent_type": "variant", "char_span": [58, 63], "tok_span": [10, 14]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [58, 63], "obj_char_span": [144, 153], "rel_type": "sensitivity", "sbj_tok_span": [10, 14], "obj_tok_span": [45, 49]}], "umls_entity_list": []}, {"text": "Our group has undertaken a randomized phase 3 trial to compare gefitinib plus carboplatin plus pemetrexed with gefitinib monotherapy for patients with NSCLC with an exon 19 deletion or an L858R , G719X , or L861Q EGFR mutation ( NEJ009 ; University Hospital Medical Information Network Clinical Trials Registry number , UMIN000006340 ) .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [63, 72], "tok_span": [11, 15]}, {"name": "L858R", "ent_type": "variant", "char_span": [188, 193], "tok_span": [41, 45]}, {"name": "gefitinib", "ent_type": "drug", "char_span": [111, 120], "tok_span": [25, 29]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [188, 193], "obj_char_span": [63, 72], "rel_type": "sensitivity", "sbj_tok_span": [41, 45], "obj_tok_span": [11, 15]}, {"subject": "L858R", "object": "gefitinib", "sbj_char_span": [188, 193], "obj_char_span": [111, 120], "rel_type": "sensitivity", "sbj_tok_span": [41, 45], "obj_tok_span": [25, 29]}], "umls_entity_list": []}, {"text": "Most NSCLC patients who harbor activating EGFR mutations , including deletions in exon 19 or the point mutation L858R in exon 21 , experience an initial marked response to the EGFR-TKIs gefitinib or erlotinib . ", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [186, 195], "tok_span": [37, 41]}, {"name": "L858R", "ent_type": "variant", "char_span": [112, 117], "tok_span": [18, 22]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [112, 117], "obj_char_span": [186, 195], "rel_type": "sensitivity", "sbj_tok_span": [18, 22], "obj_tok_span": [37, 41]}], "umls_entity_list": []}, {"text": "H1975 cancer cell line with mutations in EGFR exons 21 ( L858R ) and 20 ( T790M ) was refractory to reversible EGFR-TKIs , gefitinib , and erlotinib , but was sensitive to irreversible EGFR-TKIs , such as BIBW2992 ( afatinib ) .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [123, 132], "tok_span": [35, 39]}, {"name": "T790M", "ent_type": "variant", "char_span": [74, 79], "tok_span": [21, 25]}, {"name": "L858R", "ent_type": "variant", "char_span": [57, 62], "tok_span": [13, 17]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [74, 79], "obj_char_span": [123, 132], "rel_type": "resistance or non-response", "sbj_tok_span": [21, 25], "obj_tok_span": [35, 39]}, {"subject": "L858R", "object": "gefitinib", "sbj_char_span": [57, 62], "obj_char_span": [123, 132], "rel_type": "sensitivity", "sbj_tok_span": [13, 17], "obj_tok_span": [35, 39]}], "umls_entity_list": []}, {"text": "Kim and colleagues demonstrated that the combination of lapatinib with cetuximab overcame gefitinib resistance due to the secondary T790M mutation in NSCLC by inducing enhanced cytotoxicity both in vitro and in vivo .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [90, 99], "tok_span": [19, 23]}, {"name": "T790M", "ent_type": "variant", "char_span": [132, 137], "tok_span": [28, 32]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [132, 137], "obj_char_span": [90, 99], "rel_type": "resistance or non-response", "sbj_tok_span": [28, 32], "obj_tok_span": [19, 23]}], "umls_entity_list": []}, {"text": "Gefitinib has been registered for the therapy of advanced NSCLC harbouring activating EGFR mutations in the tyrosine kinase domain , the most frequent being L858R in exon 21 and Del ( 746–750 ) in exon 19 .", "entity_list": [{"name": "Gefitinib", "ent_type": "drug", "char_span": [0, 9], "tok_span": [0, 3]}, {"name": "L858R", "ent_type": "variant", "char_span": [157, 162], "tok_span": [28, 32]}], "relation_list": [{"subject": "L858R", "object": "Gefitinib", "sbj_char_span": [157, 162], "obj_char_span": [0, 9], "rel_type": "sensitivity", "sbj_tok_span": [28, 32], "obj_tok_span": [0, 3]}], "umls_entity_list": []}, {"text": "In particular , the L858R mutant is 10- to 100-fold more sensitive to erlotinib and gefitinib than the wild-type kinase , ,, and significantly more sensitive than the G719S mutant .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [84, 93], "tok_span": [24, 28]}, {"name": "G719S", "ent_type": "variant", "char_span": [167, 172], "tok_span": [43, 47]}, {"name": "L858R", "ent_type": "variant", "char_span": [20, 25], "tok_span": [4, 8]}, {"name": "erlotinib", "ent_type": "drug", "char_span": [70, 79], "tok_span": [19, 23]}], "relation_list": [{"subject": "G719S", "object": "gefitinib", "sbj_char_span": [167, 172], "obj_char_span": [84, 93], "rel_type": "sensitivity", "sbj_tok_span": [43, 47], "obj_tok_span": [24, 28]}, {"subject": "L858R", "object": "gefitinib", "sbj_char_span": [20, 25], "obj_char_span": [84, 93], "rel_type": "sensitivity", "sbj_tok_span": [4, 8], "obj_tok_span": [24, 28]}, {"subject": "L858R", "object": "erlotinib", "sbj_char_span": [20, 25], "obj_char_span": [70, 79], "rel_type": "sensitivity", "sbj_tok_span": [4, 8], "obj_tok_span": [19, 23]}], "umls_entity_list": []}, {"text": "In the xenograft model of mice , the combination of cetuximab and afatinib can lead to a significant reduction of erlotinib-resistant tumor harboring T790M , compared to gefitinib plus cetuximab .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [170, 179], "tok_span": [40, 44]}, {"name": "T790M", "ent_type": "variant", "char_span": [150, 155], "tok_span": [33, 37]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [150, 155], "obj_char_span": [170, 179], "rel_type": "resistance or non-response", "sbj_tok_span": [33, 37], "obj_tok_span": [40, 44]}], "umls_entity_list": []}, {"text": "PFS was 4.4 months , whereas median overall survival was 19 months ; two patients with acquired T790M mutations had SD for 9 months and 1 month , respectively The most common afatinib related toxicities were diarrhea in all patients and rash/acne in 91.9 % of patients LUX-Lung 7 , NCT01466660 IIb Yes First-line Afatinib versus gefitinib PFS ; DCR – –", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [329, 338], "tok_span": [80, 84]}, {"name": "T790M", "ent_type": "variant", "char_span": [96, 101], "tok_span": [19, 23]}, {"name": "afatinib", "ent_type": "drug", "char_span": [175, 183], "tok_span": [37, 39]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [96, 101], "obj_char_span": [329, 338], "rel_type": "resistance or non-response", "sbj_tok_span": [19, 23], "obj_tok_span": [80, 84]}, {"subject": "T790M", "object": "afatinib", "sbj_char_span": [96, 101], "obj_char_span": [175, 183], "rel_type": "response", "sbj_tok_span": [19, 23], "obj_tok_span": [37, 39]}], "umls_entity_list": []}, {"text": "Moreover , the second-generation irreversible EGFR inhibitors were shown in preclinical models to be more potent targeting T790M mutation than gefitinib or erlotinib .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [143, 152], "tok_span": [25, 29]}, {"name": "T790M", "ent_type": "variant", "char_span": [123, 128], "tok_span": [19, 23]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [123, 128], "obj_char_span": [143, 152], "rel_type": "resistance or non-response", "sbj_tok_span": [19, 23], "obj_tok_span": [25, 29]}], "umls_entity_list": []}, {"text": "Cytology showed the development of right pleural effusion after gefitinib treatment , and a second mutation of T790M was found in the primary lesion .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [64, 73], "tok_span": [10, 14]}, {"name": "T790M", "ent_type": "variant", "char_span": [111, 116], "tok_span": [21, 25]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [111, 116], "obj_char_span": [64, 73], "rel_type": "resistance or non-response", "sbj_tok_span": [21, 25], "obj_tok_span": [10, 14]}], "umls_entity_list": []}, {"text": "NSCLC patients harboring exon 19 deletion or exon 21 L858R somatic mutations experience significant tumor regression when prescribed the reversible small molecular tyrosine kinase inhibitors ( TKIs ) such as gefitinib and erlotinib .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [208, 217], "tok_span": [34, 38]}, {"name": "L858R", "ent_type": "variant", "char_span": [53, 58], "tok_span": [9, 13]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [53, 58], "obj_char_span": [208, 217], "rel_type": "sensitivity", "sbj_tok_span": [9, 13], "obj_tok_span": [34, 38]}], "umls_entity_list": []}, {"text": "A secondary point mutation in exon 20 of EGFR ( T790M ) is associated with acquired resistance to gefitinib or Erlotinib , but this can be overcome by the irreversible EGFR-tyrosine kinase inhibitor BIBW2992 ( BIBW ) .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [98, 107], "tok_span": [21, 25]}, {"name": "T790M", "ent_type": "variant", "char_span": [48, 53], "tok_span": [10, 14]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [48, 53], "obj_char_span": [98, 107], "rel_type": "resistance or non-response", "sbj_tok_span": [10, 14], "obj_tok_span": [21, 25]}], "umls_entity_list": []}, {"text": "The T790M mutation in exon 20 of the kinase domain is relatively rare in untreated patients but occurs in up to 50 % of patients with acquired resistance to erlotinib or gefitinib .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [170, 179], "tok_span": [37, 41]}, {"name": "T790M", "ent_type": "variant", "char_span": [4, 9], "tok_span": [1, 5]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [4, 9], "obj_char_span": [170, 179], "rel_type": "resistance or non-response", "sbj_tok_span": [1, 5], "obj_tok_span": [37, 41]}], "umls_entity_list": []}, {"text": "The H1975 and H820 cell lines had EGFR T790M mutations in exon 20 , associated with gefitinib and erlotinib resistance .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [84, 93], "tok_span": [23, 27]}, {"name": "T790M", "ent_type": "variant", "char_span": [39, 44], "tok_span": [12, 16]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [39, 44], "obj_char_span": [84, 93], "rel_type": "resistance or non-response", "sbj_tok_span": [12, 16], "obj_tok_span": [23, 27]}], "umls_entity_list": []}, {"text": "Through this approach , they showed that Src Family Kinases (SFKs) , as well as EGFR , are relevant targets for the Src inhibitor dasatinib and that acquired T790M mutations render cells resistant not only to erlotinib and gefitinib , but also to dasatinib .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [223, 232], "tok_span": [49, 53]}, {"name": "T790M", "ent_type": "variant", "char_span": [158, 163], "tok_span": [33, 37]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [158, 163], "obj_char_span": [223, 232], "rel_type": "resistance or non-response", "sbj_tok_span": [33, 37], "obj_tok_span": [49, 53]}], "umls_entity_list": []}, {"text": "The T790M mutation is known to mediate secondary resistance to EGFR TKIs , yet there is evidence that it can be detected even before treatment with erlotinib or gefitinib when a high sensitivity method of detection is applied .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [161, 170], "tok_span": [35, 39]}, {"name": "T790M", "ent_type": "variant", "char_span": [4, 9], "tok_span": [1, 5]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [4, 9], "obj_char_span": [161, 170], "rel_type": "resistance or non-response", "sbj_tok_span": [1, 5], "obj_tok_span": [35, 39]}], "umls_entity_list": []}, {"text": "In addition , other EGFR mutations have also demonstrated contribution to the development of drug resistance to erlotinib and gefitinib , including secondary EGFR kinase mutations , L858R mutations , and secondary D761Y point mutations .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [126, 135], "tok_span": [22, 26]}, {"name": "L858R", "ent_type": "variant", "char_span": [182, 187], "tok_span": [33, 37]}, {"name": "erlotinib", "ent_type": "drug", "char_span": [112, 121], "tok_span": [17, 21]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [182, 187], "obj_char_span": [126, 135], "rel_type": "sensitivity", "sbj_tok_span": [33, 37], "obj_tok_span": [22, 26]}, {"subject": "L858R", "object": "erlotinib", "sbj_char_span": [182, 187], "obj_char_span": [112, 121], "rel_type": "sensitivity", "sbj_tok_span": [33, 37], "obj_tok_span": [17, 21]}], "umls_entity_list": []}, {"text": "Tyrosine kinase inhibitors ( TKIs ) targeting the epidermal growth factor receptor (EGFR) , such as gefitinib and erlotinib , have shown remarkable activity in the patients with NSCLC , and particularly these TKIs are more effective to NSCLC with EGFR mutations in 19 exon ( in-frame deletions ) and exon 21 ( L858R point mutation ) , which are found to be more prevalent in Asian patients .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [100, 109], "tok_span": [20, 24]}, {"name": "L858R", "ent_type": "variant", "char_span": [310, 315], "tok_span": [66, 70]}], "relation_list": [{"subject": "L858R", "object": "gefitinib", "sbj_char_span": [310, 315], "obj_char_span": [100, 109], "rel_type": "sensitivity", "sbj_tok_span": [66, 70], "obj_tok_span": [20, 24]}], "umls_entity_list": []}, {"text": "Indeed , in non-small cell lung cancers treated with gefitinib or erlotinib , sensitive patients have the EGFR T790M mutation in only a few cells , whereas resistant patients exhibit EGFR T790M in the majority of the tumour cells ( ; ) .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [53, 62], "tok_span": [11, 15]}, {"name": "T790M", "ent_type": "variant", "char_span": [111, 116], "tok_span": [26, 30]}], "relation_list": [{"subject": "T790M", "object": "gefitinib", "sbj_char_span": [111, 116], "obj_char_span": [53, 62], "rel_type": "resistance or non-response", "sbj_tok_span": [26, 30], "obj_tok_span": [11, 15]}], "umls_entity_list": []}, {"text": "Moreover , serial genotyping of circulating lung cancer cells during gefitinib therapy demonstrated the emergence of the kinase inhibitor resistance–associated mutation T790M at increasing allelic ratios , coinciding with clinical relapse .", "entity_list": [{"name": "gefitinib", "ent_type": "drug", "char_span": [69, 78], "tok_span": [10, 14]}, {"name": "mutation T790M", "ent_type": "variant", "char_span": [160, 174], "tok_span": [25, 30]}], "relation_list": [{"subject": "mutation T790M", "object": "gefitinib", "sbj_char_span": [160, 174], "obj_char_span": [69, 78], "rel_type": "resistance or non-response", "sbj_tok_span": [25, 30], "obj_tok_span": [10, 14]}], "umls_entity_list": []}, {"text": "Acquired resistance , including EGFR secondary mutations ( T790M and other rare mutations ) , MET gene amplification , PTEN gene downregulation , high-level hepatocyte growth factor expression , epithelial–mesenchymal transition , and conversion to small cell lung cancer , – continues to restrict the durable long-term outcomes of erlotinib .", "entity_list": [{"name": "of erlotinib", "ent_type": "drug", "char_span": [329, 341], "tok_span": [60, 65]}, {"name": "T790M", "ent_type": "variant", "char_span": [59, 64], "tok_span": [9, 13]}], "relation_list": [{"subject": "T790M", "object": "of erlotinib", "sbj_char_span": [59, 64], "obj_char_span": [329, 341], "rel_type": "resistance or non-response", "sbj_tok_span": [9, 13], "obj_tok_span": [60, 65]}], "umls_entity_list": []}, {"text": "The second-generation TKIs may overcome resistance to the treatment of erlotinib or gefitinib via the T790M gatekeeper mutation .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [71, 80], "tok_span": [13, 17]}, {"name": "T790M", "ent_type": "variant", "char_span": [102, 107], "tok_span": [24, 28]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [102, 107], "obj_char_span": [71, 80], "rel_type": "resistance or non-response", "sbj_tok_span": [24, 28], "obj_tok_span": [13, 17]}], "umls_entity_list": []}, {"text": "Phase II XL647 41 patients with relapsed or recurrent advanced NSCLC who progressed after ≥ 12 weeks of stable disease or response to erlotinib or gefitinib and/or those patients with a documented EGFR T790M Objective RR The objective RR was 3 % , 67 % of the patients harbored T790M had progression of disease , while14 % of those without this mutation , 11 patients ( 28 % ) had a dose reduction due to toxicity .", "entity_list": [{"name": "to erlotinib", "ent_type": "drug", "char_span": [131, 143], "tok_span": [25, 30]}, {"name": "EGFR T790M", "ent_type": "variant", "char_span": [197, 207], "tok_span": [43, 48]}], "relation_list": [{"subject": "EGFR T790M", "object": "to erlotinib", "sbj_char_span": [197, 207], "obj_char_span": [131, 143], "rel_type": "resistance or non-response", "sbj_tok_span": [43, 48], "obj_tok_span": [25, 30]}], "umls_entity_list": []}, {"text": "The RR with erlotinib was 70.6 % , 12.2 % presented complete responses and a better outcome was associated with the exon 19 deletion than with the L858R mutation ( odds ratio 3.08 ; P = 0.001 ) .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [12, 21], "tok_span": [3, 7]}, {"name": "L858R", "ent_type": "variant", "char_span": [147, 152], "tok_span": [34, 38]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [147, 152], "obj_char_span": [12, 21], "rel_type": "sensitivity", "sbj_tok_span": [34, 38], "obj_tok_span": [3, 7]}], "umls_entity_list": []}, {"text": "MTS assay was used to evaluate the effects of erlotinib ( a ) , bevacizumab ( c ) , and combination of erlotinib and bevacizumab ( d ) on the growth of NSCLC cell lines , which included cell lines with EGFR mutations : PC9 ( EGFR exon 19 deletion ) , 11–18 ( EGFR L858 ) , H1975 ( EGFR L858R and T790 M mutations ) and EGFR wild-type cell lines : H157 , H460 and A549 .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [46, 55], "tok_span": [10, 14]}, {"name": "EGFR L858R", "ent_type": "variant", "char_span": [281, 291], "tok_span": [76, 81]}, {"name": "erlotinib", "ent_type": "drug", "char_span": [103, 112], "tok_span": [27, 31]}], "relation_list": [{"subject": "EGFR L858R", "object": "erlotinib", "sbj_char_span": [281, 291], "obj_char_span": [46, 55], "rel_type": "sensitivity", "sbj_tok_span": [76, 81], "obj_tok_span": [10, 14]}, {"subject": "EGFR L858R", "object": "erlotinib", "sbj_char_span": [281, 291], "obj_char_span": [103, 112], "rel_type": "sensitivity", "sbj_tok_span": [76, 81], "obj_tok_span": [27, 31]}], "umls_entity_list": []}, {"text": "A recent study demonstrated that using a combination of erlotinib and cetuximab reversed the drug resistance in NSCLC in T790M and L858R mutation lung cancer cell lines ( Wang et al. , ) .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [56, 65], "tok_span": [9, 13]}, {"name": "L858R", "ent_type": "variant", "char_span": [131, 136], "tok_span": [30, 34]}, {"name": "T790M", "ent_type": "variant", "char_span": [121, 126], "tok_span": [25, 29]}, {"name": "cetuximab", "ent_type": "drug", "char_span": [70, 79], "tok_span": [14, 18]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [131, 136], "obj_char_span": [56, 65], "rel_type": "sensitivity", "sbj_tok_span": [30, 34], "obj_tok_span": [9, 13]}, {"subject": "T790M", "object": "erlotinib", "sbj_char_span": [121, 126], "obj_char_span": [56, 65], "rel_type": "resistance or non-response", "sbj_tok_span": [25, 29], "obj_tok_span": [9, 13]}, {"subject": "T790M", "object": "cetuximab", "sbj_char_span": [121, 126], "obj_char_span": [70, 79], "rel_type": "response", "sbj_tok_span": [25, 29], "obj_tok_span": [14, 18]}], "umls_entity_list": []}, {"text": "On the basis of this study , in May 2013 the U.S Food and Drug Administration ( FDA ) approved erlotinib for use in patients with lung cancers harboring EGFR exon 19 deletions and EGFR L858R substitutions . ", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [95, 104], "tok_span": [22, 26]}, {"name": "L858R", "ent_type": "variant", "char_span": [185, 190], "tok_span": [40, 44]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [185, 190], "obj_char_span": [95, 104], "rel_type": "sensitivity", "sbj_tok_span": [40, 44], "obj_tok_span": [22, 26]}], "umls_entity_list": []}, {"text": "Finally , a recent study shows not only that EGFR mutations are statistically associated with Asian ethnicity and never-smoker status , but also that patients with EGFR exon 19 deletions have significantly longer median survival than patients with EGFR L858R mutation ( 34 vs. 8 months , p=0.01 ) after treatment with gefitinib or erlotinib .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [331, 340], "tok_span": [68, 72]}, {"name": "L858R", "ent_type": "variant", "char_span": [253, 258], "tok_span": [42, 46]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [253, 258], "obj_char_span": [331, 340], "rel_type": "sensitivity", "sbj_tok_span": [42, 46], "obj_tok_span": [68, 72]}], "umls_entity_list": []}, {"text": "First , a secondary mutation in exon 20 , leading to a substitution of methionine for threonine at position 790 ( T790M ) in the kinase domain , is reported in 2 of 5 patients with acquired resistance to gefitinib or erlotinib .", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [217, 226], "tok_span": [49, 53]}, {"name": "T790M", "ent_type": "variant", "char_span": [114, 119], "tok_span": [23, 27]}], "relation_list": [{"subject": "T790M", "object": "erlotinib", "sbj_char_span": [114, 119], "obj_char_span": [217, 226], "rel_type": "resistance or non-response", "sbj_tok_span": [23, 27], "obj_tok_span": [49, 53]}], "umls_entity_list": []}, {"text": "For example , 11–18 cells , which harbor an erlotinib-sensitive EGFR mutation ( L858R ) , undergo only G1 arrest in response to erlotinib but undergo apoptosis when co-treated with R1507 and erlotinib .", "entity_list": [{"name": "an erlotinib-sensitive", "ent_type": "drug", "char_span": [41, 63], "tok_span": [10, 17]}, {"name": "( L858R", "ent_type": "variant", "char_span": [78, 85], "tok_span": [19, 24]}, {"name": "to erlotinib", "ent_type": "drug", "char_span": [125, 137], "tok_span": [33, 38]}, {"name": "and erlotinib", "ent_type": "drug", "char_span": [187, 200], "tok_span": [49, 54]}], "relation_list": [{"subject": "( L858R", "object": "an erlotinib-sensitive", "sbj_char_span": [78, 85], "obj_char_span": [41, 63], "rel_type": "sensitivity", "sbj_tok_span": [19, 24], "obj_tok_span": [10, 17]}, {"subject": "( L858R", "object": "to erlotinib", "sbj_char_span": [78, 85], "obj_char_span": [125, 137], "rel_type": "sensitivity", "sbj_tok_span": [19, 24], "obj_tok_span": [33, 38]}, {"subject": "( L858R", "object": "and erlotinib", "sbj_char_span": [78, 85], "obj_char_span": [187, 200], "rel_type": "sensitivity", "sbj_tok_span": [19, 24], "obj_tok_span": [49, 54]}], "umls_entity_list": []}, {"text": "Two EGFR mutations ( exon 19 deletion and exon 21 L858R substitution ) that cluster around the adenosine-5′-triphosphate binding pocket of the EGFR tyrosine kinase ( TK ) domain are highly responsive to EGFR TK inhibitors ( TKIs ) like gefitinib or erlotinib .", "entity_list": [{"name": "or erlotinib", "ent_type": "drug", "char_span": [246, 258], "tok_span": [57, 62]}, {"name": "L858R", "ent_type": "variant", "char_span": [50, 55], "tok_span": [10, 14]}], "relation_list": [{"subject": "L858R", "object": "or erlotinib", "sbj_char_span": [50, 55], "obj_char_span": [246, 258], "rel_type": "sensitivity", "sbj_tok_span": [10, 14], "obj_tok_span": [57, 62]}], "umls_entity_list": []}, {"text": "EGFR mutations ( 51 patients screened ) del 19 7 13.7 L858R 2 3.9 Total 9 17.6 K-ras mutations ( 56 patients screened ) 10 17.8 First-line therapy Chemotherapy 52 Erlotinib 7 Chemotherapy + erlotinib 1", "entity_list": [{"name": "Erlotinib", "ent_type": "drug", "char_span": [163, 172], "tok_span": [47, 50]}, {"name": "L858R", "ent_type": "variant", "char_span": [54, 59], "tok_span": [13, 17]}, {"name": "erlotinib", "ent_type": "drug", "char_span": [190, 199], "tok_span": [54, 58]}], "relation_list": [{"subject": "L858R", "object": "Erlotinib", "sbj_char_span": [54, 59], "obj_char_span": [163, 172], "rel_type": "sensitivity", "sbj_tok_span": [13, 17], "obj_tok_span": [47, 50]}, {"subject": "L858R", "object": "erlotinib", "sbj_char_span": [54, 59], "obj_char_span": [190, 199], "rel_type": "sensitivity", "sbj_tok_span": [13, 17], "obj_tok_span": [54, 58]}], "umls_entity_list": []}, {"text": "As previously demonstrated , cells with the deletion mutant and the point mutation L858R were inhibited by the TKIs gefitinib and erlotinib , while the exon 20 insertion mutation was resistant . ", "entity_list": [{"name": "erlotinib", "ent_type": "drug", "char_span": [130, 139], "tok_span": [28, 32]}, {"name": "L858R", "ent_type": "variant", "char_span": [83, 88], "tok_span": [13, 17]}], "relation_list": [{"subject": "L858R", "object": "erlotinib", "sbj_char_span": [83, 88], "obj_char_span": [130, 139], "rel_type": "sensitivity", "sbj_tok_span": [13, 17], "obj_tok_span": [28, 32]}], "umls_entity_list": []}, {"text": "Interestingly , four EGFR FISH+ patients with KRAS mutations ( G12V in one case , G12D in another one , G13D in the remaining two cases ) responded to cetuximab therapy .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [151, 160], "tok_span": [37, 41]}, {"name": "G12D", "ent_type": "variant", "char_span": [82, 86], "tok_span": [19, 22]}, {"name": "G13D", "ent_type": "variant", "char_span": [104, 108], "tok_span": [26, 29]}], "relation_list": [{"subject": "G12D", "object": "cetuximab", "sbj_char_span": [82, 86], "obj_char_span": [151, 160], "rel_type": "sensitivity", "sbj_tok_span": [19, 22], "obj_tok_span": [37, 41]}, {"subject": "G13D", "object": "cetuximab", "sbj_char_span": [104, 108], "obj_char_span": [151, 160], "rel_type": "resistance or non-response", "sbj_tok_span": [26, 29], "obj_tok_span": [37, 41]}], "umls_entity_list": []}, {"text": "Di Nicolantonio et al. ( ) also demonstrated that introduction of the BRAF V600E allele could confer resistance to either cetuximab or panitumumab in wild-type BRAF colorectal cancer cells .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [122, 131], "tok_span": [27, 31]}, {"name": "V600E", "ent_type": "variant", "char_span": [75, 80], "tok_span": [18, 21]}], "relation_list": [{"subject": "V600E", "object": "cetuximab", "sbj_char_span": [75, 80], "obj_char_span": [122, 131], "rel_type": "resistance or non-response", "sbj_tok_span": [18, 21], "obj_tok_span": [27, 31]}], "umls_entity_list": []}, {"text": "Loupakis et al. analyzed 87 patients with KRAS WT tumors for the BRAF V600E mutation who were receiving irinotecan and cetuximab for refractory metastatic CRC .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [119, 128], "tok_span": [30, 34]}, {"name": "V600E", "ent_type": "variant", "char_span": [70, 75], "tok_span": [18, 21]}], "relation_list": [{"subject": "V600E", "object": "cetuximab", "sbj_char_span": [70, 75], "obj_char_span": [119, 128], "rel_type": "resistance or non-response", "sbj_tok_span": [18, 21], "obj_tok_span": [30, 34]}], "umls_entity_list": []}, {"text": "In this study , we engineer the T670I mutation into the mouse c-kit locus , an allele originally identified in GIST patients with refractory responses to imatinib , and bred the strain onto the NOD background to generate imatinib-resistant c-Kit mice that develop T1D .", "entity_list": [{"name": "imatinib", "ent_type": "drug", "char_span": [154, 162], "tok_span": [32, 34]}, {"name": "T670I", "ent_type": "variant", "char_span": [32, 37], "tok_span": [7, 11]}, {"name": "imatinib-resistant", "ent_type": "drug", "char_span": [221, 239], "tok_span": [46, 50]}], "relation_list": [{"subject": "T670I", "object": "imatinib", "sbj_char_span": [32, 37], "obj_char_span": [154, 162], "rel_type": "resistance", "sbj_tok_span": [7, 11], "obj_tok_span": [32, 34]}, {"subject": "T670I", "object": "imatinib-resistant", "sbj_char_span": [32, 37], "obj_char_span": [221, 239], "rel_type": "resistance", "sbj_tok_span": [7, 11], "obj_tok_span": [46, 50]}], "umls_entity_list": []}, {"text": "We characterize the imatinib response of diabetic NOD mice expressing wild-type or T670I mutant c-kit alleles and ask whether inhibition of c-Kit is required for efficacy of imatinib in this model .", "entity_list": [{"name": "imatinib", "ent_type": "drug", "char_span": [20, 28], "tok_span": [3, 5]}, {"name": "T670I", "ent_type": "variant", "char_span": [83, 88], "tok_span": [15, 19]}, {"name": "imatinib", "ent_type": "drug", "char_span": [174, 182], "tok_span": [37, 39]}], "relation_list": [{"subject": "T670I", "object": "imatinib", "sbj_char_span": [83, 88], "obj_char_span": [20, 28], "rel_type": "resistance", "sbj_tok_span": [15, 19], "obj_tok_span": [3, 5]}, {"subject": "T670I", "object": "imatinib", "sbj_char_span": [83, 88], "obj_char_span": [174, 182], "rel_type": "resistance", "sbj_tok_span": [15, 19], "obj_tok_span": [37, 39]}], "umls_entity_list": []}, {"text": "The T670I allele of c-Kit is a mutation originally identified in GIST patients with refractory responses to imatinib .", "entity_list": [{"name": "imatinib", "ent_type": "drug", "char_span": [108, 116], "tok_span": [23, 25]}, {"name": "T670I", "ent_type": "variant", "char_span": [4, 9], "tok_span": [1, 5]}], "relation_list": [{"subject": "T670I", "object": "imatinib", "sbj_char_span": [4, 9], "obj_char_span": [108, 116], "rel_type": "resistance", "sbj_tok_span": [1, 5], "obj_tok_span": [23, 25]}], "umls_entity_list": []}, {"text": "To develop imatinib-resistant c-Kit NOD mice , we generated mice that carried the c-kit T670I mutation ( ) , and then bred this allele onto the NOD background for 10 generations and until known genomic insulin dependent diabetes (Idd) loci were fixed .", "entity_list": [{"name": "imatinib-resistant", "ent_type": "drug", "char_span": [11, 29], "tok_span": [2, 6]}, {"name": "T670I", "ent_type": "variant", "char_span": [88, 93], "tok_span": [21, 25]}], "relation_list": [{"subject": "T670I", "object": "imatinib-resistant", "sbj_char_span": [88, 93], "obj_char_span": [11, 29], "rel_type": "resistance", "sbj_tok_span": [21, 25], "obj_tok_span": [2, 6]}], "umls_entity_list": []}, {"text": "Approximately 5 % to 7 % of GIST harbour oncogenic mutations in PDGFRA , typically in the juxtamembrane domain ( exon 12 ) or activation loop ( exon 18 ) ; the D842V substitution in exon 18 , is highly resistant to imatinib .", "entity_list": [{"name": "imatinib", "ent_type": "drug", "char_span": [215, 223], "tok_span": [52, 54]}, {"name": "D842V", "ent_type": "variant", "char_span": [160, 165], "tok_span": [39, 43]}], "relation_list": [{"subject": "D842V", "object": "imatinib", "sbj_char_span": [160, 165], "obj_char_span": [215, 223], "rel_type": "resistance or non-response", "sbj_tok_span": [39, 43], "obj_tok_span": [52, 54]}], "umls_entity_list": []}, {"text": "Further , although approximately 70 % of c-Kit mutations in melanoma and GIST occur in exon 11 , there is a preponderance of the activating L576P , exon 11 variant in melanoma ( ~34 % of c-Kit mutations ) and this mutation shows poor imatinib sensitivity in GIST , and variable sensitivity in melanoma . ", "entity_list": [{"name": "imatinib", "ent_type": "drug", "char_span": [234, 242], "tok_span": [55, 57]}, {"name": "L576P", "ent_type": "variant", "char_span": [140, 145], "tok_span": [30, 34]}], "relation_list": [{"subject": "L576P", "object": "imatinib", "sbj_char_span": [140, 145], "obj_char_span": [234, 242], "rel_type": "resistance or non-response", "sbj_tok_span": [30, 34], "obj_tok_span": [55, 57]}], "umls_entity_list": []}, {"text": "Cells with an A829P c-Kit mutation are resistant to imatinib but are still sensitive to the tyrosine kinase inhibitors nilotinib and dasatinib .", "entity_list": [{"name": "imatinib", "ent_type": "drug", "char_span": [52, 60], "tok_span": [14, 16]}, {"name": "A829P", "ent_type": "variant", "char_span": [14, 19], "tok_span": [3, 7]}], "relation_list": [{"subject": "A829P", "object": "imatinib", "sbj_char_span": [14, 19], "obj_char_span": [52, 60], "rel_type": "resistance", "sbj_tok_span": [3, 7], "obj_tok_span": [14, 16]}], "umls_entity_list": []}, {"text": "Additionally , the T670I c-Kit mutation mediates resistance to imatinib , nilotinib , and dasatinib but remains sensitive to sunitinib .", "entity_list": [{"name": "imatinib", "ent_type": "drug", "char_span": [63, 71], "tok_span": [14, 16]}, {"name": "T670I", "ent_type": "variant", "char_span": [19, 24], "tok_span": [3, 7]}], "relation_list": [{"subject": "T670I", "object": "imatinib", "sbj_char_span": [19, 24], "obj_char_span": [63, 71], "rel_type": "resistance", "sbj_tok_span": [3, 7], "obj_tok_span": [14, 16]}], "umls_entity_list": []}, {"text": "In vitro analyses identified three point mutations , L755S , L755P , and T798M to confer resistance to lapatinib ( Kancha et al. , ) .", "entity_list": [{"name": "lapatinib", "ent_type": "drug", "char_span": [103, 112], "tok_span": [27, 30]}, {"name": "L755S", "ent_type": "variant", "char_span": [53, 58], "tok_span": [8, 12]}], "relation_list": [{"subject": "L755S", "object": "lapatinib", "sbj_char_span": [53, 58], "obj_char_span": [103, 112], "rel_type": "resistance or non-response", "sbj_tok_span": [8, 12], "obj_tok_span": [27, 30]}], "umls_entity_list": []}, {"text": ", Concerning PDGFRA mutations , concordant in vitro data and clinical results support that the D842V substitution and other mutations within the kinase domain activation loop ( exon 18 ) are predictive of primary resistance to imatinib , whereas it is efficient in cases of juxtamembrane domain mutations. , ,", "entity_list": [{"name": "imatinib", "ent_type": "drug", "char_span": [227, 235], "tok_span": [41, 43]}, {"name": "D842V", "ent_type": "variant", "char_span": [95, 100], "tok_span": [17, 21]}], "relation_list": [{"subject": "D842V", "object": "imatinib", "sbj_char_span": [95, 100], "obj_char_span": [227, 235], "rel_type": "resistance or non-response", "sbj_tok_span": [17, 21], "obj_tok_span": [41, 43]}], "umls_entity_list": []}, {"text": "Some PDGFRA mutant GISTs show at least partial response to imatinib ; however , the most common PDGFRA mutation in GISTs ( D842V ) confers a complete resistance to the drug. , In KIT mutant GISTs , a mutation in exon 11 was associated with a higher response rate ( 67 % –83 % ) than a mutation in exon 9 ( 35 % –48 % ) .", "entity_list": [{"name": "imatinib", "ent_type": "drug", "char_span": [59, 67], "tok_span": [12, 14]}, {"name": "D842V", "ent_type": "variant", "char_span": [123, 128], "tok_span": [27, 31]}], "relation_list": [{"subject": "D842V", "object": "imatinib", "sbj_char_span": [123, 128], "obj_char_span": [59, 67], "rel_type": "resistance or non-response", "sbj_tok_span": [27, 31], "obj_tok_span": [12, 14]}], "umls_entity_list": []}, {"text": "Similarly , a patient developed resistance to crizotinib after 5 months of treatment and molecular analyses revealed the resistant tumor harbored two acquired but independent mutations within the kinase domain of EML4-ALK , C1156Y , and the gatekeeper mutation L1196M .", "entity_list": [{"name": "crizotinib", "ent_type": "drug", "char_span": [46, 56], "tok_span": [7, 11]}, {"name": "L1196M", "ent_type": "variant", "char_span": [261, 267], "tok_span": [53, 57]}, {"name": "C1156Y", "ent_type": "variant", "char_span": [224, 230], "tok_span": [42, 46]}], "relation_list": [{"subject": "L1196M", "object": "crizotinib", "sbj_char_span": [261, 267], "obj_char_span": [46, 56], "rel_type": "resistance", "sbj_tok_span": [53, 57], "obj_tok_span": [7, 11]}, {"subject": "C1156Y", "object": "crizotinib", "sbj_char_span": [224, 230], "obj_char_span": [46, 56], "rel_type": "resistance", "sbj_tok_span": [42, 46], "obj_tok_span": [7, 11]}], "umls_entity_list": []}, {"text": "However , to date , the number of patients reported with identified resistance mechanisms to crizotinib remains extremely small ( less than four so far ) and therefore it is premature to say that the L1196M gate-keeper mutation will be the most important mechanism of acquired resistance to crizotinib than other mechanisms that can bypass the ALK signaling pathway .", "entity_list": [{"name": "crizotinib", "ent_type": "drug", "char_span": [93, 103], "tok_span": [15, 19]}, {"name": "L1196M", "ent_type": "variant", "char_span": [200, 206], "tok_span": [38, 42]}, {"name": "crizotinib", "ent_type": "drug", "char_span": [291, 301], "tok_span": [57, 61]}], "relation_list": [{"subject": "L1196M", "object": "crizotinib", "sbj_char_span": [200, 206], "obj_char_span": [93, 103], "rel_type": "resistance", "sbj_tok_span": [38, 42], "obj_tok_span": [15, 19]}, {"subject": "L1196M", "object": "crizotinib", "sbj_char_span": [200, 206], "obj_char_span": [291, 301], "rel_type": "resistance", "sbj_tok_span": [38, 42], "obj_tok_span": [57, 61]}], "umls_entity_list": []}, {"text": "Comparison of Ki between crizotinib and AP26113 for wild-type ALK and ALK with LII96M gate-keeper mutation Ki ( nM ) ALK wild-type ALK ( L1196M )", "entity_list": [{"name": "crizotinib", "ent_type": "drug", "char_span": [25, 35], "tok_span": [4, 8]}, {"name": "L1196M", "ent_type": "variant", "char_span": [137, 143], "tok_span": [43, 47]}], "relation_list": [{"subject": "L1196M", "object": "crizotinib", "sbj_char_span": [137, 143], "obj_char_span": [25, 35], "rel_type": "resistance", "sbj_tok_span": [43, 47], "obj_tok_span": [4, 8]}], "umls_entity_list": []}, {"text": "A recent report of a G2032R mutation in the ROS1 TK domain leading to crizotinib resistance has also been identified ( ) .", "entity_list": [{"name": "crizotinib", "ent_type": "drug", "char_span": [70, 80], "tok_span": [18, 22]}, {"name": "G2032R", "ent_type": "variant", "char_span": [21, 27], "tok_span": [5, 9]}], "relation_list": [{"subject": "G2032R", "object": "crizotinib", "sbj_char_span": [21, 27], "obj_char_span": [70, 80], "rel_type": "resistance", "sbj_tok_span": [5, 9], "obj_tok_span": [18, 22]}], "umls_entity_list": []}, {"text": "Drug Company Activity against Activity against Ongoing trials Study phase Previous treatment other kinases L1196M mutation LDK378 ( ceritinib ) Novartis IFG-1R Yes NCT01772797 Phase I None c-MET NCT02040870 Phase I/II Crizotinib/chemotherapy NCT01685138 Phase II 0-3 lines of chemotherapy NCT01685060 Phase II Crizotinib or 1-3 lines of chemotherapy NCT01947608 Phase II Crizotinib NCT01964157 Phase II 1 line of chemotherapy NCT01828099 Phase III None NCT01828112 Phase III Crizotinib", "entity_list": [{"name": "Crizotinib/chemotherapy", "ent_type": "drug", "char_span": [218, 241], "tok_span": [60, 66]}, {"name": "L1196M", "ent_type": "variant", "char_span": [107, 113], "tok_span": [15, 19]}, {"name": "Crizotinib", "ent_type": "drug", "char_span": [310, 320], "tok_span": [87, 91]}, {"name": "Crizotinib", "ent_type": "drug", "char_span": [371, 381], "tok_span": [106, 110]}, {"name": "Crizotinib", "ent_type": "drug", "char_span": [475, 485], "tok_span": [138, 142]}], "relation_list": [{"subject": "L1196M", "object": "Crizotinib/chemotherapy", "sbj_char_span": [107, 113], "obj_char_span": [218, 241], "rel_type": "resistance", "sbj_tok_span": [15, 19], "obj_tok_span": [60, 66]}, {"subject": "L1196M", "object": "Crizotinib", "sbj_char_span": [107, 113], "obj_char_span": [310, 320], "rel_type": "resistance", "sbj_tok_span": [15, 19], "obj_tok_span": [87, 91]}, {"subject": "L1196M", "object": "Crizotinib", "sbj_char_span": [107, 113], "obj_char_span": [371, 381], "rel_type": "resistance", "sbj_tok_span": [15, 19], "obj_tok_span": [106, 110]}, {"subject": "L1196M", "object": "Crizotinib", "sbj_char_span": [107, 113], "obj_char_span": [475, 485], "rel_type": "resistance", "sbj_tok_span": [15, 19], "obj_tok_span": [138, 142]}], "umls_entity_list": []}, {"text": "The effect of the C1156Y mutation is unclear , although it may have an indirect effect on crizotinib binding , and further studies will be required to establish its mechanism . ", "entity_list": [{"name": "crizotinib", "ent_type": "drug", "char_span": [90, 100], "tok_span": [20, 24]}, {"name": "C1156Y", "ent_type": "variant", "char_span": [18, 24], "tok_span": [4, 8]}], "relation_list": [{"subject": "C1156Y", "object": "crizotinib", "sbj_char_span": [18, 24], "obj_char_span": [90, 100], "rel_type": "resistance", "sbj_tok_span": [4, 8], "obj_tok_span": [20, 24]}], "umls_entity_list": []}, {"text": "One of these is AP26113 from Ariad , which inhibits the growth of crizotinib-resistant H3122 cell lines and xenograft mouse models that carry the L1196M EML4–ALK mutation ( ) .", "entity_list": [{"name": "crizotinib-resistant", "ent_type": "drug", "char_span": [66, 86], "tok_span": [17, 23]}, {"name": "L1196M", "ent_type": "variant", "char_span": [146, 152], "tok_span": [36, 40]}], "relation_list": [{"subject": "L1196M", "object": "crizotinib-resistant", "sbj_char_span": [146, 152], "obj_char_span": [66, 86], "rel_type": "resistance", "sbj_tok_span": [36, 40], "obj_tok_span": [17, 23]}], "umls_entity_list": []}, {"text": "Other compounds , such as the Hsp90-inhibitor geldenamycin derivatives IPI-504 and 17-AAG , appear to have effects in NSCLC patients with ALK translocations , and this effect appears to extend to ELM4–ALK ( L1196M ) suggesting they may be useful in overcoming crizotinib-resistant tumors .", "entity_list": [{"name": "overcoming crizotinib-resistant", "ent_type": "drug", "char_span": [249, 280], "tok_span": [63, 71]}, {"name": "( L1196M", "ent_type": "variant", "char_span": [205, 213], "tok_span": [51, 56]}], "relation_list": [{"subject": "( L1196M", "object": "overcoming crizotinib-resistant", "sbj_char_span": [205, 213], "obj_char_span": [249, 280], "rel_type": "resistance", "sbj_tok_span": [51, 56], "obj_tok_span": [63, 71]}], "umls_entity_list": []}, {"text": "Overall , this pooled analysis confirmed that first-line afatinib significantly improved OS in patients with advanced NSCLC harboring common EGFR mutations ( Del19 and L858R ) compared with standard chemotherapy .", "entity_list": [{"name": "afatinib", "ent_type": "drug", "char_span": [57, 65], "tok_span": [10, 12]}, {"name": "L858R", "ent_type": "variant", "char_span": [168, 173], "tok_span": [28, 32]}], "relation_list": [{"subject": "L858R", "object": "afatinib", "sbj_char_span": [168, 173], "obj_char_span": [57, 65], "rel_type": "sensitivity", "sbj_tok_span": [28, 32], "obj_tok_span": [10, 12]}], "umls_entity_list": []}, {"text": "These second-generation EGFR inhibitors have also been shown to drive drug resistance through the acquisition of T790M in both preclinical and clinical settings , suggesting low potency against T790M. , As a potential solution , afatinib was combined with the EGFR antibody cetuximab in a Phase IIB study , which demonstrated an impressive response rate of 32 % in patients with EGFR mutant lung cancers resistant to first-generation EGFR inhibitors .", "entity_list": [{"name": "afatinib", "ent_type": "drug", "char_span": [229, 237], "tok_span": [44, 46]}, {"name": "T790M", "ent_type": "variant", "char_span": [113, 118], "tok_span": [18, 22]}], "relation_list": [{"subject": "T790M", "object": "afatinib", "sbj_char_span": [113, 118], "obj_char_span": [229, 237], "rel_type": "response", "sbj_tok_span": [18, 22], "obj_tok_span": [44, 46]}], "umls_entity_list": []}, {"text": "Based on the clinical data of achievable plasma concentrations of continuous daily dosing of neratinib , dacomitinib and afatinib , it is thought that primary resistance to these agents will still be encountered for the EGFR T790M mutation as well as exon 20 insertions and clinical trial results thus far with the second-generation EGFR TKIs had generally supported this prediction with few exceptions ( see below ) .", "entity_list": [{"name": "afatinib", "ent_type": "drug", "char_span": [121, 129], "tok_span": [24, 26]}, {"name": "T790M", "ent_type": "variant", "char_span": [225, 230], "tok_span": [43, 47]}], "relation_list": [{"subject": "T790M", "object": "afatinib", "sbj_char_span": [225, 230], "obj_char_span": [121, 129], "rel_type": "response", "sbj_tok_span": [43, 47], "obj_tok_span": [24, 26]}], "umls_entity_list": []}, {"text": "Although afatinib and dacomitinib have been introduced to overcome acquired resistance , they showed limited efficacy in NSCLC with T790M and were more than 100-fold less potent in NSCLC cells with EGFR T790M mutation than in NSCLC cells with EGFR activating mutation .", "entity_list": [{"name": "afatinib", "ent_type": "drug", "char_span": [9, 17], "tok_span": [1, 3]}, {"name": "T790M", "ent_type": "variant", "char_span": [132, 137], "tok_span": [23, 27]}], "relation_list": [{"subject": "T790M", "object": "afatinib", "sbj_char_span": [132, 137], "obj_char_span": [9, 17], "rel_type": "response", "sbj_tok_span": [23, 27], "obj_tok_span": [1, 3]}], "umls_entity_list": []}, {"text": "Due to their ability to potently inhibit EGFR , both afatinib and neratinib have been assessed in lung cancer that has become resistant to gefitinib and erlotinib due to the T790M point mutation in the kinase domain .", "entity_list": [{"name": "afatinib", "ent_type": "drug", "char_span": [53, 61], "tok_span": [11, 13]}, {"name": "T790M", "ent_type": "variant", "char_span": [174, 179], "tok_span": [41, 45]}], "relation_list": [{"subject": "T790M", "object": "afatinib", "sbj_char_span": [174, 179], "obj_char_span": [53, 61], "rel_type": "response", "sbj_tok_span": [41, 45], "obj_tok_span": [11, 13]}], "umls_entity_list": []}, {"text": "The new therapy methods , which could be effective in patients with T790M mutation includes irreversible EGFR-TKIs ( afatinib , neratinib ) .", "entity_list": [{"name": "afatinib", "ent_type": "drug", "char_span": [117, 125], "tok_span": [24, 26]}, {"name": "T790M", "ent_type": "variant", "char_span": [68, 73], "tok_span": [12, 16]}], "relation_list": [{"subject": "T790M", "object": "afatinib", "sbj_char_span": [68, 73], "obj_char_span": [117, 125], "rel_type": "response", "sbj_tok_span": [12, 16], "obj_tok_span": [24, 26]}], "umls_entity_list": []}, {"text": "Wu YL ( 2014 ) LUXLUNG6 ( III ) Afatinib 40 mg/d , po Gemcitabine 1000 mg/m2 , d1,8 , iv , q3w + 19 186 ( 124/62 ) 0.20 ( 0.13–0.33 ) cisplatin 75 mg/m2 , d1 , iv , q3w×≤6 cycles 21 138 ( 92/46 ) 0.32 ( 0.19–0.52 ) Exon of EGFR mutation means either exon 19 deletion or exon 21 L858R mutation .", "entity_list": [{"name": "Afatinib", "ent_type": "drug", "char_span": [32, 40], "tok_span": [13, 15]}, {"name": "L858R", "ent_type": "variant", "char_span": [278, 283], "tok_span": [111, 115]}], "relation_list": [{"subject": "L858R", "object": "Afatinib", "sbj_char_span": [278, 283], "obj_char_span": [32, 40], "rel_type": "sensitivity", "sbj_tok_span": [111, 115], "obj_tok_span": [13, 15]}], "umls_entity_list": []}, {"text": "AST1306 could potently inhibit the EGFR T790M mutant , exhibiting an IC50 value of 12 ± 2 nmol/L , which is similar to afatinib ( 10 nmol/L ) and approximately 500-fold more potent than lapatinib .", "entity_list": [{"name": "to afatinib", "ent_type": "drug", "char_span": [116, 127], "tok_span": [31, 34]}, {"name": "T790M", "ent_type": "variant", "char_span": [40, 45], "tok_span": [9, 13]}], "relation_list": [{"subject": "T790M", "object": "to afatinib", "sbj_char_span": [40, 45], "obj_char_span": [116, 127], "rel_type": "response", "sbj_tok_span": [9, 13], "obj_tok_span": [31, 34]}], "umls_entity_list": []}, {"text": "One approach to circumvent T790M mediated resistance has been the use of irreversible small molecule inhibitors such as afatinib , which has demonstrated activity against T790M mutant cells and tumors in preclinical models .", "entity_list": [{"name": "afatinib", "ent_type": "drug", "char_span": [120, 128], "tok_span": [21, 23]}, {"name": "T790M", "ent_type": "variant", "char_span": [27, 32], "tok_span": [4, 8]}], "relation_list": [{"subject": "T790M", "object": "afatinib", "sbj_char_span": [27, 32], "obj_char_span": [120, 128], "rel_type": "response", "sbj_tok_span": [4, 8], "obj_tok_span": [21, 23]}], "umls_entity_list": []}, {"text": "KIT W557R V559A/D L576P K642E D816H 23 % Acral 16 % Mucosal 28 % CSD , , Sensitive to : Imatinib Nilotinib Sunitinib Dasatinib Decreased sensitivity to : Imatinib ( D816H only ) , , , ,", "entity_list": [{"name": "Dasatinib", "ent_type": "drug", "char_span": [117, 126], "tok_span": [51, 53]}, {"name": "L576P", "ent_type": "variant", "char_span": [18, 23], "tok_span": [12, 16]}], "relation_list": [{"subject": "L576P", "object": "Dasatinib", "sbj_char_span": [18, 23], "obj_char_span": [117, 126], "rel_type": "sensitivity", "sbj_tok_span": [12, 16], "obj_tok_span": [51, 53]}], "umls_entity_list": []}, {"text": "Ponatinib ( AP24534 ) , a third generation pan-BCR-ABL kinase inhibitor generated from the structure guided drug design strategy , is able to inhibit native BCR-ABL kinase , most of the clinically relevant mutants including T315I mutation .", "entity_list": [{"name": "Ponatinib", "ent_type": "drug", "char_span": [0, 9], "tok_span": [0, 2]}, {"name": "T315I", "ent_type": "variant", "char_span": [224, 229], "tok_span": [47, 51]}, {"name": "AP24534", "ent_type": "drug", "char_span": [12, 19], "tok_span": [3, 7]}], "relation_list": [{"subject": "T315I", "object": "Ponatinib", "sbj_char_span": [224, 229], "obj_char_span": [0, 9], "rel_type": "response", "sbj_tok_span": [47, 51], "obj_tok_span": [0, 2]}, {"subject": "T315I", "object": "AP24534", "sbj_char_span": [224, 229], "obj_char_span": [12, 19], "rel_type": "response", "sbj_tok_span": [47, 51], "obj_tok_span": [3, 7]}], "umls_entity_list": []}, {"text": "The free energy of BCR-ABLT315I complexed with imatinib is −9.89 kcal/mol indicating that ponatinib has higher binding towards T315I mutation compared to imatinib .", "entity_list": [{"name": "that ponatinib", "ent_type": "drug", "char_span": [85, 99], "tok_span": [25, 30]}, {"name": "towards T315I", "ent_type": "variant", "char_span": [119, 132], "tok_span": [33, 38]}], "relation_list": [{"subject": "towards T315I", "object": "that ponatinib", "sbj_char_span": [119, 132], "obj_char_span": [85, 99], "rel_type": "response", "sbj_tok_span": [33, 38], "obj_tok_span": [25, 30]}], "umls_entity_list": []}, {"text": "Figure shows clearly that T315I affinity for ponatinib analogs vary according to variations in their hydrophobic binding interactions .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [45, 54], "tok_span": [10, 14]}, {"name": "T315I", "ent_type": "variant", "char_span": [26, 31], "tok_span": [4, 8]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [26, 31], "obj_char_span": [45, 54], "rel_type": "response", "sbj_tok_span": [4, 8], "obj_tok_span": [10, 14]}], "umls_entity_list": []}, {"text": "It has been speculated that a growing selection pressure in TKI treatment will promote the appearance of T315I mutations.– Novel compounds such as the aurora kinase inhibitors – including danusertib ( formerly PHA-739358 ) , homoharringtonine , and ponatinib – successfully target the T315I mutation .", "entity_list": [{"name": "and ponatinib", "ent_type": "drug", "char_span": [245, 258], "tok_span": [58, 63]}, {"name": "T315I", "ent_type": "variant", "char_span": [105, 110], "tok_span": [18, 22]}], "relation_list": [{"subject": "T315I", "object": "and ponatinib", "sbj_char_span": [105, 110], "obj_char_span": [245, 258], "rel_type": "response", "sbj_tok_span": [18, 22], "obj_tok_span": [58, 63]}], "umls_entity_list": []}, {"text": "For patients with mutations such as T315I which is known to confer resistance to all TKIs currently approved for first-line treatment of CML , one of the newer agents such as ponatinib ( AP24534 ) which is effective against this mutation and very recently been approved by FDA for TKI-resistant CML , or allogeneic transplantation must be considered .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [175, 184], "tok_span": [37, 41]}, {"name": "T315I", "ent_type": "variant", "char_span": [36, 41], "tok_span": [6, 10]}, {"name": "AP24534", "ent_type": "drug", "char_span": [187, 194], "tok_span": [42, 46]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [36, 41], "obj_char_span": [175, 184], "rel_type": "response", "sbj_tok_span": [6, 10], "obj_tok_span": [37, 41]}, {"subject": "T315I", "object": "AP24534", "sbj_char_span": [36, 41], "obj_char_span": [187, 194], "rel_type": "response", "sbj_tok_span": [6, 10], "obj_tok_span": [42, 46]}], "umls_entity_list": []}, {"text": "Ponatinib is highly active in patients with Ph-positive leukemias , including those with BCR-ABL T315I mutations .", "entity_list": [{"name": "T315I", "ent_type": "variant", "char_span": [97, 102], "tok_span": [21, 25]}, {"name": "Ponatinib", "ent_type": "drug", "char_span": [0, 9], "tok_span": [0, 2]}], "relation_list": [{"subject": "T315I", "object": "Ponatinib", "sbj_char_span": [97, 102], "obj_char_span": [0, 9], "rel_type": "response", "sbj_tok_span": [21, 25], "obj_tok_span": [0, 2]}], "umls_entity_list": []}, {"text": "It is conceivable that the development of third-generation TKIs such as ponatinib will take care of mutation related resistance , as ponatinib potently inhibits the most feared T315I “gatekeeper” mutation , the single mutation that has sounded the death knell for all treatment options based on TKIs .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [72, 81], "tok_span": [15, 19]}, {"name": "T315I", "ent_type": "variant", "char_span": [177, 182], "tok_span": [39, 43]}, {"name": "ponatinib", "ent_type": "drug", "char_span": [133, 142], "tok_span": [28, 32]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [177, 182], "obj_char_span": [72, 81], "rel_type": "response", "sbj_tok_span": [39, 43], "obj_tok_span": [15, 19]}, {"subject": "T315I", "object": "ponatinib", "sbj_char_span": [177, 182], "obj_char_span": [133, 142], "rel_type": "response", "sbj_tok_span": [39, 43], "obj_tok_span": [28, 32]}], "umls_entity_list": []}, {"text": "In this regard , ponatinib ( formerly AP24534 ) , a multitargeted kinase inhibitor , was shown experimentally to be active against all tested BCR-ABL mutants , including T315I , in vitro .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [17, 26], "tok_span": [4, 8]}, {"name": "T315I", "ent_type": "variant", "char_span": [170, 175], "tok_span": [39, 43]}, {"name": "AP24534", "ent_type": "drug", "char_span": [38, 45], "tok_span": [11, 15]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [170, 175], "obj_char_span": [17, 26], "rel_type": "response", "sbj_tok_span": [39, 43], "obj_tok_span": [4, 8]}, {"subject": "T315I", "object": "AP24534", "sbj_char_span": [170, 175], "obj_char_span": [38, 45], "rel_type": "response", "sbj_tok_span": [39, 43], "obj_tok_span": [11, 15]}], "umls_entity_list": []}, {"text": "However , novel compounds such as the aurora kinase inhibitors , eg , danusertib ( formerly PHA-739358 ) , homoharringtonine , and ponatinib , successfully target the T315I mutation , and clinical trials are currently being carried out , with the first results looking very promising , as reviewed elsewhere .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [131, 140], "tok_span": [37, 41]}, {"name": "T315I", "ent_type": "variant", "char_span": [167, 172], "tok_span": [45, 49]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [167, 172], "obj_char_span": [131, 140], "rel_type": "response", "sbj_tok_span": [45, 49], "obj_tok_span": [37, 41]}], "umls_entity_list": []}, {"text": "Further study is needed to determine the effect of everolimus on T315I mutated leukemia , especially in combination with a T315I inhibitor such as AP24534 ( ponatinib ) .", "entity_list": [{"name": "AP24534", "ent_type": "drug", "char_span": [147, 154], "tok_span": [32, 36]}, {"name": "T315I", "ent_type": "variant", "char_span": [65, 70], "tok_span": [13, 17]}, {"name": "ponatinib", "ent_type": "drug", "char_span": [157, 166], "tok_span": [37, 41]}], "relation_list": [{"subject": "T315I", "object": "AP24534", "sbj_char_span": [65, 70], "obj_char_span": [147, 154], "rel_type": "response", "sbj_tok_span": [13, 17], "obj_tok_span": [32, 36]}, {"subject": "T315I", "object": "ponatinib", "sbj_char_span": [65, 70], "obj_char_span": [157, 166], "rel_type": "response", "sbj_tok_span": [13, 17], "obj_tok_span": [37, 41]}], "umls_entity_list": []}, {"text": "The clinically most notorious Abl1 mutant is T315I , which is resistant to all KIs except ponatinib ( recently approved in the US and EU ) and rebastinib ( currently studied in clinical trials ) .", "entity_list": [{"name": "ponatinib", "ent_type": "drug", "char_span": [90, 99], "tok_span": [24, 28]}, {"name": "T315I", "ent_type": "variant", "char_span": [45, 50], "tok_span": [11, 15]}], "relation_list": [{"subject": "T315I", "object": "ponatinib", "sbj_char_span": [45, 50], "obj_char_span": [90, 99], "rel_type": "response", "sbj_tok_span": [11, 15], "obj_tok_span": [24, 28]}], "umls_entity_list": []}, {"text": "An L576P mutation in exon 11 of KIT was identified in the clitorectomy specimen and imatinib was commenced at a 400 mg daily dose .", "entity_list": [{"name": "imatinib", "ent_type": "drug", "char_span": [84, 92], "tok_span": [21, 23]}, {"name": "L576P", "ent_type": "variant", "char_span": [3, 8], "tok_span": [1, 5]}], "relation_list": [{"subject": "L576P", "object": "imatinib", "sbj_char_span": [3, 8], "obj_char_span": [84, 92], "rel_type": "resistance or non-response", "sbj_tok_span": [1, 5], "obj_tok_span": [21, 23]}], "umls_entity_list": []}, {"text": "The convincing clinical response observed in the patient with the L576P mutation in exon 11 ( Case 3 ) is interesting to note in the context of in vitro data demonstrating reduced sensitivity to imatinib compared with other exon 11 mutations ( ) .", "entity_list": [{"name": "imatinib", "ent_type": "drug", "char_span": [195, 203], "tok_span": [37, 39]}, {"name": "L576P", "ent_type": "variant", "char_span": [66, 71], "tok_span": [10, 14]}], "relation_list": [{"subject": "L576P", "object": "imatinib", "sbj_char_span": [66, 71], "obj_char_span": [195, 203], "rel_type": "resistance or non-response", "sbj_tok_span": [10, 14], "obj_tok_span": [37, 39]}], "umls_entity_list": []}, {"text": "Imatinib ( Gleevec® ) was the first compound used in therapy , but mutations on TK1 domain , known also ATP binding pocket , ( V654A , T670I gatekeeper mutations of c-kit ) led to reduced effectiveness or ineffectiveness of this treatment .", "entity_list": [{"name": "Imatinib", "ent_type": "drug", "char_span": [0, 8], "tok_span": [0, 2]}, {"name": "( V654A", "ent_type": "variant", "char_span": [125, 132], "tok_span": [29, 34]}, {"name": "Gleevec®", "ent_type": "drug", "char_span": [11, 19], "tok_span": [3, 7]}, {"name": ", T670I", "ent_type": "variant", "char_span": [133, 140], "tok_span": [34, 39]}], "relation_list": [{"subject": "( V654A", "object": "Imatinib", "sbj_char_span": [125, 132], "obj_char_span": [0, 8], "rel_type": "resistance", "sbj_tok_span": [29, 34], "obj_tok_span": [0, 2]}, {"subject": "( V654A", "object": "Gleevec®", "sbj_char_span": [125, 132], "obj_char_span": [11, 19], "rel_type": "resistance", "sbj_tok_span": [29, 34], "obj_tok_span": [3, 7]}, {"subject": ", T670I", "object": "Imatinib", "sbj_char_span": [133, 140], "obj_char_span": [0, 8], "rel_type": "resistance", "sbj_tok_span": [34, 39], "obj_tok_span": [0, 2]}, {"subject": ", T670I", "object": "Gleevec®", "sbj_char_span": [133, 140], "obj_char_span": [11, 19], "rel_type": "resistance", "sbj_tok_span": [34, 39], "obj_tok_span": [3, 7]}], "umls_entity_list": []}, {"text": "We studied the role of gatekeeper mutations V654A and T670I , which are located into the activation loop ( A-loop of catalytic domain ) , in relation to the binding of therapeutic drugs ( Imatinib , Sunitinib and other important inhibitors ) .", "entity_list": [{"name": "Imatinib", "ent_type": "drug", "char_span": [188, 196], "tok_span": [44, 46]}, {"name": "V654A", "ent_type": "variant", "char_span": [44, 49], "tok_span": [9, 13]}, {"name": "T670I", "ent_type": "variant", "char_span": [54, 59], "tok_span": [14, 18]}], "relation_list": [{"subject": "V654A", "object": "Imatinib", "sbj_char_span": [44, 49], "obj_char_span": [188, 196], "rel_type": "resistance", "sbj_tok_span": [9, 13], "obj_tok_span": [44, 46]}, {"subject": "T670I", "object": "Imatinib", "sbj_char_span": [54, 59], "obj_char_span": [188, 196], "rel_type": "resistance", "sbj_tok_span": [14, 18], "obj_tok_span": [44, 46]}], "umls_entity_list": []}, {"text": "Ba/F3 cells expressing T674I F/P resistant to Imatinib ( IR ) have been described previously .", "entity_list": [{"name": "Imatinib", "ent_type": "drug", "char_span": [46, 54], "tok_span": [15, 17]}, {"name": "T674I", "ent_type": "variant", "char_span": [23, 28], "tok_span": [6, 10]}], "relation_list": [{"subject": "T674I", "object": "Imatinib", "sbj_char_span": [23, 28], "obj_char_span": [46, 54], "rel_type": "resistance", "sbj_tok_span": [6, 10], "obj_tok_span": [15, 17]}], "umls_entity_list": []}, {"text": "JAK2 inhibition blocks cellular proliferation in EOL-1 , primary F/P ( + ) CEL cells ( PC ) and T674I F/P Imatinib-resistant cells ( IR )", "entity_list": [{"name": "Imatinib-resistant", "ent_type": "drug", "char_span": [106, 124], "tok_span": [33, 37]}, {"name": "T674I", "ent_type": "variant", "char_span": [96, 101], "tok_span": [26, 30]}], "relation_list": [{"subject": "T674I", "object": "Imatinib-resistant", "sbj_char_span": [96, 101], "obj_char_span": [106, 124], "rel_type": "resistance", "sbj_tok_span": [26, 30], "obj_tok_span": [33, 37]}], "umls_entity_list": []}, {"text": "10.1371/journal.pone.0034912.g004JAK2 inhibition or knock-down by AG490 or transfection of JAK2 siRNA significantly inhibited cellular proliferation in EOL-1 , primary F/P ( + ) cells ( PC ) and T674I F/P Imatinib-resistant cells ( IR ) .", "entity_list": [{"name": "Imatinib-resistant", "ent_type": "drug", "char_span": [205, 223], "tok_span": [64, 68]}, {"name": "T674I", "ent_type": "variant", "char_span": [195, 200], "tok_span": [57, 61]}], "relation_list": [{"subject": "T674I", "object": "Imatinib-resistant", "sbj_char_span": [195, 200], "obj_char_span": [205, 223], "rel_type": "resistance", "sbj_tok_span": [57, 61], "obj_tok_span": [64, 68]}], "umls_entity_list": []}, {"text": "of patients Treatment outcome c-KIT aberration 2 Complete response L576P exon 11 mutation & amp ; amplification 2 Partial response L576P exon 11 mutation & amp ; exon 13 mutations 6 Stable disease Exon 13 mutations with or without amplification 2 No response Mutations known to cause resistance to Gleevec in GIST", "entity_list": [{"name": "Gleevec", "ent_type": "drug", "char_span": [298, 305], "tok_span": [60, 63]}, {"name": "L576P", "ent_type": "variant", "char_span": [67, 72], "tok_span": [13, 17]}], "relation_list": [{"subject": "L576P", "object": "Gleevec", "sbj_char_span": [67, 72], "obj_char_span": [298, 305], "rel_type": "resistance or non-response", "sbj_tok_span": [13, 17], "obj_tok_span": [60, 63]}], "umls_entity_list": []}, {"text": "More recently , Ashida et al. investigated six acral melanoma cell lines , indicating that sunitinib was better sensitive to c-kit D820Y mutant cells with the secondary resistance to imatinib while the wild type cells did not change .", "entity_list": [{"name": "imatinib", "ent_type": "drug", "char_span": [183, 191], "tok_span": [39, 41]}, {"name": "D820Y", "ent_type": "variant", "char_span": [131, 136], "tok_span": [28, 32]}], "relation_list": [{"subject": "D820Y", "object": "imatinib", "sbj_char_span": [131, 136], "obj_char_span": [183, 191], "rel_type": "response", "sbj_tok_span": [28, 32], "obj_tok_span": [39, 41]}], "umls_entity_list": []}, {"text": "A second patient ( case # 5 , Table ) with two known EGFR-sensitive mutations ( L858R and G873E in exon 21 ) and a PIK3CA mutation ( E542K in exon 9 ) had a PR ( 55 % decrease ; duration=9+ months ) on erlotinib/cetuximab/bevacizumab .", "entity_list": [{"name": "erlotinib/cetuximab/bevacizumab", "ent_type": "drug", "char_span": [202, 233], "tok_span": [62, 74]}, {"name": "E542K", "ent_type": "variant", "char_span": [133, 138], "tok_span": [39, 43]}], "relation_list": [{"subject": "E542K", "object": "erlotinib/cetuximab/bevacizumab", "sbj_char_span": [133, 138], "obj_char_span": [202, 233], "rel_type": "resistance or non-response", "sbj_tok_span": [39, 43], "obj_tok_span": [62, 74]}], "umls_entity_list": []}, {"text": "Computed tomography ( CT ) scans of a NSCLC patient ( case # 5 , Table ) with two sensitive EGFR mutations ( L858R in exon 21 and G873E in exon 21 ) and a PIK3CA mutation ( E542K in exon 9 ) a ) CT at baseline , and b ) CT taken 5 months after treatment initiation with erlotinib/cetuximab/bevacizumab demonstrating a PR ( -55 % ) .", "entity_list": [{"name": "erlotinib/cetuximab/bevacizumab", "ent_type": "drug", "char_span": [270, 301], "tok_span": [73, 85]}, {"name": "E542K", "ent_type": "variant", "char_span": [173, 178], "tok_span": [48, 52]}], "relation_list": [{"subject": "E542K", "object": "erlotinib/cetuximab/bevacizumab", "sbj_char_span": [173, 178], "obj_char_span": [270, 301], "rel_type": "resistance or non-response", "sbj_tok_span": [48, 52], "obj_tok_span": [73, 85]}], "umls_entity_list": []}, {"text": "A recently published experience found a correlation between BRAF V600E activating mutation , mutually exclusive with KRAS ones , and resistance to the treatment with cetuximab and panitumumab administered alone or in combination with chemotherapy ( ) .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [166, 175], "tok_span": [28, 32]}, {"name": "V600E", "ent_type": "variant", "char_span": [65, 70], "tok_span": [9, 12]}], "relation_list": [{"subject": "V600E", "object": "cetuximab", "sbj_char_span": [65, 70], "obj_char_span": [166, 175], "rel_type": "resistance or non-response", "sbj_tok_span": [9, 12], "obj_tok_span": [28, 32]}], "umls_entity_list": []}, {"text": "To optimise the selection of patients who are more likely to benefit from anti-EGFR we investigated in a cohort of patients treated with the combination of cetuximab and irinotecan and bearing KRAS codons 12 and 13 wild-type tumours , the association of KRAS codons 61 and 146 mutations and BRAF V600E mutation with clinical outcomes .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [156, 165], "tok_span": [29, 33]}, {"name": "V600E", "ent_type": "variant", "char_span": [296, 301], "tok_span": [63, 66]}], "relation_list": [{"subject": "V600E", "object": "cetuximab", "sbj_char_span": [296, 301], "obj_char_span": [156, 165], "rel_type": "resistance or non-response", "sbj_tok_span": [63, 66], "obj_tok_span": [29, 33]}], "umls_entity_list": []}, {"text": "We and others have recently demonstrated that the V600E mutation can also preclude responsiveness to panitumumab or cetuximab in mCRC patients and cellular models of CRC . ", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [116, 125], "tok_span": [22, 26]}, {"name": "V600E", "ent_type": "variant", "char_span": [50, 55], "tok_span": [8, 11]}], "relation_list": [{"subject": "V600E", "object": "cetuximab", "sbj_char_span": [50, 55], "obj_char_span": [116, 125], "rel_type": "resistance or non-response", "sbj_tok_span": [8, 11], "obj_tok_span": [22, 26]}], "umls_entity_list": []}, {"text": "They found that ligand independent phosphorylation of the T790M lines was unaffected by cetuximab ( as measured by assays for phosphorylated EGFR , and downstream phosphorylated molecules Akt and MAPK ) and cellular proliferation was inhibited .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [88, 97], "tok_span": [16, 20]}, {"name": "T790M", "ent_type": "variant", "char_span": [58, 63], "tok_span": [8, 12]}], "relation_list": [{"subject": "T790M", "object": "cetuximab", "sbj_char_span": [58, 63], "obj_char_span": [88, 97], "rel_type": "response", "sbj_tok_span": [8, 12], "obj_tok_span": [16, 20]}], "umls_entity_list": []}, {"text": "More recently , a combination of afatinib and cetuximab , allowing for a complete EGFR blockade , has shown clinical benefit with a 36 % partial response ( PR ) rate overall and a 29 % PR rate in confirmed T790M mutations .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [46, 55], "tok_span": [9, 13]}, {"name": "T790M", "ent_type": "variant", "char_span": [206, 211], "tok_span": [44, 48]}, {"name": "afatinib", "ent_type": "drug", "char_span": [33, 41], "tok_span": [6, 8]}], "relation_list": [{"subject": "T790M", "object": "cetuximab", "sbj_char_span": [206, 211], "obj_char_span": [46, 55], "rel_type": "response", "sbj_tok_span": [44, 48], "obj_tok_span": [9, 13]}, {"subject": "T790M", "object": "afatinib", "sbj_char_span": [206, 211], "obj_char_span": [33, 41], "rel_type": "response", "sbj_tok_span": [44, 48], "obj_tok_span": [6, 8]}], "umls_entity_list": []}, {"text": "Furthermore , Chen et al. showed that the knockdown of T790M transcript by siRNAs , recovered the sensitivity of T790M mutant cells to TKIs , decreasing cell growth and inducing apoptosis of T790M mutant NSCLC cell line H1975 treated with TKIs , or cetuximab .", "entity_list": [{"name": "cetuximab", "ent_type": "drug", "char_span": [249, 258], "tok_span": [58, 62]}, {"name": "T790M", "ent_type": "variant", "char_span": [55, 60], "tok_span": [11, 15]}], "relation_list": [{"subject": "T790M", "object": "cetuximab", "sbj_char_span": [55, 60], "obj_char_span": [249, 258], "rel_type": "response", "sbj_tok_span": [11, 15], "obj_tok_span": [58, 62]}], "umls_entity_list": []}, {"text": "Two patients whose melanomas harbored L576P responded to dasatinib .", "entity_list": [{"name": "dasatinib", "ent_type": "drug", "char_span": [57, 66], "tok_span": [13, 15]}, {"name": "L576P", "ent_type": "variant", "char_span": [38, 43], "tok_span": [7, 11]}], "relation_list": [{"subject": "L576P", "object": "dasatinib", "sbj_char_span": [38, 43], "obj_char_span": [57, 66], "rel_type": "sensitivity", "sbj_tok_span": [7, 11], "obj_tok_span": [13, 15]}], "umls_entity_list": []}, {"text": "Known mechanisms for resistance to crizotinib include the gatekeeper L1196M mutation , other secondary ALK gene mutations ( F1174L , C1156Y , G1202R , S1206Y , 1151-T-ins , and G1269A ) , ALK amplification , and activation of bypass signals via activation of other receptors ( KIT amplification and epidermal growth factor receptor (EGFR) autophosphorylation ) .", "entity_list": [{"name": "crizotinib", "ent_type": "drug", "char_span": [35, 45], "tok_span": [6, 10]}, {"name": "F1174L", "ent_type": "variant", "char_span": [124, 130], "tok_span": [28, 32]}, {"name": "S1206Y", "ent_type": "variant", "char_span": [151, 157], "tok_span": [43, 47]}, {"name": "L1196M", "ent_type": "variant", "char_span": [69, 75], "tok_span": [15, 19]}, {"name": "G1202R", "ent_type": "variant", "char_span": [142, 148], "tok_span": [38, 42]}, {"name": "G1269A", "ent_type": "variant", "char_span": [177, 183], "tok_span": [56, 60]}, {"name": "C1156Y", "ent_type": "variant", "char_span": [133, 139], "tok_span": [33, 37]}], "relation_list": [{"subject": "F1174L", "object": "crizotinib", "sbj_char_span": [124, 130], "obj_char_span": [35, 45], "rel_type": "resistance", "sbj_tok_span": [28, 32], "obj_tok_span": [6, 10]}, {"subject": "S1206Y", "object": "crizotinib", "sbj_char_span": [151, 157], "obj_char_span": [35, 45], "rel_type": "resistance", "sbj_tok_span": [43, 47], "obj_tok_span": [6, 10]}, {"subject": "L1196M", "object": "crizotinib", "sbj_char_span": [69, 75], "obj_char_span": [35, 45], "rel_type": "resistance", "sbj_tok_span": [15, 19], "obj_tok_span": [6, 10]}, {"subject": "G1202R", "object": "crizotinib", "sbj_char_span": [142, 148], "obj_char_span": [35, 45], "rel_type": "resistance", "sbj_tok_span": [38, 42], "obj_tok_span": [6, 10]}, {"subject": "G1269A", "object": "crizotinib", "sbj_char_span": [177, 183], "obj_char_span": [35, 45], "rel_type": "resistance", "sbj_tok_span": [56, 60], "obj_tok_span": [6, 10]}, {"subject": "C1156Y", "object": "crizotinib", "sbj_char_span": [133, 139], "obj_char_span": [35, 45], "rel_type": "resistance", "sbj_tok_span": [33, 37], "obj_tok_span": [6, 10]}], "umls_entity_list": []}, {"text": "Resistance to crizotinib in a patient with CD74-ROS1 fusion was already reported , apparently as a consequence of a de novo mutation of G2032R in the ROS1-kinase domain .", "entity_list": [{"name": "crizotinib", "ent_type": "drug", "char_span": [14, 24], "tok_span": [2, 6]}, {"name": "G2032R", "ent_type": "variant", "char_span": [136, 142], "tok_span": [30, 34]}], "relation_list": [{"subject": "G2032R", "object": "crizotinib", "sbj_char_span": [136, 142], "obj_char_span": [14, 24], "rel_type": "resistance", "sbj_tok_span": [30, 34], "obj_tok_span": [2, 6]}], "umls_entity_list": []}]